

# CITATION REPORT

List of articles citing

**Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions**

**DOI: 10.1111/j.1572-0241.1999.01377.x**

**American Journal of Gastroenterology, 1999, 94, 2467-74.**

**Source:** <https://exaly.com/paper-pdf/30657900/citation-report.pdf>

**Version:** 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2303	Pathology of the liver. <b>2000</b> , 16, 200-7		
2302	Liver biopsy interpretation for the gastroenterologist. <b>2000</b> , 2, 27-32		20
2301	Ubiquitin as a marker of cell injury in nonalcoholic steatohepatitis. <b>2000</b> , 114, 860-6		39
2300	Minocycline as a cause of drug-induced autoimmune hepatitis. Report of four cases and comparison with autoimmune hepatitis. <b>2000</b> , 114, 591-8		64
2299	Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. <b>2000</b> , 33, 716-24		207
2298	Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. <b>2001</b> , 120, 1183-92		1546
2297	Nonalcoholic steatohepatitis. <b>2001</b> , 121, 710-23		388
2296	Liver inflammatory cells, apoptosis, regeneration and stellate cell activation in non-alcoholic steatohepatitis. <b>2001</b> , 33, 768-77		16
2295	Steatosis and steatohepatitis. <b>2001</b> , 7, 141-147		5
2294	Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. <b>2001</b> , 281, G1135-9		257
2293	Nutritional and metabolic considerations in the etiology of nonalcoholic steatohepatitis. <b>2001</b> , 46, 2347-52		118
2292	Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. <b>2001</b> , 7, 363-73		323
2291	Non-alcoholic steatohepatitis: a common cause of progressive chronic liver injury?. <b>2002</b> , 55, 689-92		71
2290	Role of liver biopsy in the diagnosis of hepatic iron overload in the era of genetic testing. <b>2002</b> , 118, 73-81		13
2289	Non-alcoholic steatohepatitis (NASH): where are we now and where are we going?. <b>2002</b> , 50, 585-8		127
2288	Update on nonalcoholic fatty liver disease. <b>2002</b> , 34, 255-62		243
2287	The clinicopathologic spectrum and management of nonalcoholic fatty liver disease. <b>2002</b> , 9, 37-51		52

2286	Management of nonalcoholic steatohepatitis: an analytic review. <b>2002</b> , 35, 253-61	26
2285	Nonalcoholic fatty liver disease. <b>2002</b> , 346, 1221-31	3875
2284	Reply. <b>2002</b> , 122, 841-842	10
2283	Fasting insulin and uric acid levels but not indices of iron metabolism are independent predictors of non-alcoholic fatty liver disease. A case-control study. <b>2002</b> , 34, 204-11	87
2282	AGA technical review on nonalcoholic fatty liver disease. <b>2002</b> , 123, 1705-25	802
2281	In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. <b>2002</b> , 37, 56-62	398
2280	Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. <b>2002</b> , 37, 154-60	296
2279	Hepatocellular carcinoma: predisposing conditions and precursor lesions. <b>2002</b> , 31, 641-62	16
2278	La esteatosis hepática grave en el donante de Órganos: valor diagnóstico de la tomografía computarizada abdominal. <b>2002</b> , 26, 399-403	
2277	Alcoholic and nonalcoholic steatohepatitis. <b>2002</b> , 6, 399-420, vii	75
2276	Non-alcoholic steatohepatitis: definitions and pathogenesis. <b>2002</b> , 17 Suppl 3, S377-84	124
2275	Non-alcoholic fatty liver disease: an overview. <b>2002</b> , 17, 1136-43	146
2274	Liver regeneration is not altered in patients with nonalcoholic steatohepatitis (NASH) when compared to chronic hepatitis C infection with similar grade of inflammation. <b>2002</b> , 47, 1926-31	12
2273	Nonalcoholic fatty liver disease: an agenda for clinical research. <b>2002</b> , 35, 746-52	175
2272	Pathology of steatohepatitis. <b>2002</b> , 16, 691-707	46
2271	NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. <b>2002</b> , 35, 373-9	795
2270	Obesity-related fatty liver is unchanged in mice deficient for mitochondrial uncoupling protein 2. <b>2002</b> , 35, 753-61	66
2269	HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity. <b>2002</b> , 36, 142-9	175

2268	Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity?. <b>2002</b> , 36, 403-9	252
2267	Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. <b>2002</b> , 36, 729-36	258
2266	Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response. <b>2002</b> , 36, 1266-72	272
2265	One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation. <b>2002</b> , 8, 1114-22	216
2264	Non-organ-specific autoantibodies in nonalcoholic fatty liver disease: prevalence and correlates. <b>2003</b> , 48, 2173-81	107
2263	Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. <b>2003</b> , 37, 917-23	1891
2262	Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. <b>2003</b> , 37, 1202-19	1468
2261	Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. <b>2003</b> , 37, 1286-92	766
2260	Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. <b>2003</b> , 38, 413-9	366
2259	Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. <b>2003</b> , 38, 420-7	305
2258	CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. <b>2003</b> , 38, 428-35	114
2257	High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. <b>2003</b> , 38, 639-44	276
2256	Interaction of iron, insulin resistance, and nonalcoholic steatohepatitis. <b>2003</b> , 5, 18-25	67
2255	Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. <b>2003</b> , 38, 999-1007	473
2254	Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR- $\alpha$ ligand rosiglitazone. <b>2003</b> , 38, 1008-1017	568
2253	Non-alcoholic fatty liver syndrome: a hepatic consequence of common metabolic diseases. <b>2003</b> , 18, 588-94	129
2252	Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region?. <b>2003</b> , 18, 124-38	164
2251	Clinical and histological features of nonalcoholic steatohepatitis in Iranian patients. <b>2003</b> , 3, 27	20

2250	Pathological significance of oxidative cellular damage in human alcoholic liver disease. <b>2003</b> , 42, 365-71	38
2249	Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease. <b>2003</b> , 16, 49-56	131
2248	Hepatocellular carcinoma: predisposing conditions and precursor lesions. <b>2003</b> , 17, 625-646	1
2247	[Current knowledge of nonalcoholic steatohepatitis]. <b>2003</b> , 121, 102-8	2
2246	[Non-alcoholic steatohepatitis]. <b>2003</b> , 120, 670-5	3
2245	Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. <b>2003</b> , 125, 437-43	803
2244	Advances in the understanding and treatment of nonalcoholic fatty liver disease. <b>2003</b> , 63, 2379-94	43
2243	Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease. <b>2003</b> , 163, 1301-11	340
2242	Serum thioredoxin levels as a predictor of steatohepatitis in patients with nonalcoholic fatty liver disease. <b>2003</b> , 38, 32-8	158
2241	Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study. <b>2003</b> , 38, 414-8	99
2240	Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. <b>2003</b> , 38, 434-40	102
2239	Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics. <b>2003</b> , 38, 681-7	155
2238	Pro-fibrotic polymorphisms predictive of advanced liver fibrosis in the severely obese. <b>2003</b> , 39, 967-71	77
2237	Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. <b>2003</b> , 143, 500-5	371
2236	Non-alcoholic fatty liver: a common manifestation of a metabolic disorder. <b>2003</b> , 96, 699-709	41
2235	Low ghrelin concentrations in nonalcoholic fatty liver disease are related to insulin resistance. <b>2003</b> , 88, 5674-9	44
2234	Serum lipids, lipoproteins and apolipoproteins levels in patients with nonalcoholic steatohepatitis. <b>2003</b> , 37, 177-82	43
2233	Recurrence of insulin resistant metabolic syndrome following liver transplantation. <b>2003</b> , 15, 99-102	13

2232	Nonalcoholic fatty liver disease. <b>2004</b> , 3, 93-99	28
2231	Nonalcoholic fatty liver disease: is all the fat bad?. <b>2004</b> , 34, 187-91	27
2230	Metformin in the treatment of patients with non-alcoholic steatohepatitis. <b>2004</b> , 19, 537-44	283
2229	Clinical and histological features of non-alcoholic fatty liver disease in Hong Kong Chinese. <b>2004</b> , 20, 45-9	42
2228	Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. <b>2004</b> , 20, 23-8	253
2227	A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. <b>2004</b> , 20, 623-8	134
2226	Polymorphisms of interleukin-1 beta and beta 3-adrenergic receptor in Japanese patients with nonalcoholic steatohepatitis. <b>2004</b> , 28, 106S-110S	24
2225	Comparison of Hepatocellular Carcinoma Patients With Alcoholic Liver Disease and Nonalcoholic Steatohepatitis. <b>2004</b> , 28, 164S-168S	31
2224	Levels of serum vitamin A, alpha-tocopherol and malondialdehyde in patients with non-alcoholic steatohepatitis: relationship with histopathologic severity. <b>2005</b> , 59, 318-23	20
2223	Hepatic steatosis in hepatitis C virus genotype 3 infection: does it correlate with body mass index, fibrosis, and HCV risk factors?. <b>2004</b> , 49, 25-9	47
2222	Dietary composition and nonalcoholic fatty liver disease. <b>2004</b> , 49, 1578-83	152
2221	Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. <b>2004</b> , 27, 2057-66	157
2220	Non-alcoholic fatty liver disease: an emerging pathological spectrum. <b>2004</b> , 444, 3-12	81
2219	Genes for systemic vascular complications are differentially expressed in the livers of type 2 diabetic patients. <b>2004</b> , 47, 638-47	48
2218	Nonalcoholic Steatohepatitis. <b>2004</b> , 7, 423-430	2
2217	PPAR $\alpha$ in the pathogenesis of fatty liver disease. <b>2004</b> , 40, 783-786	13
2216	Natural history of nonalcoholic steathepatitis: A longitudinal study of repeat liver biopsies. <b>2004</b> , 40, 820-826	12
2215	Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. <b>2004</b> , 39, 770-8	549

2214	Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. <b>2004</b> , 39, 909-14	175
2213	High sensitivity C-reactive protein values do not reliably predict the severity of histological changes in NAFLD. <b>2004</b> , 39, 1458-9	48
2212	Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. <b>2004</b> , 39, 1647-54	591
2211	Portal fibrosis and hepatic steatosis in morbidly obese subjects: A spectrum of nonalcoholic fatty liver disease. <b>2004</b> , 40, 475-83	160
2210	Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. <b>2004</b> , 40, 1387-95	2757
2209	The effect of donor weight reduction on hepatic steatosis for living donor liver transplantation. <b>2004</b> , 10, 721-5	73
2208	Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): diagnosis and clinical course. <b>2004</b> , 18, 1089-104	58
2207	Liver fatty change classification using 25 MHz high frequency ultrasound.	
2206	A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. <b>2004</b> , 2, 1107-15	331
2205	Nonalcoholic fatty liver disease in the pediatric population. <b>2004</b> , 8, 549-58, viii-ix	148
2204	The histologic spectrum of nonalcoholic fatty liver disease. <b>2004</b> , 8, 481-500, vii	47
2203	Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. <b>2004</b> , 8, 861-79, ix	89
2202	Splanchnic haemodynamics in non-alcoholic fatty liver disease: effect of a dietary/pharmacological treatment. A pilot study. <b>2004</b> , 36, 406-11	36
2201	Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease. <b>2004</b> , 8, 575-94, ix	112
2200	The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. <b>2004</b> , 8, 521-33, viii	402
2199	Non-alcoholic steatohepatitis in patients cared in metabolic units. <b>2004</b> , 63, 143-51	18
2198	Non-alcoholic steatohepatitis: review of a growing medical problem. <b>2004</b> , 15, 10-21	75
2197	Deficiency of inducible nitric oxide synthase exacerbates hepatic fibrosis in mice fed high-fat diet. <b>2005</b> , 326, 45-51	35

2196	Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. <b>2004</b> , 35, 196-9	122
2195	Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens. <b>2004</b> , 35, 1070-82	123
2194	Aerobic exercise: a potential therapeutic intervention for patients with liver disease. <b>2004</b> , 62, 935-41	15
2193	Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis. <b>2004</b> , 40, 781-6	186
2192	Curcumin inhibits NF-kappaB activation and reduces the severity of experimental steatohepatitis in mice. <b>2004</b> , 41, 926-34	170
2191	Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. <b>2004</b> , 41, 943-9	150
2190	Vitamin E treatment in patients with nonalcoholic steatohepatitis: A six-month, open-label study of sixteen patients. <b>2004</b> , 65, 266-77	5
2189	[Nucleoside induced hepatopathy in HIV patients. Diagnostic value of liver biopsy assessment]. <b>2004</b> , 25, 406-11	0
2188	Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. <b>2004</b> , 174, 193-6	148
2187	Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States. <b>2004</b> , 40, 147-54	94
2186	Esteatohepatitis no alcoho?lica. <b>2004</b> , 9, 459-465	
2185	Fatty liver. <b>2004</b> , 65, 609-12	2
2184	Hepatitis C virus is independently associated with increased insulin resistance after liver transplantation. <b>2004</b> , 77, 703-10	98
2183	Prevalence and significance of autoantibodies in patients with non-alcoholic steatohepatitis. <b>2004</b> , 38, 801-4	90
2182	The wide spectrum of steatohepatitis: a report of four cases and a review of the literature. <b>2004</b> , 16, 1043-50	13
2181	Should a liver biopsy be done in patients with subclinical chronically elevated transaminases?. <b>2004</b> , 16, 879-83	14
2180	Nonalcoholic steatohepatitis with improved hepatic fibrosis after weight reduction. <b>2004</b> , 43, 289-94	13
2179	Sex differences in choline-deficient diet-induced steatohepatitis in mice. <b>2004</b> , 229, 158-62	22



2178 Bile acids for non-alcoholic fatty liver disease and/or steatohepatitis. **2004,**

2177 Zone 3 Predominance of Histopathological Features in Nonalcoholic Steatohepatitis. **2005, 50-57**

2

2176 Nonalcoholic fatty liver disease in the pediatric population: a review. **2005, 17, 636-41**

91

2175 Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. **2005, 242, 610-7; discussion 618-20**

258

2174 Type 2 diabetes mellitus complicated with smoldering myeloma and non-alcoholic steatohepatitis. **2005, 44, 838-42**

2

2173 Non-alcoholic fatty liver disease and insulin resistance: importance of risk factors and histological spectrum. **2005, 17, 837-41**

32

2172 Total body metabolism of <sup>13</sup>C-octanoic acid is preserved in patients with non-alcoholic steatohepatitis, but differs between women and men. **2005, 17, 1181-4**

23

2171 Peroxisome proliferator-activated receptor alpha L162V polymorphism in nonalcoholic steatohepatitis and genotype 1 hepatitis C virus-related liver steatosis. **2005, 53, 353-9**

3

2170 Liver steatosis classification using high-frequency ultrasound. **2005, 31, 599-605**

20

2169 Nonalcoholic steatohepatitis: recent advances from experimental models to clinical management. **2005, 38, 203-17**

80

2168 Proposal for a histological scoring and grading system for non-alcoholic fatty liver disease. **2005, 25, 294-304**

41

2167 Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. **2005, 25, 779-86**

143

2166 Noninvasive assessment of liver steatosis, fibrosis and inflammation in chronic hepatitis C virus infection. **2005, 25, 1150-5**

26

2165 Liver histopathology in human immunodeficiency virus-hepatitis C virus co-infected patients with fatal liver disease. **2005, 20, 739-45**

7

2164 Elevated plasma homocysteine concentrations as a predictor of steatohepatitis in patients with non-alcoholic fatty liver disease. **2005, 20, 1448-55**

79

2163 Hepatic steatosis and the risk of hepatocellular carcinoma in chronic hepatitis C. **2005, 20, 1395-400**

37

2162 Ciprofloxacin suppresses bacterial overgrowth, increases fasting insulin but does not correct low acylated ghrelin concentration in non-alcoholic steatohepatitis. **2005, 22, 291-9**

58

2161 Hepatic steatosis in chronic hepatitis C: impact on response to anti-viral treatment with peg-interferon and ribavirin. **2005, 22, 943-9**

10

2160	Review article: the treatment of non-alcoholic steatohepatitis with thiazolidinediones. <b>2005</b> , 22, 897-905	31
2159	Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease. <b>2005</b> , 13, 1180-6	139
2158	Effects of oligofructose on glucose and lipid metabolism in patients with nonalcoholic steatohepatitis: results of a pilot study. <b>2005</b> , 59, 723-6	143
2157	Difference and similarity between non-alcoholic steatohepatitis and alcoholic liver disease. <b>2005</b> , 29, 259S-63S	36
2156	Comparison of liver histology between patients with non-alcoholic steatohepatitis and patients with alcoholic steatohepatitis in Japan. <b>2005</b> , 29, 277S-81S	18
2155	Clinical significance of soluble TNF receptor in Japanese patients with non-alcoholic steatohepatitis. <b>2005</b> , 29, 298S-303S	15
2154	Semiquantitative evaluation overestimates the degree of steatosis in liver biopsies: a comparison to stereological point counting. <b>2005</b> , 18, 912-6	87
2153	Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. <b>2005</b> , 200, 845-53	397
2152	Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. <b>2005</b> , 41, 372-9	274
2151	Fibrosis correlates with a ductular reaction in hepatitis C: roles of impaired replication, progenitor cells and steatosis. <b>2005</b> , 41, 809-18	284
2150	Design and validation of a histological scoring system for nonalcoholic fatty liver disease. <b>2005</b> , 41, 1313-21	6503
2149	Chronic liver injury during obstructive sleep apnea. <b>2005</b> , 41, 1290-6	189
2148	Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. <b>2005</b> , 42, 473-80	469
2147	Hepatic steatosis in HIV/hepatitis C coinfection: prevalence and significance compared with hepatitis C mono-infection. <b>2005</b> , 42, 310-6	53
2146	Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases. <b>2005</b> , 42, 838-45	161
2145	Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women. <b>2005</b> , 42, 650-6	160
2144	Histopathology of pediatric nonalcoholic fatty liver disease. <b>2005</b> , 42, 641-9	549
2143	Associations between liver histology and early carotid atherosclerosis in subjects with nonalcoholic fatty liver disease. <b>2005</b> , 42, 974-5; discussion 975	21

2142	Sonographic measurement of the thickness of subcutaneous tissues in nonalcoholic fatty liver disease versus other chronic liver diseases. <b>2005</b> , 33, 439-41	11
2141	Tumor necrosis factor-alpha, interleukin-1beta and nitric oxide: induction of liver megamitochondria in prehepatic portal hypertensive rats. <b>2005</b> , 29, 903-8	20
2140	Epidemiology and natural history of hepatocellular carcinoma. <b>2005</b> , 19, 3-23	251
2139	Elevated urine neopterin levels in nonalcoholic steatohepatitis. <b>2005</b> , 38, 187-90	13
2138	Nonalcoholic fatty liver disease: a clinical review. <b>2005</b> , 50, 171-80	200
2137	A clinical-morphological study on cholestatic presentation of nonalcoholic fatty liver disease. <b>2005</b> , 50, 1130-5	31
2136	High rate of seropositivity of Chlamydia pneumoniae IgA in male patients with nonalcoholic steatohepatitis. <b>2005</b> , 50, 1141-5	2
2135	Symptoms of obstructive sleep apnea in patients with nonalcoholic fatty liver disease. <b>2005</b> , 50, 2338-43	66
2134	Feeding apolipoprotein E-knockout mice with cholesterol and fat enriched diets may be a model of non-alcoholic steatohepatitis. <b>2005</b> , 268, 53-8	64
2133	Measurement of the total antioxidant response using a novel automated method in subjects with nonalcoholic steatohepatitis. <b>2005</b> , 5, 35	40
2132	The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. <b>2005</b> , 4, 10	227
2131	Genetic Background of Japanese Patients with Nonalcoholic Steatohepatitis (NASH). <b>2005</b> , 58-63	
2130	Alcoholic liver disease. An update. <b>2005</b> , 4, 32-42	26
2129	Hypoadiponectinemia and insulin resistance are associated with nonalcoholic fatty liver disease. <b>2005</b> , 20, 421-6	19
2128	Serum laminin, type IV collagen and hyaluronan as fibrosis markers in non-alcoholic fatty liver disease. <b>2005</b> , 38, 747-53	67
2127	Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. <b>2005</b> , 11, 255-9	119
2126	Fibrosis Heterogeneity in Nonalcoholic Steatohepatitis and Hepatitis C Virus Needle Core Biopsy Specimens. <b>2005</b> , 123, 382-387	80
2125	Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study. <b>2005</b> , 54, 122-7	238

2124	Plasma adiponectin is decreased in nonalcoholic fatty liver disease. <b>2005</b> , 152, 113-8		200
2123	Treatment strategies in nonalcoholic fatty liver disease. <b>2005</b> , 2, 148-55		48
2122	Clinical Features of Patients with Nonalcoholic Fatty Liver Disease. <b>2005</b> , 73-83		
2121	Nonalcoholic Fatty Liver (NAFL): Overview. <b>2005</b> , 1-43		
2120	Nonalcoholic fatty liver disease: a review. <b>2005</b> , 10, 661-70		1
2119	Predictors of Nonalcoholic Steatohepatitis in Japanese Patients: Thioredoxin and NASH. <b>2005</b> , 64-72		3
2118	Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. <b>2005</b> , 330, 932		150
2117	Nonalcoholic fatty liver disease. <b>2005</b> , 172, 899-905		364
2116	Anti-tissue transglutaminase antibodies in patients with abnormal liver tests: is it always coeliac disease?. <i>American Journal of Gastroenterology</i> , <b>2005</b> , 100, 2472-7	0.7	48
2115	Increased acylation stimulating protein concentrations in nonalcoholic fatty liver disease are associated with insulin resistance. <i>American Journal of Gastroenterology</i> , <b>2005</b> , 100, 842-9	0.7	39
2114	RAGE limits regeneration after massive liver injury by coordinated suppression of TNF-alpha and NF-kappaB. <b>2005</b> , 201, 473-84		123
2113	Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis. <b>2005</b> , 54, 987-93		149
2112	Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. <b>2005</b> , 90, 3498-504		322
2111	Fructose-induced fatty liver disease: hepatic effects of blood pressure and plasma triglyceride reduction. <b>2005</b> , 45, 1012-8		170
2110	Associations between liver histology and carotid intima-media thickness in patients with nonalcoholic fatty liver disease. <b>2005</b> , 25, 2687-8		25
2109	Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. <b>2005</b> , 288, E462-8		1132
2108	Non-alcoholic fatty liver disease. <b>2005</b> , 66, 106-11		1
2107	Should nonalcoholic fatty liver disease be renamed?. <b>2005</b> , 23, 72-82		54

2106	Evaluaci3n macrosc3pica y microsc3pica del efecto de la atorvastatina sobre la progresi3n-regresi3n de la esteatosis hep3tica en un modelo aviar. <b>2005</b> , 17, 270-276	
2105	[Iron overload and insulin resistance]. <b>2005</b> , 34, 1391-8	1
2104	Increase in liver antioxidant enzyme activities in non-alcoholic fatty liver disease. <b>2005</b> , 25, 946-53	68
2103	Use of serum carbohydrate-deficient transferrin values to exclude alcoholic hepatitis from non-alcoholic steatohepatitis: a pilot study. <b>2005</b> , 29, 236S-9S	13
2102	Nonalcoholic steatohepatitis: pathologic features and differential diagnosis. <b>2005</b> , 22, 330-8	77
2101	Race and comorbid factors predict nonalcoholic fatty liver disease histopathology in severely obese patients. <b>2005</b> , 1, 6-11	41
2100	Approach to the diagnosis and treatment of nonalcoholic fatty liver disease. <b>2005</b> , 9, 617-34, vi	26
2099	Hepatic stellate cells and fibrosis progression in patients with nonalcoholic fatty liver disease. <b>2005</b> , 3, 384-9	46
2098	Hepatic complications of obesity. <b>2005</b> , 34, 45-61	23
2097	Hepatic fat fraction: MR imaging for quantitative measurement and display--early experience. <b>2005</b> , 237, 1048-55	232
2096	Abnormal glucose tolerance is a predictor of steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease. <b>2005</b> , 40, 1469-77	63
2095	The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. <b>2005</b> , 42, 132-8	680
2094	NASH: a hidden and silent fibroser finally revealed?. <b>2005</b> , 42, 12-4	23
2093	Heme oxygenase-1 levels and oxidative stress-related parameters in non-alcoholic fatty liver disease patients. <b>2005</b> , 42, 585-91	123
2092	Hepatic steatosis in chronic hepatitis B and C: predictors, distribution and effect on fibrosis. <b>2005</b> , 43, 38-44	140
2091	Serum adiponectin correlates with viral characteristics but not histologic features in patients with chronic hepatitis C. <b>2005</b> , 43, 235-42	59
2090	Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. <b>2005</b> , 43, 434-41	257
2089	St3atopathies h3patiques non alcooliques. <b>2005</b> , 2, 269-283	0

2088	Morphology of alcoholic liver disease. <b>2005</b> , 9, 37-53		147
2087	Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic Fatty liver disease. <i>American Journal of Gastroenterology</i> , <b>2005</b> , 100, 850-5	0.7	210
2086	Mice heterozygous for a defect in mitochondrial trifunctional protein develop hepatic steatosis and insulin resistance. <b>2005</b> , 128, 1381-90		138
2085	Cystathionine beta synthase deficiency promotes oxidative stress, fibrosis, and steatosis in mice liver. <b>2005</b> , 128, 1405-15		141
2084	Sampling variability of liver biopsy in nonalcoholic fatty liver disease. <b>2005</b> , 128, 1898-906		1346
2083	The natural history of nonalcoholic fatty liver disease: a population-based cohort study. <b>2005</b> , 129, 113-21		2108
2082	A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. <i>American Journal of Gastroenterology</i> , <b>2005</b> , 100, 1082-90	0.7	516
2081	Hepatic steatosis and HIV infection. <b>2005</b> , 19, 356-65		37
2080	The inflammatory C-reactive protein is increased in both liver and adipose tissue in severely obese patients independently from metabolic syndrome, Type 2 diabetes, and NASH. <i>American Journal of Gastroenterology</i> , <b>2006</b> , 101, 1824-33	0.7	137
2079	Acute and chronic hepatitis. <b>2006</b> , 23, 132-48		18
2078	Alcoholic liver disease. <b>2006</b> , 23, 149-60		122
2077	Nonalcoholic fatty liver disease manifesting esophageal variceal bleeding. <b>2006</b> , 69, 175-8		3
2076	The evolution of severe steatosis after bariatric surgery is related to insulin resistance. <b>2006</b> , 130, 1617-24		106
2075	Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. <b>2006</b> , 4, 1537-43		265
2074	Effects of vitamins E and C supplementation on hepatic glutathione peroxidase activity and tissue injury associated with ethanol ingestion in malnourished rats. <b>2006</b> , 67, 118-37		9
2073	<i>Psammomys obesus</i> (sand rat), a new animal model of non-alcoholic fatty liver disease. <b>2006</b> , 72, 1-5		17
2072	Hepatic steatosis and insulin resistance: does etiology make a difference?. <b>2006</b> , 44, 190-6		116
2071	Adult onset type II citrullinemia as a cause of non-alcoholic steatohepatitis. <b>2006</b> , 44, 236-9		31

2070	Non-alcoholic steatohepatitis: from cell biology to clinical practice. <b>2006</b> , 44, 197-208	152
2069	Impact of human immunodeficiency virus infection on the prevalence and severity of steatosis in patients with chronic hepatitis C virus infection. <b>2006</b> , 44, 1026-32	68
2068	Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. <b>2006</b> , 44, 1167-74	407
2067	Interleukin-15 increases hepatic regenerative activity. <b>2006</b> , 45, 410-8	34
2066	Diagnostic and predictive factors of significant liver fibrosis and minimal lesions in patients with persistent unexplained elevated transaminases. A prospective multicenter study. <b>2006</b> , 45, 592-9	47
2065	Hepatic histology in obese patients undergoing bariatric surgery. <b>2006</b> , 45, 600-6	401
2064	Relationship between high-sensitivity C-reactive protein levels and liver histology in subjects with non-alcoholic fatty liver disease. <b>2006</b> , 45, 879-81; author reply 881-2	65
2063	Synemin expression is widespread in liver fibrosis and is induced in proliferating and malignant biliary epithelial cells. <b>2006</b> , 37, 1200-10	28
2062	Nonalcoholic fatty liver disease and obesity. <b>2006</b> , 21 Suppl 1, 72-8	8
2061	Liver Biopsy Histopathology. <b>2006</b> , 205-234	
2060	Non alcoholic fatty liver disease: a clinical approach and review. <b>2006</b> , 20, 345-9	20
2059	[Steatosis and non-alcoholic steatohepatitis in patients with chronic hepatitis due to hepatitis C virus infection]. <b>2006</b> , 43, 265-8	2
2058	Metabolic syndrome, non-alcoholic steatohepatitis (NASH), and hepatocyte growth factor (HGF). <b>2006</b> , 5, 109-114	14
2057	Expression of p53, Bax and Bcl-2 proteins in hepatocytes in non-alcoholic fatty liver disease. <b>2006</b> , 12, 6198-202	67
2056	Effect of Cordyceps Sinensis on Uncoupling Protein 2 in Experimental Rats with Nonalcoholic Fatty Liver. <b>2006</b> , 52, 390-396	2
2055	Steatosis and hepatitis C in an Alaska Native/American Indian population. <b>2006</b> , 65, 253-60	4
2054	Design and Validation of a Histological Scoring System for Nonalcoholic Fatty Liver Disease. <b>2006</b> , 2006, 41-43	
2053	Serum levels of hepatoprotective peptide adiponectin in non-alcoholic fatty liver disease. <b>2006</b> , 18, 175-80	53

2052	Non-alcoholic steatohepatitis. <b>2006</b> , 13, 119-126	3
2051	Oxidant stress and antioxidant status among patients with nonalcoholic fatty liver disease (NAFLD). <b>2006</b> , 40, 930-5	114
2050	Altered hepatic expression of SREBP-1 and PPARgamma is associated with liver injury in insulin-resistant lipodystrophic HIV-infected patients. <b>2006</b> , 20, 387-95	78
2049	Nonalcoholic fatty liver disease decrease in obese adolescents after multidisciplinary therapy. <b>2006</b> , 18, 1241-5	74
2048	NAFLD, NASH and now NAS. <b>2006</b> , 13, 101	
2047	Computed tomography features of nonalcoholic steatohepatitis with histopathologic correlation. <b>2006</b> , 30, 37-43	73
2046	[Diagnosis of and therapy for nonalcoholic steatohepatitis]. <b>2006</b> , 95, 1876-80	
2045	Patient age is a strong independent predictor of 13C-aminopyrine breath test results: a comparative study with histology, duplex-Doppler and a laboratory index in patients with chronic hepatitis C virus infection. <b>2006</b> , 33, 300-4	13
2044	Living donor liver transplantation: histological abnormalities found on liver biopsies of apparently healthy potential donors. <b>2006</b> , 21, 381-3	59
2043	Predictors of fibrosis in Asian patients with non-alcoholic steatohepatitis. <b>2006</b> , 21, 116-21	23
2042	Long-term prognosis of nonalcoholic fatty liver disease: is pharmacological therapy actually necessary?. <b>2006</b> , 21, 169-73	11
2041	Effect of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis. <b>2006</b> , 21, 191-8	154
2040	Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis. <b>2007</b> , 22, 634-8	93
2039	Regulation of fibrogenesis during the early phase of common bile duct obstruction. <b>2006</b> , 76, 645-8	2
2038	The effect of the metabolic syndrome, hepatic steatosis and steatohepatitis on liver fibrosis in hereditary hemochromatosis. <b>2006</b> , 26, 298-304	18
2037	Differential findings for CD14-positive hepatic monocytes/macrophages in primary biliary cirrhosis, chronic hepatitis C and nonalcoholic steatohepatitis. <b>2006</b> , 26, 559-65	16
2036	Distinguishing nonalcoholic steatohepatitis from fatty liver: serum-free fatty acids, insulin resistance, and serum lipoproteins. <b>2006</b> , 26, 566-71	14
2035	Intracellular retention of hepatic serpins caused by severe hyperlipidemia. <b>2006</b> , 26, 708-15	8



2034	Unexplained CK elevations in patients with nonalcoholic steatohepatitis. <b>2006</b> , 26, 899-900	2
2033	Non-invasive markers to predict the liver fibrosis in non-alcoholic fatty liver disease. <b>2006</b> , 26, 864-71	67
2032	Increased expression of Ob-Rb and its relationship with the overexpression of TGF-beta1 and the stage of fibrosis in patients with nonalcoholic steatohepatitis. <b>2006</b> , 26, 1065-71	32
2031	Useful parameters for distinguishing nonalcoholic steatohepatitis with mild steatosis from cryptogenic chronic hepatitis in the Japanese population. <b>2006</b> , 26, 956-63	24
2030	Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis. <b>2006</b> , 26, 1119-25	42
2029	Values and limitations of serum aminotransferases in clinical trials of nonalcoholic steatohepatitis. <b>2006</b> , 26, 1209-16	46
2028	Nutritional aspects of non-alcoholic steatohepatitis treatment. <b>2006</b> , 63, 79-90	5
2027	Melatonin ameliorates nonalcoholic fatty liver induced by high-fat diet in rats. <b>2006</b> , 41, 79-84	110
2026	Associations between liver histology and cortisol secretion in subjects with nonalcoholic fatty liver disease. <b>2006</b> , 64, 337-41	67
2025	Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease. <b>2006</b> , 64, 679-83	141
2024	Blood oxidative stress markers are unreliable markers of hepatic steatosis. <b>2006</b> , 23, 91-8	53
2023	Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. <b>2006</b> , 23, 1143-51	318
2022	Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease. <b>2006</b> , 24, 1215-22	80
2021	Histological assessment of non-alcoholic fatty liver disease. <b>2006</b> , 49, 450-65	210
2020	Proposal of a new staging and grading system of the liver for primary biliary cirrhosis. <b>2006</b> , 49, 466-78	48
2019	Exploration of global gene expression in human liver steatosis by high-density oligonucleotide microarray. <b>2006</b> , 86, 154-65	76
2018	Combined effects of high-fat diet and ethanol induce oxidative stress in rat liver. <b>2006</b> , 40, 185-91	50
2017	Predictors of cirrhosis in Hispanic patients with nonalcoholic steatohepatitis. <b>2006</b> , 51, 1725-9	8

2016	Nonalcoholic fatty liver disease treated by gastroplasty. <b>2006</b> , 51, 21-6	51
2015	Risk factors and ultrasound can predict chronic hepatitis caused by nonalcoholic fatty liver disease. <b>2006</b> , 51, 41-4	13
2014	Computed tomography in nonalcoholic fatty liver disease: a useful tool for hepatosteatosis assessment?. <b>2006</b> , 51, 346-51	40
2013	Bedside ultrasound can predict nonalcoholic fatty liver disease in the hands of clinicians using a prototype image. <b>2006</b> , 51, 982-5	11
2012	The restorative effect of taurine on experimental nonalcoholic steatohepatitis. <b>2006</b> , 51, 2225-34	41
2011	Clinical features of nonalcoholic steatohepatitis in Japan: Evidence from the literature. <b>2006</b> , 41, 725-32	43
2010	Hépatopathie non alcoolique: de la stéatose à la cirrhose. <b>2006</b> , 36, 299-314	1
2009	Increased liver pathology in hepatitis C virus transgenic mice expressing the hepatitis B virus X protein. <b>2006</b> , 347, 466-75	30
2008	Nonalcoholic fatty liver disease: from steatosis to cirrhosis. <b>2006</b> , 43, S99-S112	1802
2007	Localization of oxidized phosphatidylcholine in nonalcoholic fatty liver disease: impact on disease progression. <b>2006</b> , 43, 506-14	111
2006	Long-term follow-up of patients with NAFLD and elevated liver enzymes. <b>2006</b> , 44, 865-73	1699
2005	Alpha 1-antitrypsin mutations in NAFLD: high prevalence and association with altered iron metabolism but not with liver damage. <b>2006</b> , 44, 857-64	74
2004	Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. <b>2006</b> , 44, 874-80	241
2003	Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. <b>2006</b> , 44, 1511-7	382
2002	Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis. <b>2006</b> , 44, 1648-55	126
2001	Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. <b>2006</b> , 44, 1675-84	131
2000	Serum adipokine and ghrelin levels in nonalcoholic steatohepatitis. <b>2006</b> , 2006, 34295	32
1999	Breast cancer resistance protein (BCRP/ABCG2) is expressed by progenitor cells/reactive ductules and hepatocytes and its expression pattern is influenced by disease etiology and species type: possible functional consequences. <b>2006</b> , 54, 1051-9	58

1998	Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. <b>2006</b> , 43, 365-72		130
1997	Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. <b>2006</b> , 29, 1325-30		312
1996	Chitotriosidase gene expression in Kupffer cells from patients with non-alcoholic fatty liver disease. <b>2006</b> , 55, 1313-20		75
1995	Breath biomarkers and non-alcoholic fatty liver disease: preliminary observations. <b>2006</b> , 11, 174-83		43
1994	Demographic and clinicopathological characteristics of nonalcoholic fatty liver disease in the East-Southeastern Anatolia regions in Turkey. <b>2006</b> , 15, 62-8		8
1993	An appraisal of the histopathological assessment of liver fibrosis. <b>2006</b> , 55, 569-78		299
1992	Potential role of chitotriosidase gene in nonalcoholic fatty liver disease evolution. <i>American Journal of Gastroenterology</i> , <b>2006</b> , 101, 2060-9	0.7	57
1991	Contributions to hepatic fibrosis in HIV-HCV coinfecting and HCV monoinfected patients. <i>American Journal of Gastroenterology</i> , <b>2006</b> , 101, 1509-15	0.7	23
1990	Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery. <i>American Journal of Gastroenterology</i> , <b>2006</b> , 101, 368-73	0.7	176
1989	Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis. <i>American Journal of Gastroenterology</i> , <b>2007</b> , 102, 1931-8	0.7	120
1988	Nonalcoholic fatty liver disease and diabetes mellitus. <b>2007</b> , 32, 59-69		16
1987	Post-load insulin resistance is an independent predictor of hepatic fibrosis in virus C chronic hepatitis and in non-alcoholic fatty liver disease. <b>2007</b> , 56, 1296-301		56
1986	Plasma PAI-1 levels are increased in patients with nonalcoholic steatohepatitis. <b>2007</b> , 30, e31-2		51
1985	[Candidate drugs for non-alcoholic steatohepatitis (NASH)]. <b>2007</b> , 129, 271-5		
1984	Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. <b>2007</b> , CD005166		50
1983	Evaluation of vulnerable coronary plaques and non-alcoholic fatty liver disease (NAFLD) by 64-detector multislice computed tomography (MSCT). <b>2008</b> , 72, 618-25		81
1982	Five-year follow-up of waist circumference, insulin and ALT levels in familial combined hyperlipidaemia. <b>2007</b> , 113, 375-81		6
1981	Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. <b>2007</b> , 86, 285-300		292

1980	Nonalcoholic Fatty Liver Disease. 830-839	2
1979	Etiologies of chronic liver diseases in Hong Kong. <b>2007</b> , 19, 659-64	19
1978	Potential of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) for differential diagnosis of nonalcoholic steatohepatitis and fatty liver in rats using magnetic resonance imaging. <b>2007</b> , 42, 242-7	83
1977	Steatosis as a risk factor in liver surgery. <b>2007</b> , 245, 20-30	214
1976	Nonalcoholic steatohepatitis in donors for living donor liver transplantation. <b>2007</b> , 83, 257-62	45
1975	Primary liver cancers with nonalcoholic steatohepatitis. <b>2007</b> , 19, 827-34	64
1974	Response to antiviral therapy and hepatic expression of cyclooxygenases in chronic hepatitis C. <b>2007</b> , 19, 927-33	2
1973	HIV-positive patients with nonalcoholic fatty liver disease have a lower body mass index and are more physically active than HIV-negative patients. <b>2007</b> , 45, 432-8	56
1972	Glucose intolerance and hypoadiponectinemia are already present in lean patients with chronic hepatitis C infected with genotype non-3 viruses. <b>2007</b> , 19, 671-7	15
1971	Relationship among histologic, radiologic, and biochemical assessments of hepatic steatosis: a study of human liver samples. <b>2007</b> , 41, 206-10	44
1970	Hepatic steatosis has no impact on the outcome of treatment in patients with chronic hepatitis B infection. <b>2007</b> , 41, 513-7	41
1969	Lower expression of Nrf2 mRNA in older donor livers: a possible contributor to increased ischemia-reperfusion injury?. <b>2007</b> , 84, 1272-8	14
1968	Hepatic structural alteration in adult programmed offspring (severe maternal protein restriction) is aggravated by post-weaning high-fat diet. <b>2007</b> , 98, 1159-69	40
1967	Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. <b>2007</b> , 17, 517-24	294
1966	Identification of a gene-pathway associated with non-alcoholic steatohepatitis. <b>2007</b> , 46, 708-18	44
1965	Evaluation of serum biomarkers of fibrosis and injury in Egyptian patients with chronic hepatitis C. <b>2007</b> , 46, 620-7	42
1964	The phosphatidylethanolamine N-methyltransferase gene V175M single nucleotide polymorphism confers the susceptibility to NASH in Japanese population. <b>2007</b> , 46, 915-20	84
1963	Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C. <b>2007</b> , 46, 1126-32	133

1962	Influence of TNF gene polymorphisms in Japanese patients with NASH and simple steatosis. <b>2007</b> , 46, 1104-10		122
1961	Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. <b>2007</b> , 47, 239-44		199
1960	Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. <b>2007</b> , 47, 135-41		211
1959	Iron preloading aggravates nutritional steatohepatitis in rats by increasing apoptotic cell death. <b>2007</b> , 47, 851-9		29
1958	Grading and staging systems for inflammation and fibrosis in chronic liver diseases. <b>2007</b> , 47, 598-607		496
1957	Erythrophagocytosis by liver macrophages (Kupffer cells) promotes oxidative stress, inflammation, and fibrosis in a rabbit model of steatohepatitis: implications for the pathogenesis of human nonalcoholic steatohepatitis. <b>2007</b> , 170, 967-80		116
1956	Postmortem findings in morbidly obese individuals dying after gastric bypass procedures. <b>2007</b> , 38, 593-7		17
1955	Combined pantethine and probucol therapy for Japanese patients with non-alcoholic steatohepatitis. <b>2007</b> , 37, 872-7		12
1954	Decrease in accumulation of ultrasound contrast microbubbles in non-alcoholic steatohepatitis. <b>2007</b> , 37, 722-30		73
1953	Clinicopathological significance of antinuclear antibodies in non-alcoholic steatohepatitis. <b>2007</b> , 37, 923-31		31
1952	Nonalcoholic fatty liver disease in severely obese subjects. <i>American Journal of Gastroenterology</i> , <b>2007</b> , 102, 399-408	0.7	227
1951	Non-alcoholic fatty liver disease. <b>2007</b> , 42, 1023-30		39
1950	Role of radiologic modalities in the management of non-alcoholic steatohepatitis. <b>2007</b> , 11, 37-54, viii		153
1949	The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. <i>American Journal of Gastroenterology</i> , <b>2007</b> , 102, 2708-15	0.7	514
1948	Nonalcoholic Fatty liver disease and obesity. <b>2007</b> , 22, 1-10		51
1947	Liver fat: effect of hepatic iron deposition on evaluation with opposed-phase MR imaging. <b>2007</b> , 242, 450-5		134
1946	Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis. <b>2007</b> , CD004996		36
1945	Metabolic conditions of fatty liver in non-diabetic obese women. <b>2007</b> , 30, 672-6		1

1944	Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. <b>2007</b> , 56, 968-73	596
1943	Pathologic assessment of non-alcoholic fatty liver disease. <b>2007</b> , 11, 17-23, vii	53
1942	Assessment of hepatic fibrosis with magnetic resonance elastography. <b>2007</b> , 5, 1207-1213.e2	723
1941	Optimizing diagnosis from the medical liver biopsy. <b>2007</b> , 5, 898-907	40
1940	Transgenic mice expressing nuclear sterol regulatory element-binding protein 1c in adipose tissue exhibit liver histology similar to nonalcoholic steatohepatitis. <b>2007</b> , 56, 470-5	63
1939	Regulation of adiponectin receptor expression in human liver and a hepatocyte cell line. <b>2007</b> , 56, 1478-85	35
1938	[Utility of liver biopsy in the etiologic diagnosis of biochemical liver abnormalities of unknown cause]. <b>2007</b> , 30, 325-30	3
1937	Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. <b>2007</b> , 132, 282-93	197
1936	Growth hormone reverses nonalcoholic steatohepatitis in a patient with adult growth hormone deficiency. <b>2007</b> , 132, 938-43	115
1935	Increased gene and protein expression of the novel eNOS regulatory protein NOSTRIN and a variant in alcoholic hepatitis. <b>2007</b> , 132, 2533-41	41
1934	Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. <b>2007</b> , 133, 80-90	363
1933	Improvement of NASH with two-year Treatment with oral polyenephosphatidylcholine. <b>2007</b> , 2, 67-73	2
1932	Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease. <b>2007</b> , 13, 3540-53	177
1931	Monounsaturated fat decreases hepatic lipid content in non-alcoholic fatty liver disease in rats. <b>2007</b> , 13, 361-8	65
1930	Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions. <b>2007</b> , 6, 222-226	73
1929	Dipeptidyl peptidase IV (DDP IV) in NASH patients. <b>2007</b> , 6, 242-250	95
1928	What is the reason of elevated alanine aminotransferase level in HBeAg negative patients with low viremia: NAFLD or chronic hepatitis?. <b>2007</b> , 6, 92-96	14
1927	Changes in histological criteria lead to different prevalences of nonalcoholic steatohepatitis in severe obesity. <b>2007</b> , 6, 255-261	12

1926	Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. <b>2007</b> , 94, 274-86	383
1925	Increasing dimethylarginine levels are associated with adverse clinical outcome in severe alcoholic hepatitis. <b>2007</b> , 45, 62-71	87
1924	Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. <b>2007</b> , 45, 1366-74	728
1923	Evidence for a role of nonalcoholic steatohepatitis in hepatitis C: a prospective study. <b>2007</b> , 46, 380-7	109
1922	Neutrophil dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts the outcome. <b>2007</b> , 46, 831-40	235
1921	HFE C282Y mutations are associated with advanced hepatic fibrosis in Caucasians with nonalcoholic steatohepatitis. <b>2007</b> , 46, 723-9	94
1920	The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome. <b>2007</b> , 46, 1091-100	84
1919	Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. <b>2007</b> , 46, 1392-403	368
1918	Effects of rosiglitazone on methionine-choline deficient diet-induced nonalcoholic steatohepatitis. <b>2007</b> , 46, 2045; author reply 2045-6	2
1917	Diacylglycerol acyltransferase 1 anti-sense oligonucleotides reduce hepatic fibrosis in mice with nonalcoholic steatohepatitis. <b>2008</b> , 47, 625-35	75
1916	Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease. <b>2008</b> , 47, 484-92	71
1915	De novo nonalcoholic fatty liver disease after liver transplantation. <b>2007</b> , 13, 844-7	140
1914	De novo nonalcoholic fatty liver disease after liver transplantation. <b>2007</b> , 13, 788-90	9
1913	Natural history of unexplained chronic hepatitis after liver transplantation. <b>2007</b> , 13, 984-9	48
1912	Measurement of liver fat content using selective saturation at 3.0 T. <b>2007</b> , 25, 743-8	25
1911	Pathology of fatty liver disease. <b>2007</b> , 20 Suppl 1, S40-8	153
1910	Restriction of dietary calories, fat and iron improves non-alcoholic fatty liver disease. <b>2007</b> , 22, 498-503	54
1909	Non-alcoholic steatohepatitis and hepatocellular carcinoma: lessons from hepatocyte-specific phosphatase and tensin homolog (PTEN)-deficient mice. <b>2007</b> , 22 Suppl 1, S96-S100	60

1908	Preventive role of genistein in an experimental non-alcoholic steatohepatitis model. <b>2007</b> , 22, 2009-14	48
1907	Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis. <b>2007</b> , 22, 1112-9	136
1906	Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines. <b>2007</b> , 22, 778-87	227
1905	LAPAROSCOPIC FEATURES AND INTEROBSERVER VARIATION OF HISTOLOGICAL DIAGNOSIS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE. <b>2007</b> , 20, 22-28	1
1904	Non-alcoholic fatty liver disease in Malaysia: a demographic, anthropometric, metabolic and histological study. <b>2007</b> , 8, 58-64	28
1903	Patterns of histological change in liver disease: my approach to 'medical' liver biopsy reporting. <b>2007</b> , 51, 585-96	15
1902	The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. <b>2007</b> , 25, 1181-91	59
1901	Histological progression of non-alcoholic fatty liver disease: a critical reassessment based on liver sampling variability. <b>2007</b> , 26, 821-30	43
1900	Review article: Non-alcoholic fatty liver disease in morbidly obese patients and the effect of bariatric surgery. <b>2007</b> , 26 Suppl 2, 195-201	82
1899	Metabolic syndrome is associated with severe fibrosis in chronic viral hepatitis and non-alcoholic steatohepatitis. <b>2008</b> , 27, 80-9	56
1898	Serum intercellular adhesion molecule-1 in patients with nonalcoholic steatohepatitis: comparison with alcoholic hepatitis. <b>2007</b> , 31, S83-7	27
1897	Prevalence and clinical associations of posttransplant fatty liver disease. <b>2007</b> , 27, 76-80	62
1896	Open-label pilot study of folic acid in patients with nonalcoholic steatohepatitis. <b>2007</b> , 27, 220-6	14
1895	Hepatic steatosis correlates with the postoperative recurrence of hepatitis C virus-associated hepatocellular carcinoma. <b>2007</b> , 27, 620-6	23
1894	HIV/HCV co-infection: histopathologic findings, natural history, fibrosis, and impact of antiretroviral treatment: a review article. <b>2007</b> , 27, 598-606	16
1893	Transjugular liver biopsy in patients with diffuse liver disease: comparison of three cores with one or two cores for accurate histological interpretation. <b>2007</b> , 27, 646-53	24
1892	Expression and activity of the cytochrome P450 2E1 in patients with nonalcoholic steatosis and steatohepatitis. <b>2007</b> , 27, 764-71	41
1891	Exposure to a high total dosage of glucocorticoids produces non-alcoholic steatohepatitis. <b>2007</b> , 57, 388-9	21



1890	From Mallory to Mallory-Denk bodies: what, how and why?. <b>2007</b> , 313, 2033-49	252
1889	Dietary habits and nutrient intake in non-alcoholic steatohepatitis. <b>2007</b> , 23, 46-52	185
1888	[Metabolic fatty liver diseases: hepatic consequences of the metabolic syndrome]. <b>2007</b> , 31, 1127-34	2
1887	Correlation of serum adiponectin levels and hepatic steatosis in hepatitis C virus genotype 1 infection. <b>2007</b> , 24, 972-82	8
1886	[Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis]. <b>2007</b> , 48, 154-63	6
1885	Musculoskeletal complaints and serum autoantibodies associated with chronic hepatitis C and nonalcoholic fatty liver disease. <b>2007</b> , 52, 1177-82	8
1884	The clinicopathological profile of Indian patients with nonalcoholic fatty liver disease (NAFLD) is different from that in the West. <b>2007</b> , 52, 2368-74	83
1883	The effects of rosiglitazone, metformin, and diet with exercise in nonalcoholic fatty liver disease. <b>2007</b> , 52, 2359-67	34
1882	Protective effect of soy isoflavones and activity levels of plasma paraoxonase and arylesterase in the experimental nonalcoholic steatohepatitis model. <b>2007</b> , 52, 2006-14	45
1881	Clinical implications of hepatic steatosis in patients with chronic hepatitis C: a multicenter study of U.S. veterans. <b>2007</b> , 52, 570-8	24
1880	The effect of a low-carbohydrate, ketogenic diet on nonalcoholic fatty liver disease: a pilot study. <b>2007</b> , 52, 589-93	146
1879	Orlistat reverse fatty infiltration and improves hepatic fibrosis in obese patients with nonalcoholic steatohepatitis (NASH). <b>2007</b> , 52, 2512-9	61
1878	Flare-up of nonalcoholic steatohepatitis after hepatectomy resulted in hepatic failure in a patient with type 2 diabetes mellitus. <b>2007</b> , 52, 3473-6	4
1877	Effects of pentoxifylline on TNF-alpha production by peripheral blood mononuclear cells in patients with nonalcoholic steatohepatitis. <b>2007</b> , 52, 2520-4	34
1876	Rosiglitazone attenuates liver inflammation in a rat model of nonalcoholic steatohepatitis. <b>2007</b> , 52, 3465-72	44
1875	Liver steatosis, but not fibrosis, is associated with insulin resistance in nonalcoholic fatty liver disease. <b>2007</b> , 42, 312-7	36
1874	Role of growth hormone, insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in development of non-alcoholic fatty liver disease. <b>2007</b> , 1, 287-94	81
1873	Pathological study of 130 cases of nonalcoholic fatty liver disease based on NASH-CRN system. <b>2007</b> , 1, 413-7	1

1872	Diagnostic value of ultrasonographic examination for nonalcoholic steatohepatitis in morbidly obese patients undergoing laparoscopic bariatric surgery. <b>2007</b> , 17, 45-56	44
1871	Relationship between obstructive sleep apnea and liver abnormalities in morbidly obese patients: a prospective study. <b>2007</b> , 17, 478-85	70
1870	Resolution of nonalcoholic steatohepatitis after gastric bypass surgery. <b>2007</b> , 17, 486-92	120
1869	IL-6 and IGF-1 are independent prognostic factors of liver steatosis and non-alcoholic steatohepatitis in morbidly obese patients. <b>2007</b> , 17, 493-503	86
1868	Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. <b>2007</b> , 17, 1374-80	211
1867	Metabolic syndrome is related to nonalcoholic steatohepatitis in severely obese subjects. <b>2007</b> , 17, 1457-63	42
1866	Oxidative stress and antioxidant defenses in serum of patients with non-alcoholic steatohepatitis. <b>2007</b> , 40, 776-80	81
1865	Independent predictors of steatohepatitis and fibrosis in Asian Indian patients with non-alcoholic steatohepatitis. <b>2008</b> , 53, 1967-76	38
1864	Liver histology changes in nonalcoholic steatohepatitis after one year of treatment with probucol. <b>2008</b> , 53, 2246-50	35
1863	Comparative studies on expression of alpha-smooth muscle actin in hepatic stellate cells in chronic hepatitis B and C. <b>2008</b> , 53, 1364-9	15
1862	Association of apolipoprotein E polymorphisms in patients with non-alcoholic steatohepatitis. <b>2008</b> , 53, 3218-24	55
1861	Effects of a long-term high-fat diet and switching from a high-fat to low-fat, standard diet on hepatic fat accumulation in Sprague-Dawley rats. <b>2008</b> , 53, 3206-12	22
1860	The treatment with antibody of TNF-alpha reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet. <b>2008</b> , 31, 91-8	101
1859	[Quality and quantity in hepatopathology. Diagnostic and clinically relevant grading for non-tumourous liver diseases]. <b>2008</b> , 29, 15-26	5
1858	Routine liver biopsy to screen for nonalcoholic fatty liver disease (NAFLD) during cholecystectomy for gallstone disease: is it justified?. <b>2008</b> , 12, 2097-102; discussion 2102	20
1857	Development from simple steatosis to liver cirrhosis and hepatocellular carcinoma: a 27-year follow-up case. <b>2008</b> , 1, 116-121	22
1856	Bariatric surgery can correct iron depletion in morbidly obese women: a link with chronic inflammation. <b>2008</b> , 18, 709-14	58
1855	The utility of the "NAFLD fibrosis score" in morbidly obese subjects with NAFLD. <b>2008</b> , 18, 264-70	48

1854	Fatty liver disease: predictors of nonalcoholic steatohepatitis and gallbladder disease in morbid obesity. <b>2008</b> , 18, 847-53	31
1853	High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: a contributor to severe hepatic steatosis. <b>2008</b> , 18, 371-7	195
1852	Nonalcoholic fatty liver disease in a district general hospital: clinical presentation and risk factors. <b>2008</b> , 2, 190-5	8
1851	A randomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH). <b>2008</b> , 2, 196-201	59
1850	Differentiation of nonalcoholic from alcoholic steatohepatitis: are routine laboratory markers useful?. <b>2008</b> , 120, 25-30	8
1849	Management of hepatic metastasis from colorectal cancers: an update. <b>2008</b> , 15, 570-80	55
1848	Liver diseases and metabolic syndrome. <b>2008</b> , 43, 509-18	128
1847	Transient elastography for measurement of liver stiffness measurement can detect early significant hepatic fibrosis in Japanese patients with viral and nonviral liver diseases. <b>2008</b> , 43, 720-8	59
1846	Hepatitis C virus infection acquired in childhood. <b>2008</b> , 167, 219-24	18
1845	Resveratrol inhibits nonalcoholic fatty liver disease in rats. <b>2008</b> , 8, 40	156
1844	Liver surgery in the presence of cirrhosis or steatosis: Is morbidity increased?. <b>2008</b> , 2, 8	13
1843	Prospective study of liver transplant recipients with HCV infection: evidence for a causal relationship between HCV and insulin resistance. <b>2008</b> , 14, 193-201	50
1842	Methylenetetrahydrofolate reductase gene polymorphisms in patients with nonalcoholic steatohepatitis (NASH). <b>2008</b> , 26, 291-6	27
1841	Increased hepatic UCP2 expression in rats with nonalcoholic steatohepatitis is associated with upregulation of Sp1 binding to its motif within the proximal promoter region. <b>2008</b> , 105, 277-89	22
1840	Steatohepatitis: Risk factors and impact on disease severity in human immunodeficiency virus/hepatitis C virus coinfection. <b>2008</b> , 47, 1118-27	46
1839	Health-related fitness and physical activity in patients with nonalcoholic fatty liver disease. <b>2008</b> , 47, 1158-66	105
1838	The future is around the corner: Noninvasive diagnosis of progressive nonalcoholic steatohepatitis. <b>2008</b> , 47, 373-5	28
1837	Reply:. <b>2008</b> , 47, 759-760	

1836	Prevention of free fatty acid-induced hepatic lipotoxicity by 18beta-glycyrrhetic acid through lysosomal and mitochondrial pathways. <b>2008</b> , 47, 1905-15	132
1835	Retinol-binding protein 4: a new marker of virus-induced steatosis in patients infected with hepatitis c virus genotype 1. <b>2008</b> , 48, 28-37	49
1834	Tranilast, an antifibrogenic agent, ameliorates a dietary rat model of nonalcoholic steatohepatitis. <b>2008</b> , 48, 109-18	43
1833	Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. <b>2008</b> , 48, 449-57	418
1832	Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. <b>2008</b> , 48, 442-8	292
1831	Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. <b>2008</b> , 48, 792-8	481
1830	The genetic background modulates susceptibility to mouse liver Mallory-Denk body formation and liver injury. <b>2008</b> , 48, 943-52	40
1829	Pathology of fatty liver: differential diagnosis of non-alcoholic fatty liver disease. <b>2008</b> , 14, 586-597	3
1828	NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. <b>2008</b> , 16, 1394-9	152
1827	Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in non-alcoholic steatohepatitis. <b>2008</b> , 28, 1026-33	156
1826	Epigallocatechin gallate attenuates experimental non-alcoholic steatohepatitis induced by high fat diet. <b>2008</b> , 23, e465-70	50
1825	Genetic polymorphisms of adiponectin and tumor necrosis factor-alpha and nonalcoholic fatty liver disease in Chinese people. <b>2008</b> , 23, 914-21	53
1824	8-Hydroxy-2'-deoxy-guanosine is a risk factor for development of hepatocellular carcinoma in patients with chronic hepatitis C virus infection. <b>2008</b> , 23, 1431-6	46
1823	Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection. <b>2008</b> , 23, 1419-25	67
1822	The HFE gene heterozygosis H63D: a cofactor for liver damage in patients with steatohepatitis? Epidemiological and clinical considerations. <b>2008</b> , 38, 254-8	10
1821	Endothelial dysfunction in Turkish patients with non-alcoholic fatty liver disease. <b>2008</b> , 38, 183-9	29
1820	Associates of change in liver fat content in the morbidly obese after laparoscopic gastric banding surgery. <b>2008</b> , 10, 661-7	30
1819	The spectrum of hepatic functional impairment in compensated chronic hepatitis C: results from the Hepatitis C Anti-viral Long-term Treatment against Cirrhosis Trial. <b>2008</b> , 27, 798-809	19

1818	Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis. <b>2008</b> , 28, 200-8	93
1817	Assessment of asymptomatic liver fibrosis in alcoholic patients using fibroscan: prospective comparison with seven non-invasive laboratory tests. <b>2008</b> , 28, 1188-98	160
1816	Alterations of hepatic ATP homeostasis and respiratory chain during development of non-alcoholic steatohepatitis in a rodent model. <b>2008</b> , 38, 245-52	81
1815	Altered expression of cell cycle and apoptotic proteins in chronic hepatitis C virus infection. <b>2008</b> , 8, 133	17
1814	AFP, PIVKAI, GP3, SCCA-1 and follistatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease. <b>2008</b> , 8, 200	94
1813	Olmesartan ameliorates a dietary rat model of non-alcoholic steatohepatitis through its pleiotropic effects. <b>2008</b> , 588, 316-24	29
1812	Preoperative radiographic assessment of hepatic steatosis with histologic correlation. <b>2008</b> , 206, 480-8	80
1811	Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. <b>2008</b> , 57, 1711-8	156
1810	Evaluation of blood oxidative stress-related parameters in alcoholic liver disease and non-alcoholic fatty liver disease. <b>2008</b> , 68, 323-34	39
1809	Diagnosis and therapy of nonalcoholic steatohepatitis. <b>2008</b> , 134, 1682-98	277
1808	Magnetic resonance elastography for the noninvasive staging of liver fibrosis. <b>2008</b> , 135, 32-40	575
1807	Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. <b>2008</b> , 135, 100-10	490
1806	Copper availability contributes to iron perturbations in human nonalcoholic fatty liver disease. <b>2008</b> , 135, 680-8	106
1805	Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. <b>2008</b> , 135, 1176-84	516
1804	Influence of cannabis use on severity of hepatitis C disease. <b>2008</b> , 6, 69-75	110
1803	Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity. <b>2008</b> , 43, 1128-36	70
1802	Nutritional assessment and hepatic fatty acid composition in non-alcoholic fatty liver disease (NAFLD): a cross-sectional study. <b>2008</b> , 48, 300-7	169
1801	Liver stiffness values in apparently healthy subjects: influence of gender and metabolic syndrome. <b>2008</b> , 48, 606-13	324

1800	Ballooned hepatocytes in steatohepatitis: the value of keratin immunohistochemistry for diagnosis. <b>2008</b> , 48, 821-8	182
1799	Fructose consumption as a risk factor for non-alcoholic fatty liver disease. <b>2008</b> , 48, 993-9	597
1798	Angiotensin II-induced non-alcoholic fatty liver disease is mediated by oxidative stress in transgenic TG(mRen2)27(Ren2) rats. <b>2008</b> , 49, 417-28	77
1797	Assessment of liver fibrosis using transient elastography in patients with alcoholic liver disease. <b>2008</b> , 49, 1062-8	185
1796	Activation of ATM signaling pathway is involved in oxidative stress-induced expression of mito-inhibitory p21WAF1/Cip1 in chronic non-suppurative destructive cholangitis in primary biliary cirrhosis: an immunohistochemical study. <b>2008</b> , 31, 73-8	36
1795	Carotid artery intima-media thickness in nonalcoholic fatty liver disease. <b>2008</b> , 121, 72-8	164
1794	Molecular determinants of insulin resistance, cell apoptosis and lipid accumulation in non-alcoholic steatohepatitis. <b>2008</b> , 18, 545-52	14
1793	Evolving trends in nonalcoholic fatty liver disease. <b>2008</b> , 19, 75-82	25
1792	Hepatic complications following preoperative chemotherapy with oxaliplatin or irinotecan for hepatic colorectal metastases. <b>2008</b> , 34, 609-14	87
1791	Genetic variants in STAT3 are associated with nonalcoholic fatty liver disease. <b>2008</b> , 44, 201-6	44
1790	Nonalcoholic Fatty Liver Disease: Pathogenesis, Identification, Progression, and Management. <b>2008</b> , 65, 376-384	33
1789	L-carnitine treatment reduces steatosis in patients with chronic hepatitis C treated with alpha-interferon and ribavirin. <b>2008</b> , 53, 1114-21	29
1788	Prevalence of esophagogastric varices in patients with non-alcoholic steatohepatitis. <b>2008</b> , 38, 572-9	12
1787	Serum neopterin levels in patients with non-alcoholic steatohepatitis. <b>2008</b> , 38, 904-8	1
1786	The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease. <b>2008</b> , 135, 282-291.e1	149
1785	Definition and natural history of metabolic steatosis: histology and cellular aspects. <b>2008</b> , 34, 638-42	36
1784	Non-invasive diagnosis of steatosis and fibrosis. <b>2008</b> , 34, 674-9	50
1783	Disease progression in a patient with nonalcoholic steatohepatitis. <b>2008</b> , 107, 816-21	6

1782	Predictors of nonalcoholic steatohepatitis in patients undergoing bariatric surgery: when is liver biopsy indicated?. <b>2008</b> , 4, 612-7		16
1781	Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. <b>2008</b> , 6, 1396-402		363
1780	Placebo in nonalcoholic steatohepatitis: insight into natural history and implications for future clinical trials. <b>2008</b> , 6, 1243-8		33
1779	Assessment of fibrosis by transient elastography compared with liver biopsy and morphometry in chronic liver diseases. <b>2008</b> , 6, 1027-35		127
1778	Laparoscopic bariatric surgery improves candidacy in morbidly obese patients awaiting transplantation. <b>2008</b> , 4, 159-64; discussion 164-5		158
1777	Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 1682-8	0.7	82
1776	Chitosan ameliorates the severity of steatohepatitis induced by high fat diet in rats. <b>2008</b> , 43, 1371-7		8
1775	Nonalcoholic steatohepatitis and the metabolic syndrome. <b>2008</b> , 6, 1-7		32
1774	A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies. <b>2008</b> , 19, 1802-9		42
1773	TRIF and IRF-3 binding to the TNF promoter results in macrophage TNF dysregulation and steatosis induced by chronic ethanol. <b>2008</b> , 181, 3049-56		94
1772	Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. <b>2008</b> , 47, 1260-9		165
1771	Usefulness of six non-proprietary indirect markers of liver fibrosis in patients with chronic hepatitis C. <b>2008</b> , 46, 253-9		8
1770	Plasma adiponectin levels in primary biliary cirrhosis: a novel perspective for link between hypercholesterolemia and protection against atherosclerosis. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 1959-65	0.7	36
1769	Association between non-alcoholic fatty liver disease and cardiovascular disease: a first message should pass. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 3036-8	0.7	18
1768	Role of nonalcoholic fatty liver disease in the development of insulin resistance and diabetes. <b>2008</b> , 2, 705-11		29
1767	Nonalcoholic fatty liver disease and mitochondrial dysfunction. <b>2008</b> , 14, 193-9		245
1766	Premature cell cycle entry induced by hepatitis B virus regulatory HBx protein during compensatory liver regeneration. <b>2008</b> , 68, 10341-8		29
1765	The epidemiology of newly diagnosed chronic liver disease in gastroenterology practices in the United States: results from population-based surveillance. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 2727-36; quiz 2737	0.7	111

1764	Familial aggregation in patients with non-alcoholic steatohepatitis. <b>2008</b> , 47, 405-10	9
1763	Cytoplasmic fine granular expression of 8-hydroxydeoxyguanosine reflects early mitochondrial oxidative DNA damage in nonalcoholic fatty liver disease. <b>2008</b> , 16, 71-5	39
1762	Bariatric surgery for non-alcoholic steatohepatitis in obese patients. <b>2008</b> ,	2
1761	Increased apoptosis in high-fat diet-induced nonalcoholic steatohepatitis in rats is associated with c-Jun NH2-terminal kinase activation and elevated proapoptotic Bax. <b>2008</b> , 138, 1866-71	102
1760	Histologic abnormalities are common in protocol liver allograft biopsies from patients with normal liver function tests. <b>2008</b> , 32, 965-73	55
1759	The 13C-caffeine breath test detects significant fibrosis in patients with nonalcoholic steatohepatitis. <b>2008</b> , 42, 408-12	14
1758	Risk factors associated with nonalcoholic fatty liver disease and its relationship with the hepatic histological changes. <b>2008</b> , 20, 399-403	17
1757	Decreased phagocytic activity of Kupffer cells in a rat nonalcoholic steatohepatitis model. <b>2008</b> , 14, 6036-43	30
1756	Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers. <b>2008</b> , 3, e3857	66
1755	Effect of lifestyle intervention on non-alcoholic fatty liver disease in Chinese obese children. <b>2008</b> , 14, 1598-602	89
1754	Leptin in nonalcoholic fatty liver disease. <b>2008</b> , 7, 249-254	34
1753	Hepatic expression of ghrelin and adiponectin and their receptors in patients with nonalcoholic fatty liver disease. <b>2008</b> , 7, 67-71	22
1752	Fatty Liver Disease. <b>2009</b> , 1087-1114	7
1751	Clinicopathological examination of nonalcoholic steatohepatitis (NASH) leading to hepatocellular carcinoma (HCC). <b>2009</b> , 50, 626-633	2
1750	Expression of perilipin and adipophilin in nonalcoholic fatty liver disease; relevance to oxidative injury and hepatocyte ballooning. <b>2009</b> , 16, 893-901	69
1749	IL-6 deficiency attenuates murine diet-induced non-alcoholic steatohepatitis. <b>2009</b> , 4, e7929	65
1748	[Model of experimental nonalcoholic steatohepatitis from use of methionine and choline deficient diet]. <b>2009</b> , 46, 69-74	6
1747	Chemical shift magnetic resonance imaging is helpful in detecting hepatic steatosis but not fibrosis in patients with nonalcoholic fatty liver disease (NAFLD). <b>2009</b> , 8, 21-25	12



1746	Novel Controlled Attenuation Parameter for the evaluation of fatty liver disease. <b>2009,</b>	1
1745	Kupffer cell activation by ambient air particulate matter exposure may exacerbate non-alcoholic fatty liver disease. <b>2009, 6, 266-75</b>	81
1744	Nonalcoholic Fatty Liver Disease in Pediatric Patients. <b>2009, 5, 65-71</b>	
1743	The correlation between sonographic diagnosis and laparoscopic observations on fatty liver. <b>2009, 19, 163-9</b>	2
1742	The effects of varying dietary carbohydrate and fat content on survival in a murine LNCaP prostate cancer xenograft model. <b>2009, 2, 557-65</b>	79
1741	Hepatic stearoyl-CoA desaturase (SCD)-1 activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human fatty liver. <b>2009, 58, 203-8</b>	175
1740	The Effect of Metformin and Standard Therapy versus Standard Therapy alone in Nondiabetic Patients with Insulin Resistance and Nonalcoholic Steatohepatitis (NASH): A Pilot Trial. <b>2009, 2, 157-63</b>	107
1739	Hyperlipidemic chicken as a model of non-alcoholic steatohepatitis. <b>2009, 234, 10-6</b>	29
1738	Rats fed fructose-enriched diets have characteristics of nonalcoholic hepatic steatosis. <b>2009, 139, 2067-71</b>	129
1737	Feasibility of in vivo MR elastographic splenic stiffness measurements in the assessment of portal hypertension. <b>2009, 193, 122-7</b>	151
1736	Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: a systematic review. <b>2009, 48, 587-96</b>	74
1735	Hepatic iron deposition in patients with liver disease: preliminary experience with breath-hold multiecho T2*-weighted sequence. <b>2009, 193, 1261-7</b>	51
1734	MR imaging of liver fibrosis: current state of the art. <b>2009, 29, 1615-35</b>	186
1733	Role of Toll-like receptors 2, 4, and 9 in mediating neutrophil dysfunction in alcoholic hepatitis. <b>2009, 296, G15-22</b>	61
1732	Imaging-based quantification of hepatic fat: methods and clinical applications. <b>2009, 29, 1253-77</b>	218
1731	Can nonalcoholic steatohepatitis be diagnosed without liver biopsy?. <b>2009, 3, 353-61</b>	4
1730	Iron overload is associated with hepatic oxidative damage to DNA in nonalcoholic steatohepatitis. <b>2009, 18, 424-32</b>	87
1729	Hepatic fatty acid composition differs between chronic hepatitis C patients with and without steatosis. <b>2009, 139, 691-5</b>	18

1728	Non-invasive assessment of liver fibrosis in chronic liver diseases: implementation in clinical practice and decisional algorithms. <b>2009</b> , 15, 2190-203	62
1727	Effects of adiponectin transgenic expression in liver of nonalcoholic steatohepatitis model mice. <b>2009</b> , 58, 901-8	12
1726	A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver disease. <b>2009</b> , 9, 271	59
1725	[Noninvasive tools for the diagnosis of steatosis and fibrosis in patients with NAFLD]. <b>2009</b> , 33, 405-12	2
1724	Evaluation of diffuse liver steatosis by ultrasound, computed tomography, and magnetic resonance imaging: which modality is best?. <b>2009</b> , 33, 110-5	62
1723	Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. <b>2009</b> , 49, 809-20	265
1722	Intramitochondrial crystalline inclusions in nonalcoholic steatohepatitis. <b>2009</b> , 49, 1888-95	52
1721	Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. <b>2009</b> , 49, 1926-34	119
1720	Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. <b>2009</b> , 50, 1072-8	476
1719	Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study. <b>2009</b> , 50, 1113-20	139
1718	Activation of the complement system in human nonalcoholic fatty liver disease. <b>2009</b> , 50, 1809-17	93
1717	Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. <b>2009</b> , 50, 1818-26	151
1716	Nonalcoholic steatohepatitis induced by a high-fat diet promotes diethylnitrosamine-initiated early hepatocarcinogenesis in rats. <b>2009</b> , 124, 540-6	57
1715	Glucose abnormalities in non-alcoholic fatty liver disease and chronic hepatitis C virus infection: the role of iron overload. <b>2009</b> , 25, 403-10	19
1714	Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4. <b>2009</b> , 81, 1576-83	43
1713	Donor livers with steatosis are safe to use in hepatitis C virus-positive recipients. <b>2009</b> , 15, 619-28	34
1712	Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. <b>2009</b> , 44 Suppl 19, 89-95	233
1711	Noninvasive laboratory tests proposed for predicting cirrhosis in patients with chronic hepatitis C are also useful in patients with non-alcoholic steatohepatitis. <b>2009</b> , 44, 608-14	31

1710	Influence of adiponectin gene polymorphisms in Japanese patients with non-alcoholic fatty liver disease. <b>2009</b> , 44, 976-82	53
1709	Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis. <b>2009</b> , 44, 1190-4	167
1708	MRI findings in nonalcoholic steatohepatitis: correlation with histopathology and clinical staging. <b>2009</b> , 27, 976-87	17
1707	Insulin resistance is common in patients with predominantly genotype 3 chronic hepatitis C. <b>2009</b> , 54, 1778-82	16
1706	Clinical and histological features of nonalcoholic fatty liver disease in children. <b>2009</b> , 54, 2225-30	49
1705	Pattern of expression of adiponectin receptors in human liver and its relation to nonalcoholic steatohepatitis. <b>2009</b> , 19, 467-74	41
1704	Impact of laparoscopic Roux-en-Y gastric bypass on metabolic syndrome, inflammation, and insulin resistance in super versus morbidly obese women. <b>2009</b> , 19, 577-82	40
1703	Adipokine serum levels are related to liver histology in severely obese patients undergoing bariatric surgery. <b>2009</b> , 19, 1313-23	37
1702	Improvement of steatosis after interferon therapy in HCV genotype 4 is related to weight loss. <b>2009</b> , 28, 45-8	4
1701	Hepatic 11beta-HSD1 mRNA expression in fatty liver and nonalcoholic steatohepatitis. <b>2009</b> , 70, 554-60	24
1700	Chemerin, vaspin and insulin resistance in chronic hepatitis C. <b>2010</b> , 17, 661-7	41
1699	Melatonin ameliorates methionine- and choline-deficient diet-induced nonalcoholic steatohepatitis in rats. <b>2009</b> , 46, 401-7	40
1698	Expression of adiponectin and its receptors in livers of morbidly obese patients with non-alcoholic fatty liver disease. <b>2009</b> , 24, 233-7	57
1697	The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease. <b>2009</b> , 24, 564-8	68
1696	Will non-invasive markers replace liver biopsy for diagnosing and staging fibrosis in non-alcoholic steatohepatitis?. <b>2009</b> , 24, 501-3	15
1695	Insulin resistance and endothelial dysfunction in type 2 diabetic patients with non-alcoholic steatohepatitis. <b>2009</b> , 26, 661-3	1
1694	Cyclooxygenase-2 expression in chronic liver diseases and hepatocellular carcinoma: an immunohistochemical study. <b>2009</b> , 1155, 293-9	40
1693	Diagnostic value of a group of biochemical markers of liver fibrosis in patients with non-alcoholic steatohepatitis. <b>2009</b> , 10, 201-6	52

1692	Hepatitis C virus infection enhances insulin resistance induced by visceral fat accumulation. <b>2009</b> , 29, 213-20	28
1691	Hepatic steatosis and fibrosis in young men with treatment-naïve chronic hepatitis B. <b>2009</b> , 29, 878-83	33
1690	Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease. <b>2009</b> , 29, 1431-8	102
1689	Genetic differences in oxidative stress and inflammatory responses to diet-induced obesity do not alter liver fibrosis in mice. <b>2009</b> , 29, 1262-72	25
1688	Diabetes pattern on the 75 g oral glucose tolerance test is a risk factor for hepatocellular carcinoma in patients with hepatitis C virus. <b>2009</b> , 29, 1194-201	30
1687	Microgram-order ammonium perfluorooctanoate may activate mouse peroxisome proliferator-activated receptor alpha, but not human PPARalpha. <b>2009</b> , 265, 27-33	42
1686	Polymorphisms of MRP2 (ABCC2) are associated with susceptibility to nonalcoholic fatty liver disease. <b>2009</b> , 20, 765-70	47
1685	A diagnostic model to differentiate simple steatosis from nonalcoholic steatohepatitis based on the likelihood ratio form of Bayes theorem. <b>2009</b> , 42, 624-9	18
1684	Effects of N-acetylcysteine on regeneration following partial hepatectomy in rats with nonalcoholic fatty liver disease. <b>2009</b> , 39, 592-7	16
1683	Serum protein N-glycans profiling for the discovery of potential biomarkers for nonalcoholic steatohepatitis. <b>2009</b> , 8, 463-70	44
1682	Advanced MRI methods for assessment of chronic liver disease. <b>2009</b> , 193, 14-27	144
1681	A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. <b>2009</b> , 50, 2111-6	276
1680	Selection of the most powerful predictors for the evaluation of hepatic steatosis grade: an experimental study. <b>2009</b> , 72, 118-24	1
1679	[Hepatic steatosis in chronic hepatitis C: study of risk factors and relationship with the fibrosis stage]. <b>2009</b> , 132, 574-9	2
1678	Preventive effects of total flavonoids of <i>Litsea coreana</i> leave on hepatic steatosis in rats fed with high fat diet. <b>2009</b> , 121, 54-60	52
1677	Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis. <b>2009</b> , 50, 351-7	134
1676	Liver biopsy findings from healthy potential living liver donors: reasons for disqualification, silent diseases and correlation with liver injury tests. <b>2009</b> , 50, 501-10	77
1675	Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH. <b>2009</b> , 50, 789-96	239

1674	Association between omental adipose tissue macrophages and liver histopathology in morbid obesity: influence of glycemic status. <b>2009</b> , 51, 354-62	83
1673	Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. <b>2009</b> , 51, 371-9	393
1672	Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. <b>2009</b> , 51, 433-45	556
1671	Effects of weight loss induced by bariatric surgery on hepatic adipocytokine expression. <b>2009</b> , 51, 765-77	113
1670	Thrombotic risk factors and liver histologic lesions in non-alcoholic fatty liver disease. <b>2009</b> , 51, 931-8	37
1669	Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease. <b>2009</b> , 44, 366-74	131
1668	MicroRNA expression pattern in different stages of nonalcoholic fatty liver disease. <b>2009</b> , 41, 289-97	75
1667	Elevation of serum gamma-glutamyltranspeptidase activity is frequent in chronic hepatitis C, and is associated with insulin resistance. <b>2009</b> , 41, 586-90	5
1666	Liver HCV-antigens and steatosis in chronic hepatitis C: role of different genotypes. <b>2009</b> , 41, 659-64	
1665	Serum adipokine profile in Indian men with nonalcoholic steatohepatitis: Serum adiponectin is paradoxically decreased in lean vs. obese patients. <b>2009</b> , 3, 198-203	1
1664	Serum levels of hyaluronic acid and tissue metalloproteinase inhibitor-1 combined with age predict the presence of nonalcoholic steatohepatitis in a pilot cohort of subjects with nonalcoholic fatty liver disease. <b>2009</b> , 154, 194-201	33
1663	Association of lipid profiles with hepatitis C viral load in chronic hepatitis C patients with genotype 1 or 2 infection. <i>American Journal of Gastroenterology</i> , <b>2009</b> , 104, 598-604	0.7 32
1662	Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease. <b>2009</b> , 136, 160-7	195
1661	Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. <b>2009</b> , 137, 532-40	364
1660	Hedgehog-mediated epithelial-to-mesenchymal transition and fibrogenic repair in nonalcoholic fatty liver disease. <b>2009</b> , 137, 1478-1488.e8	204
1659	Histopathology of non-alcoholic fatty liver disease. <b>2009</b> , 13, 533-44	90
1658	The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. <b>2009</b> , 58, 1538-44	452
1657	Final results of a long-term, clinical follow-up in fatty liver patients. <b>2009</b> , 44, 1236-43	151

1656	Nonalcoholic fatty liver disease: diagnostic and fat-grading accuracy of low-flip-angle multiecho gradient-recalled-echo MR imaging at 1.5 T. <b>2009</b> , 251, 67-76	258
1655	Losartan reduces liver expression of plasminogen activator inhibitor-1 (PAI-1) in a high fat-induced rat nonalcoholic fatty liver disease model. <b>2009</b> , 206, 119-26	49
1654	Increased hepatic myeloperoxidase activity in obese subjects with nonalcoholic steatohepatitis. <b>2009</b> , 175, 1473-82	163
1653	Hepatic oxidant/antioxidant status in cholesterol-fed rabbits: Effects of garlic extract. <b>2009</b> , 39, 70-7	11
1652	Assessment of hepatic steatosis and hepatic tissue blood flow by xenon computed tomography in nonalcoholic steatohepatitis. <b>2009</b> , 39, 31-9	15
1651	Analysis of hepatic genes involved in the metabolism of fatty acids and iron in nonalcoholic fatty liver disease. <b>2009</b> , 39, 366-73	109
1650	The effect of ursodeoxycholic acid on liver regeneration after partial hepatectomy in rats with non-alcoholic fatty liver disease. <b>2009</b> , 39, 814-21	8
1649	Influence of angiotensin-converting enzyme I/D gene polymorphism on clinical and histological correlates of chronic hepatitis C. <b>2009</b> , 39, 795-804	5
1648	Clinical significance of serum ornithine carbamoyltransferase in patients with non-alcoholic steatohepatitis. <b>2009</b> , 39, 939-43	5
1647	Circulating and liver tissue levels of retinol-binding protein-4 in non-alcoholic fatty liver disease. <b>2009</b> , 39, 972-8	29
1646	Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic Fatty liver disease. <b>2009</b> , 7, 481-6	127
1645	Noninvasive assessment of hepatic steatosis. <b>2009</b> , 7, 135-40	108
1644	Liver biopsy in alcoholic and non-alcoholic steatohepatitis patients. <b>2009</b> , 33, 930-9	25
1643	Apoptosis and cytokines in non-alcoholic steatohepatitis. <b>2009</b> , 13, 565-80	95
1642	Low serum adiponectin levels are predictive of advanced hepatic fibrosis in patients with NAFLD. <b>2009</b> , 43, 765-72	52
1641	Liver steatosis in patients with chronic hepatitis B infection: host and viral risk factors. <b>2009</b> , 21, 512-6	52
1640	Role of liver-infiltrating CD3+CD56+ natural killer T cells in the pathogenesis of nonalcoholic fatty liver disease. <b>2009</b> , 21, 673-80	92
1639	Relationships between fibrosis amounts assessed by morphometry and liver stiffness measurements in chronic hepatitis or steatohepatitis. <b>2009</b> , 21, 1261-8	37

1638	A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial. <b>2009</b> , 43, 990-4	204
1637	Thiazolidinediones for the treatment in NASH: sustained benefit after drug discontinuation?. <b>2009</b> , 43, 565-8	23
1636	Liver steatosis quantification using magnetic resonance imaging: a prospective comparative study with liver biopsy. <b>2009</b> , 33, 672-7	36
1635	The metabolic syndrome and nonalcoholic fatty liver disease in children. <b>2009</b> , 21, 529-35	65
1634	Prevalence and predictors of hepatic steatosis in adults with newly diagnosed chronic liver disease due to hepatitis C. <b>2009</b> , 88, 302-306	4
1633	Nonalcoholic fatty liver disease in children. <b>2009</b> , 6, 83-91	3
1632	Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis: histological diagnostic criteria and scoring systems. <b>2010</b> , 22, 643-50	57
1631	The epidemiology and clinical characteristics of patients with newly diagnosed alcohol-related liver disease: results from population-based surveillance. <b>2010</b> , 44, 301-7	28
1630	Attenuation of high cholesterol-induced oxidative stress in rabbit liver by thymoquinone. <b>2010</b> , 22, 826-34	18
1629	Bariatric surgery for non-alcoholic steatohepatitis in obese patients. <b>2010</b> , CD007340	159
1628	The nuclear receptor PXR gene variants are associated with liver injury in nonalcoholic fatty liver disease. <b>2010</b> , 20, 1-8	67
1627	Noninvasive liver steatosis quantification using MRI techniques combined with blood markers. <b>2010</b> , 22, 973-82	22
1626	The H63D genetic variant of the HFE gene is independently associated with the virological response to interferon and ribavirin therapy in chronic hepatitis C. <b>2010</b> , 22, 1204-10	5
1625	Nonalcoholic Steatohepatitis (NASH). <b>2010</b> , 15, 65-71	
1624	Bariatric surgery-induced weight loss reduces hepatic lipid peroxidation levels and affects hepatic cytochrome P-450 protein content. <b>2010</b> , 251, 1041-8	49
1623	Assessment of allograft fibrosis by transient elastography and noninvasive biomarker scoring systems in liver transplant patients. <b>2010</b> , 89, 983-93	59
1622	Hepatic steatosis in genotype 4 chronic hepatitis C patients: implication for therapy. <b>2010</b> , 44, 707-12	14
1621	Serum B12 concentration is elevated in patients receiving chronic parenteral nutrition, but is not a marker of intestinal failure-associated liver disease. <b>2010</b> , 44, 571-4	6

1620	Serum apoptotic caspase activity in chronic hepatitis C and nonalcoholic Fatty liver disease. <b>2010</b> , 44, e87-95		35
1619	Serum retinol-binding protein 4 in patients with nonalcoholic fatty liver disease: does it have a significant impact on pathogenesis?. <b>2010</b> , 22, 813-9		25
1618	Diagnostic Criteria for NASH. <b>2010</b> , 36, 8		
1617	Chemotherapy-induced liver injury in metastatic colorectal cancer: semiquantitative histologic analysis of 334 resected liver specimens shows that vascular injury but not steatohepatitis is associated with preoperative chemotherapy. <b>2010</b> , 34, 784-91		69
1616	Statins for non-alcoholic steatohepatitis. <b>2010</b> ,		3
1615	Characteristic expression pattern of oxidative stress in livers with cryptogenic hepatocellular carcinoma. <b>2010</b> , 1, 809-816		2
1614	Liver immunolocalization and plasma levels of MMP-9 in non-alcoholic steatohepatitis (NASH) and hepatitis C infection. <b>2010</b> , 112, 474-81		18
1613	Non-alcoholic fatty liver disease in liver transplant recipients: another story of "seed and soil". <i>American Journal of Gastroenterology</i> , <b>2010</b> , 105, 613-20	0.7	148
1612	[Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Grade 2 consensus-based guidelines]. <b>2010</b> , 31, 225-37		19
1611	Steatosis hepatis. <b>2010</b> , 158, 1070-1076		1
1610	Steatosis and hepatic expression of genes regulating lipid metabolism in Japanese patients infected with hepatitis C virus. <b>2010</b> , 45, 95-104		24
1609	Age-related fat deposition in multifidus muscle could be a marker for nonalcoholic fatty liver disease. <b>2010</b> , 45, 218-24		59
1608	Hepatic senescence marker protein-30 is involved in the progression of nonalcoholic fatty liver disease. <b>2010</b> , 45, 426-34		29
1607	Prospective study of hepatocellular carcinoma in nonalcoholic steatohepatitis in comparison with hepatocellular carcinoma caused by chronic hepatitis C. <b>2010</b> , 45, 960-7		58
1606	Accurate and simple method for quantification of hepatic fat content using magnetic resonance imaging: a prospective study in biopsy-proven nonalcoholic fatty liver disease. <b>2010</b> , 45, 1263-71		29
1605	Effect of liver steatosis on therapeutic response in chronic hepatitis C virus genotype 1 infected patients in hungary. <b>2010</b> , 16, 149-57		0
1604	A fatal case of progressive steatohepatitis, possibly chemotherapy-associated steatohepatitis related to gemcitabine. <b>2010</b> , 3, 191-4		1
1603	Insulin glargine and NPH insulin increase to a similar degree epithelial cell proliferation and aberrant crypt foci formation in colons of diabetic mice. <b>2010</b> , 1, 320-30		18



1602	Diagnostik der nichtalkoholischen Steatohepatitis. <b>2010</b> , 5, 108-115	
1601	A pilot trial of high-dose ursodeoxycholic acid in nonalcoholic steatohepatitis. <b>2010</b> , 4, 628-33	23
1600	Association between nonalcoholic fatty liver disease and coronary artery calcification. <b>2010</b> , 55, 1752-60	80
1599	Nonalcoholic fatty liver disease: a review and update. <b>2010</b> , 55, 560-78	245
1598	Cholesterol absorption decreases after Roux-en-Y gastric bypass but not after gastric banding. <b>2010</b> , 59, 866-72	64
1597	Prevalence and clinical relevance of pathological hepatic changes occurring after neoadjuvant chemotherapy for colorectal liver metastases. <b>2010</b> , 147, 185-94	30
1596	Clinicopathological correlations in a series of adult patients with non-alcoholic fatty liver disease. <b>2010</b> , 60, 87-92	13
1595	Application of a new histological staging and grading system for primary biliary cirrhosis to liver biopsy specimens: Interobserver agreement. <b>2010</b> , 60, 167-74	128
1594	Nuclear size measurement is a simple method for the assessment of hepatocellular aging in non-alcoholic fatty liver disease: Comparison with telomere-specific quantitative FISH and p21 immunohistochemistry. <b>2010</b> , 60, 175-83	35
1593	Maternal high-fat intake predisposes nonalcoholic fatty liver disease in C57BL/6 offspring. <b>2010</b> , 203, 495.e1-8	74
1592	Clinical review of nonalcoholic steatohepatitis in liver surgery and transplantation. <b>2010</b> , 210, 515-26	30
1591	Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. <b>2010</b> , 51, 445-53	260
1590	Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. <b>2010</b> , 51, 595-602	537
1589	Toxicant-associated steatohepatitis in vinyl chloride workers. <b>2010</b> , 51, 474-81	102
1588	Hepatitis B virus infection among American patients with chronic hepatitis C virus infection: prevalence, racial/ethnic differences, and viral interactions. <b>2010</b> , 51, 759-66	58
1587	The impact of maternal high-fat feeding on liver and abdominal fat accumulation in adult offspring under a long-term high-fat diet. <b>2010</b> , 51, 2234-5	4
1586	Hepatic steatosis in patients coinfectd with human immunodeficiency virus/hepatitis C virus: a meta-analysis of the risk factors. <b>2010</b> , 52, 71-8	38
1585	High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. <b>2010</b> , 52, 472-9	217

1584	Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease: impact of liver methylation of the peroxisome proliferator-activated receptor $\alpha$ coactivator 1 promoter. <b>2010</b> , 52, 1992-2000	233
1583	Atherogenic diets exacerbate colitis in mice deficient in glutathione peroxidase. <b>2010</b> , 16, 2043-54	8
1582	Acute exposure of rabbits to diphenyl diselenide: a toxicological evaluation. <b>2010</b> , 30, 761-8	14
1581	Serum prolidase enzyme activity and its relation to histopathological findings in patients with non-alcoholic steatohepatitis. <b>2010</b> , 24, 207-11	21
1580	Relationship between insulin resistance, inflammation and liver cell apoptosis in patients with severe obesity. <b>2010</b> , 26, 187-92	24
1579	Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. <b>2010</b> , 16, 431-9	167
1578	Controlled attenuation parameter (CAP): a novel VCTE-guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. <b>2010</b> , 36, 1825-35	514
1577	Elevated endotoxin levels in non-alcoholic fatty liver disease. <b>2010</b> , 7, 15	251
1576	Human vascular adhesion proteïn-1 (VAP-1): serum levels for hepatocellular carcinoma in non-alcoholic and alcoholic fatty liver disease. <b>2010</b> , 8, 83	11
1575	Co-expressed immune and metabolic genes in visceral and subcutaneous adipose tissue from severely obese individuals are associated with plasma HDL and glucose levels: a microarray study. <b>2010</b> , 3, 34	37
1574	Non-alcoholic fatty liver disease proteomics. <b>2010</b> , 4, 362-71	38
1573	Moderate alcohol consumption aggravates high-fat diet induced steatohepatitis in rats. <b>2010</b> , 34, 567-73	52
1572	Hepatic effects of rosiglitazone in rats with the metabolic syndrome. <b>2010</b> , 107, 663-8	28
1571	Factors that affect the diagnostic accuracy of liver fibrosis measurement by Fibroscan in patients with chronic hepatitis B. <b>2010</b> , 32, 498-505	44
1570	The relationship between liver disease stage and liver fibrosis: a tangled web. <b>2010</b> , 57, 773-84	58
1569	Visfatin serum levels in chronic hepatitis C patients. <b>2010</b> , 17, 254-60	23
1568	Increased soluble leptin receptor levels in morbidly obese patients with insulin resistance and nonalcoholic fatty liver disease. <b>2010</b> , 18, 2268-73	24
1567	Blockade of interleukin-6 signaling enhances hepatic steatosis but improves liver injury in methionine choline-deficient diet-fed mice. <b>2010</b> , 90, 1169-78	74

1566	Association of metabolic profiles with hepatic fibrosis in chronic hepatitis C patients with genotype 1 or 2 infection. <b>2010</b> , 25, 970-7	27
1565	A fresh look at NASH pathogenesis. Part 1: the metabolic movers. <b>2010</b> , 25, 672-90	132
1564	Digestive and metabolic physiology of obesity. 28-43	
1563	Visceral adipose tissue visfatin in nonalcoholic fatty liver disease. <b>2010</b> , 9, 266-270	27
1562	Nonalcoholic fatty liver disease in asymptomatic obese women. <b>2010</b> , 9, 144-149	8
1561	Insulin resistance index (HOMA-IR) in the differentiation of patients with non-alcoholic fatty liver disease and healthy individuals. <b>2010</b> , 47, 165-9	122
1560	Comparative evaluation of whole body and hepatic insulin resistance using indices from oral glucose tolerance test in morbidly obese subjects with nonalcoholic Fatty liver disease. <b>2010</b> , 2010,	18
1559	Insulin resistance derived from zinc deficiency in non-diabetic patients with chronic hepatitis C. <b>2010</b> , 1, 707-711	16
1558	Nonalcoholic Fatty Liver Disease in Children with Hypopituitarism. <b>2010</b> , 13, 51	1
1557	Mice with null mutation of Ccacam I develop nonalcoholic steatohepatitis. <b>2010</b> , 2010, 69-78	19
1556	Histopathology of nonalcoholic fatty liver disease. <b>2010</b> , 16, 5286-96	262
1555	The vitamin E reduces liver lipoperoxidation and fibrosis in a model of nonalcoholic steatohepatitis. <b>2010</b> , 47, 86-92	9
1554	Cardiovascular physiology. 1-18	
1553	Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. <b>2010</b> , 5, 2166-71	156
1552	Eicosapentaenoic acid prevents and reverses insulin resistance in high-fat diet-induced obese mice via modulation of adipose tissue inflammation. <b>2010</b> , 140, 1915-22	199
1551	Bile ductular cells undergoing cellular senescence increase in chronic liver diseases along with fibrous progression. <b>2010</b> , 133, 212-23	40
1550	Quantification of hepatic iron deposition in patients with liver disease: comparison of chemical shift imaging with single-echo T2*-weighted imaging. <b>2010</b> , 194, 1288-95	25
1549	Histological course of nonalcoholic fatty liver disease in Japanese patients: tight glycemic control, rather than weight reduction, ameliorates liver fibrosis. <b>2010</b> , 33, 284-6	61

1548	Lycopene prevents development of steatohepatitis in experimental nonalcoholic steatohepatitis model induced by high-fat diet. <b>2010</b> , 2010,	49
1547	Loss of Par-1a/MARK3/C-TAK1 kinase leads to reduced adiposity, resistance to hepatic steatosis, and defective gluconeogenesis. <b>2010</b> , 30, 5043-56	31
1546	Prevention of HIV protease inhibitor-induced dysregulation of hepatic lipid metabolism by raltegravir via endoplasmic reticulum stress signaling pathways. <b>2010</b> , 334, 530-9	20
1545	Increased arterial stiffness and impaired endothelial function in nonalcoholic Fatty liver disease: a pilot study. <b>2010</b> , 23, 1183-9	89
1544	Pentoxifylline alleviates high-fat diet-induced non-alcoholic steatohepatitis and early atherosclerosis in rats by inhibiting AGE and RAGE expression. <b>2010</b> , 31, 1367-75	18
1543	Early overnutrition results in early-onset arcuate leptin resistance and increased sensitivity to high-fat diet. <b>2010</b> , 151, 1598-610	127
1542	A novel non-alcoholic steatohepatitis animal model featured with insulin resistance, hepatic inflammation and fibrosis. <b>2010</b> , 45, 1360-71	10
1541	A role for low hepatic copper concentrations in nonalcoholic Fatty liver disease. <i>American Journal of Gastroenterology</i> , <b>2010</b> , 105, 1978-85	0.7 113
1540	Differential response to trichloroethylene-induced hepatosteatosis in wild-type and PPARalpha-humanized mice. <b>2010</b> , 118, 1557-63	30
1539	Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. <b>2010</b> , 51, 3046-54	194
1538	FATP2 is a hepatic fatty acid transporter and peroxisomal very long-chain acyl-CoA synthetase. <b>2010</b> , 299, E384-93	117
1537	Medaka as a model for human nonalcoholic steatohepatitis. <b>2010</b> , 3, 431-40	43
1536	Nonalcoholic steatohepatitis: risk factors and diagnosis. <b>2010</b> , 4, 623-35	38
1535	Lipid droplet-associated PAT-proteins show frequent and differential expression in neoplastic steatogenesis. <b>2010</b> , 23, 480-92	105
1534	Nonalcoholic fatty liver disease: US-based acoustic radiation force impulse elastography. <b>2010</b> , 256, 640-7	283
1533	Quantification of hepatic steatosis with 3-T MR imaging: validation in ob/ob mice. <b>2010</b> , 254, 119-28	66
1532	Nonalcoholic fatty liver disease: detection of elevated nicotinamide adenine dinucleotide phosphate with in vivo 3.0-T 31P MR spectroscopy with proton decoupling. <b>2010</b> , 256, 466-73	42
1531	Hepatic steatosis (fatty liver disease) in asymptomatic adults identified by unenhanced low-dose CT. <b>2010</b> , 194, 623-8	148

1530	Is alanine aminotransferase level a surrogate biomarker of hepatic apoptosis in nonalcoholic fatty liver disease?. <b>2010</b> , 4, 205-14	16
1529	[Non-alcoholic fatty liver disease]. <b>2010</b> , 30, 413-20	1
1528	Evaluation of reference intervals for biomarkers sensitive to alcohol consumption, excess body weight and oxidative stress. <b>2010</b> , 70, 104-11	11
1527	Etiology of and risk factors for transient and persistent aminotransferase elevation in a population of virus-free blood donors: a multicentre study. <b>2010</b> , 42, 441-5	2
1526	Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. <b>2010</b> , 42, 272-82	159
1525	Non-alcoholic fatty liver disease in subjects with type 2 diabetes mellitus and non-diabetics with special reference to insulin resistance and hepatic histopathological changes. <b>2010</b> , 4, 226-229	4
1524	Nonalcoholic Fatty Liver Disease. <b>2010</b> , 1153-1179	
1523	Nonalcoholic fatty liver disease: pathology and pathogenesis. <b>2010</b> , 5, 145-71	598
1522	Exploring the molecular mechanisms underlying the potentiation of exogenous growth hormone on alcohol-induced fatty liver diseases in mice. <b>2010</b> , 8, 120	16
1521	Nonalcoholic fatty liver disease. <b>2010</b> , 14, 591-604	57
1520	Albinterferon Alfa-2b was not inferior to pegylated interferon- $\beta$ in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3. <b>2010</b> , 139, 1267-76	69
1519	Albinterferon Alfa-2b was not inferior to pegylated interferon- $\beta$ in a randomized trial of patients with chronic hepatitis C virus genotype 1. <b>2010</b> , 139, 1257-66	67
1518	Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric surgery. <b>2010</b> , 95, 2892-6	198
1517	Proteomic approaches in the search for biomarkers of liver fibrosis. <b>2010</b> , 16, 171-83	15
1516	Genetic polymorphisms of interleukin-6 modulate fibrosis progression in mild chronic hepatitis C. <b>2010</b> , 71, 999-1004	31
1515	A comparison of the fibrotic potential of nonalcoholic fatty liver disease and chronic hepatitis C. <b>2010</b> , 41, 1178-85	9
1514	Impaired liver regeneration of steatotic rats after portal vein ligation: a particular emphasis on (99m)Tc-DISIDA scintigraphy and adiponectin signaling. <b>2010</b> , 52, 540-9	8
1513	In vivo 3T spectroscopic quantification of liver fat content in nonalcoholic fatty liver disease: Correlation with biochemical method and morphometry. <b>2010</b> , 53, 732-7	59

1512	Hepatocellular ballooning in NASH. <b>2010</b> , 53, 719-23	138
1511	Down-regulation of SREBP-1c is associated with the development of burned-out NASH. <b>2010</b> , 53, 724-31	75
1510	Fibroblast growth factor 21 as a biomarker for NAFLD: integrating pathobiology into clinical practice. <b>2010</b> , 53, 795-6	21
1509	Effect of atorvastatin and diet on non-alcoholic fatty liver disease activity score in hyperlipidemic chickens. <b>2010</b> , 64, 275-81	23
1508	Distribution of abdominal adipose tissue as a predictor of hepatic steatosis assessed by MRI. <b>2010</b> , 65, 695-700	15
1507	Pediatric nonalcoholic fatty liver disease: a comprehensive review. <b>2010</b> , 57, 85-140	35
1506	Pathology of NASH and fibrosis. <b>2010</b> , 10, S17-S20	1
1505	Enfermedad del hígado graso no alcohólico y riesgo cardiovascular. <b>2010</b> , 22, 259-271	
1504	Crucial role of impaired Kupffer cell phagocytosis on the decreased Sonazoid-enhanced echogenicity in a liver of a nonalcoholic steatohepatitis rat model. <b>2010</b> , 40, 823-31	19
1503	Adipocytokine involvement in hepatocellular carcinoma after sustained response to interferon for chronic hepatitis C. <b>2010</b> , 40, 911-22	13
1502	Lower circulating levels of dehydroepiandrosterone, independent of insulin resistance, is an important determinant of severity of non-alcoholic steatohepatitis in Japanese patients. <b>2010</b> , 40, 901-10	18
1501	Splanchnic balance of free fatty acids, endocannabinoids, and lipids in subjects with nonalcoholic fatty liver disease. <b>2010</b> , 139, 1961-1971.e1	52
1500	Circulating levels and hepatic expression of molecular mediators of atherosclerosis in nonalcoholic fatty liver disease. <b>2010</b> , 209, 585-91	90
1499	Liver-specific beta-catenin knockout mice exhibit defective bile acid and cholesterol homeostasis and increased susceptibility to diet-induced steatohepatitis. <b>2010</b> , 176, 744-53	83
1498	A human-type nonalcoholic steatohepatitis model with advanced fibrosis in rabbits. <b>2010</b> , 177, 153-65	33
1497	Similar progression of fibrosis between HIV/HCV-infected and HCV-infected patients: Analysis of paired liver biopsy samples. <b>2010</b> , 8, 1070-6	39
1496	Preventive effects of chronic exogenous growth hormone levels on diet-induced hepatic steatosis in rats. <b>2010</b> , 9, 78	35
1495	Pathology of nonalcoholic fatty liver disease. <b>2010</b> , 7, 195-203	350

1494	Quantification of liver fat with magnetic resonance imaging. <b>2010</b> , 18, 337-57, ix		197
1493	Adenovirus-mediated peroxisome proliferator activated receptor gamma overexpression prevents nutritional fibrotic steatohepatitis in mice. <b>2011</b> , 46, 358-69		41
1492	Differences in tissue expression of HBV markers in children with HBV-associated glomerulonephritis. <b>2011</b> , 33, 885-91		1
1491	Nonalcoholic Fatty Liver Disease. <b>2011</b> , 868-907		1
1490	Association of polymorphisms in glutamate-cysteine ligase catalytic subunit and microsomal triglyceride transfer protein genes with nonalcoholic fatty liver disease. <b>2011</b> , 30, 569-75		40
1489	Assessment of chronic hepatitis and fibrosis: comparison of MR elastography and diffusion-weighted imaging. <b>2011</b> , 196, 553-61		177
1488	Comment diagnostiquer de façon non invasive la fibrose au cours de la stéatopathie métabolique?. <b>2011</b> , 5, 60-65		
1487	Prevalence of colonic adenomas in patients with nonalcoholic fatty liver disease. <b>2011</b> , 4, 169-76		41
1486	The global epidemiology of hepatocellular carcinoma: present and future. <b>2011</b> , 15, 223-43, vii-x		352
1485	Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. <b>2011</b> , 140, 124-31		1517
1484	Incidence and risk factors for steatosis progression in adults coinfecting with HIV and hepatitis C virus. <b>2011</b> , 140, 809-17		43
1483	Association of nonalcoholic fatty liver disease with metabolic syndrome in Indian population. <b>2011</b> , 5, 76-80		1
1482	Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis C. <i>American Journal of Gastroenterology</i> , <b>2011</b> , 106, 2112-20	0.7	148
1481	Animal models of nonalcoholic fatty liver disease. <b>2011</b> , 8, 35-44		327
1480	Inflammation in nonalcoholic steatohepatitis. <b>2011</b> , 5, 189-200		60
1479	Weight control and prevention of metabolic syndrome by green tea. <b>2011</b> , 64, 146-54		124
1478	Alcohol-Induced Liver Disease. <b>2011</b> , 417-433		1
1477	Non-alcoholic fatty liver disease. <b>2011</b> , 48, 97-113		216

1476	Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. <b>2011</b> , 9, 428-33; quiz e50	292
1475	Influence of steatosis on progression of fibrosis and virological response in chronic hepatitis C cases. <b>2011</b> , 12, 136-8	5
1474	Predictors of hepatocyte proliferative activity in chronic hepatitis B and C vs. steatohepatitis as assessed by the monoclonal antibody MIB1-Ki-67. <b>2011</b> , 12, 119-24	2
1473	Effects of interventions on intra- and interobserver agreement on interpretation of nonalcoholic fatty liver disease histology. <b>2011</b> , 15, 19-24	53
1472	[Non-alcoholic fatty liver disease. How and who to screen]. <b>2011</b> , 34, 278-88	
1471	Phosphatidylcholine protects against steatosis in mice but not non-alcoholic steatohepatitis. <b>2011</b> , 1811, 1177-85	42
1470	ChREBP expression in the liver, adipose tissue and differentiated preadipocytes in human obesity. <b>2011</b> , 1811, 1194-200	43
1469	Automated quantification of serum hyaluronic acid for non-invasive assessment of liver fibrosis in chronic hepatic diseases. <b>2011</b> , 26, 217-224	1
1468	Anti-inflammatory effect of genistein on non-alcoholic steatohepatitis rats induced by high fat diet and its potential mechanisms. <b>2011</b> , 11, 762-8	85
1467	Comparing morphometric, biochemical, and visual measurements of macrovesicular steatosis of liver. <b>2011</b> , 42, 356-60	25
1466	High-grade microsteatosis and delay in hepatic function after orthotopic liver transplantation. <b>2011</b> , 42, 1337-42	22
1465	Hepatic insulin resistance is associated with increased apoptosis and fibrogenesis in nonalcoholic steatohepatitis and chronic hepatitis C. <b>2011</b> , 54, 142-52	72
1464	Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease. <b>2011</b> , 54, 160-3	57
1463	An apoptosis panel for nonalcoholic steatohepatitis diagnosis. <b>2011</b> , 54, 1224-9	137
1462	Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity. <b>2011</b> , 54, 1244-9	82
1461	UDCA for NASH: end of the story?. <b>2011</b> , 54, 856-8	21
1460	Presence and significance of microvesicular steatosis in nonalcoholic fatty liver disease. <b>2011</b> , 55, 654-659	181
1459	Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. <b>2011</b> , 55, 666-672	264



1458	Common polymorphism in the PNPLA3/adiponutrin gene confers higher risk of cirrhosis and liver damage in alcoholic liver disease. <b>2011</b> , 55, 906-12	115
1457	Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C. <b>2011</b> , 55, 1195-200	74
1456	The role of thiazolidinediones in non-alcoholic steatohepatitis - a systematic review and meta analysis. <b>2011</b> , 55, 1383-90	120
1455	NASH animal models: are we there yet?. <b>2011</b> , 55, 941-3	31
1454	No increase in the expression of key unfolded protein response genes in HCV genotype 3 patients with severe steatosis. <b>2011</b> , 160, 420-3	2
1453	Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. <b>2011</b> , 301, G825-34	275
1452	Hepatoprotective effects of geniposide in a rat model of nonalcoholic steatohepatitis. <b>2011</b> , 63, 587-93	78
1451	Cowden syndrome complicated with hepatocellular carcinoma possibly originating from non-alcoholic steatohepatitis (NASH). <b>2011</b> , 41, 189-93	1
1450	Close correlation of liver stiffness with collagen deposition and presence of myofibroblasts in non-alcoholic fatty liver disease. <b>2011</b> , 41, 897-903	13
1449	Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study. <b>2011</b> , 41, 1057-65	55
1448	Histopathological characteristics of non-alcoholic fatty liver disease in children: Comparison with adult cases. <b>2011</b> , 41, 1066-74	22
1447	Transcriptional profile of genes involved in oxidative stress and antioxidant defense in a dietary murine model of steatohepatitis. <b>2011</b> , 15, 437-45	47
1446	Nonalcoholic steatohepatitis (NASH) does not increase complications after laparoscopic bariatric surgery. <b>2011</b> , 21, 1714-20	35
1445	Association among Histopathology, Clinical Manifestation, and Ultrasonographic Grades in Pediatric Non-alcoholic Fatty Liver Disease. <b>2011</b> , 57, 158	5
1444	Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. <b>2011</b> , 10, 277-286	123
1443	[Pediatric obesity and non-alcoholic fatty liver disease: is it really problematic?]. <b>2011</b> , 57, 141-3	1
1442	The effects of diet-induced obesity on hepatocyte insulin signaling pathways and induction of non-alcoholic liver damage. <b>2011</b> , 4, 211-9	19
1441	Comparison of 1H MR spectroscopy, 3-point DIXON, and multi-echo gradient echo for measuring hepatic fat fraction. <b>2011</b> , 10, 41-8	14

1440	Methionine- and choline-deficient diet induces hepatic changes characteristic of non-alcoholic steatohepatitis. <b>2011</b> , 48, 72-9	33
1439	Microarray evidences the role of pathologic adipose tissue in insulin resistance and their clinical implications. <b>2011</b> , 2011, 587495	11
1438	Influence of Sleeve Gastrectomy on NASH and Type 2 Diabetes Mellitus. <b>2011</b> , 2011, 765473	32
1437	Hepatic and biochemical repercussions of a polyunsaturated fat-rich hypercaloric and hyperlipidic diet in Wistar rats. <b>2011</b> , 48, 153-8	2
1436	Abnormalities of Carbohydrate Metabolism and the Liver. <b>2011</b> , 795-803.e4	1
1435	Update on fatty liver disease and steatohepatitis. <b>2011</b> , 18, 294-300	43
1434	Assessment of different bariatric surgeries in the treatment of obesity and insulin resistance in mice. <b>2011</b> , 254, 73-82	46
1433	Which clinical and sonographic parameters may be useful to discriminate NASH from steatosis?. <b>2011</b> , 45, 59-63	20
1432	Generalizability of the nonalcoholic steatohepatitis Clinical Research Network histologic scoring system for nonalcoholic fatty liver disease. <b>2011</b> , 45, 55-8	85
1431	Keratin 18, Apoptosis, and Liver Disease in Children. <b>2011</b> , 7, 310-315	3
1430	Foie m�tabolique. <b>2011</b> , 6, 1-12	
1429	St�tohepatite non alcoolique. <b>2011</b> , 8, 1-12	
1428	Enhanced expression of pro-inflammatory mediators and liver X-receptor-regulated lipogenic genes in non-alcoholic fatty liver disease and hepatitis C. <b>2011</b> , 120, 239-50	98
1427	Non-Alcoholic Fatty Liver Disease and Nutrition. <b>2011</b> , 546-567	6
1426	Centrizonal arteries and microvessels in nonalcoholic steatohepatitis. <b>2011</b> , 35, 1400-4	52
1425	HCV core gene polymorphisms correlate with liver fibrosis but not sustained virological response in patients with genotype 1 infection. <b>2011</b> , 16, 227-35	5
1424	Plasma levels of vitamin E and carotenoids are decreased in patients with Nonalcoholic Steatohepatitis (NASH). <b>2011</b> , 16, 76-8	94
1423	The usefulness of liver stiffness measurement using FibroScan in chronic hepatitis C in South Korea: a multicenter, prospective study. <b>2011</b> , 26, 171-8	33

1422	Apolipoprotein E genotypes modulate fibrosis progression in patients with chronic hepatitis C and persistently normal transaminases. <b>2011</b> , 26, 328-33	15
1421	Nonalcoholic fatty liver disease across ethno-racial groups: do Asian-American adults represent a new at-risk population?. <b>2011</b> , 26, 501-9	17
1420	Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in Japan. <b>2011</b> , 26 Suppl 1, 153-62	87
1419	Sophocarpine alleviates non-alcoholic steatohepatitis in rats. <b>2011</b> , 26, 765-74	13
1418	Postprandial insulin secretion pattern is associated with histological severity in non-alcoholic fatty liver disease patients without prior known diabetes mellitus. <b>2011</b> , 26, 517-22	32
1417	Resistin is associated with breach of tolerance and anti-nuclear antibodies in patients with hepatobiliary inflammation. <b>2011</b> , 74, 463-70	9
1416	IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C. <b>2011</b> , 33, 1162-72	77
1415	Validation of the non-alcoholic fatty liver disease activity score. <b>2011</b> , 34, 214-8	40
1414	Expression of genes involved in lipogenesis is not increased in patients with HCV genotype 3 in human liver. <b>2011</b> , 18, 53-60	13
1413	Metabolic syndrome and hepatic resection: improving outcome. <b>2011</b> , 13, 846-59	9
1412	Histopathological evaluation of fatty and alcoholic liver diseases. <b>2011</b> , 12, 17-24	19
1411	High fat diet-induced liver steatosis promotes an increase in liver mitochondrial biogenesis in response to hypoxia. <b>2011</b> , 15, 1329-38	74
1410	Systemic chemotherapy and its implications for resection of colorectal liver metastasis. <b>2011</b> , 20, 57-72	25
1409	Nonalcoholic steatohepatitis and increased risk of chronic kidney disease. <b>2011</b> , 60, 735-9	108
1408	Regulation of synthesis and oxidation of fatty acids by adiponectin receptors (AdipoR1/R2) and insulin receptor substrate isoforms (IRS-1/-2) of the liver in a nonalcoholic steatohepatitis animal model. <b>2011</b> , 60, 805-14	32
1407	Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. <b>2011</b> , 60, 313-26	213
1406	The association between the metabolic syndrome and alanine amino transferase is mediated by insulin resistance via related metabolic intermediates (the Cohort on Diabetes and Atherosclerosis Maastricht [CODAM] study). <b>2011</b> , 60, 969-75	36
1405	A mouse model for nonalcoholic steatohepatitis. <b>2011</b> , 22, 979-84	20

1404	Greater age and hepatocellular aging are independent risk factors for hepatocellular carcinoma arising from non-B non-C non-alcoholic chronic liver disease. <b>2011</b> , 61, 572-6	6
1403	Impact of body mass index and viral load on liver histology in hepatitis B e antigen-negative chronic hepatitis B. <b>2011</b> , 30, 647-52	18
1402	Treatment of atherogenic liver based on the pathogenesis of nonalcoholic fatty liver disease: a novel approach to reduce cardiovascular risk?. <b>2011</b> , 42, 337-53	29
1401	Recent advances in biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis: the role of lipid analysis/profiling. <b>2011</b> , 6, 427-436	1
1400	A drug based on water-ethanol extract of oyster mushroom mycelium displays hepatoprotective properties in experimental model of steatohepatitis. <b>2011</b> , 5, 364-369	1
1399	Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. <b>2011</b> , 7, 456-65	227
1398	Intrahepatic natural killer T cell populations are increased in human hepatic steatosis. <b>2011</b> , 17, 1725-31	35
1397	Dietary history and physical activity and risk of advanced liver disease in veterans with chronic hepatitis C infection. <b>2011</b> , 56, 1835-47	3
1396	Non-contrasted computed tomography for the accurate measurement of liver steatosis in obese patients. <b>2011</b> , 56, 2145-51	30
1395	Altered phenotype and functionality of circulating immune cells characterize adult patients with nonalcoholic steatohepatitis. <b>2011</b> , 31, 1120-30	63
1394	An experimental research on chronic intermittent hypoxia leading to liver injury. <b>2011</b> , 15, 493-502	31
1393	Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. <b>2011</b> , 46, 101-7	143
1392	A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. <b>2011</b> , 46, 257-68	158
1391	The pathological role of visceral fat accumulation in steatosis, inflammation, and progression of nonalcoholic fatty liver disease. <b>2011</b> , 46 Suppl 1, 70-8	49
1390	Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. <b>2011</b> , 458, 511-23	91
1389	A critical analysis of three quantitative methods of assessment of hepatic steatosis in liver biopsies. <b>2011</b> , 459, 477-85	90
1388	Familial Mediterranean fever: an association with non-alcoholic fatty liver disease. <b>2011</b> , 30, 987-91	12
1387	Role of serum adiponectin level in the development of liver cirrhosis in patients with hepatitis C virus. <b>2011</b> , 11, 123-9	12

1386	Association of indices of liver and adipocyte insulin resistance with 19 confirmed susceptibility loci for type 2 diabetes in 6,733 non-diabetic Finnish men. <b>2011</b> , 54, 563-71	34
1385	[Steatohepatitis after chemotherapy for colorectal liver metastases (CASH)]. <b>2011</b> , 32, 330-5	5
1384	Invasive and non-invasive methods for the assessment of fibrosis and disease progression in chronic liver disease. <b>2011</b> , 25, 291-303	94
1383	Peroxisome proliferators-activated receptor $\alpha$ Pro12Ala variant is associated with body mass index in non-alcoholic fatty liver disease patients. <b>2010</b> , 5, 575-80	21
1382	NAFLD and insulin resistance do not increase the risk of postoperative complications among patients undergoing bariatric surgery--a prospective analysis. <b>2011</b> , 21, 310-5	26
1381	The Role of Hepatic Steatosis in Chronic Hepatitis B Infection. <b>2011</b> , 10, 134-141	1
1380	Protective effect of whey proteins against nonalcoholic fatty liver in rats. <b>2011</b> , 10, 57	57
1379	Dietary cholesterol, female gender and n-3 fatty acid deficiency are more important factors in the development of non-alcoholic fatty liver disease than the saturation index of the fat. <b>2011</b> , 8, 4	35
1378	The influence of iron status and genetic polymorphisms in the HFE gene on the risk for postoperative complications after bariatric surgery: a prospective cohort study in 1,064 patients. <b>2011</b> , 5, 1	16
1377	New clinical score to diagnose nonalcoholic steatohepatitis in obese patients. <b>2011</b> , 3, 3	34
1376	Black tea prevents high fat diet-induced non-alcoholic steatohepatitis. <b>2011</b> , 25, 1073-81	17
1375	Quantitative Assessment of Liver Fat with Magnetic Resonance Imaging and Spectroscopy. <b>2011</b> , 34, 729-749	509
1374	Reproducibility of MRI-determined proton density fat fraction across two different MR scanner platforms. <b>2011</b> , 34, 928-34	111
1373	Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy. <b>2011</b> , 34, sponce-sponce	94
1372	The prognostic value of changes in serum ferritin levels during therapy for hepatitis C virus infection. <b>2011</b> , 83, 1262-8	8
1371	Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. <b>2011</b> , 53, 106-15	182
1370	Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. <b>2011</b> , 53, 1874-82	422
1369	Nonalcoholic fatty liver disease activity score and Brunt's pathologic criteria for the diagnosis of nonalcoholic steatohepatitis: what do they mean and do they agree?. <b>2011</b> , 53, 2142-3; author reply 2143	7

1368	Endpoints and clinical trial design for nonalcoholic steatohepatitis. <b>2011</b> , 54, 344-53	463
1367	Diagnosing steatohepatitis and predicting liver-related mortality in patients with NAFLD: two distinct concepts. <b>2011</b> , 53, 1792-4	41
1366	Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. <b>2011</b> , 128, 2436-43	325
1365	Liver fibrosis in paediatric liver diseases. <b>2011</b> , 25, 259-68	19
1364	Perspectives on cellular dysfunction in nonalcoholic steatohepatitis: a case of 'multiorganelle failure'? Proceedings of a virtual workshop on nonalcoholic steatohepatitis. <b>2011</b> , 5, 135-9	10
1363	Measurement of ER stress response and inflammation in the mouse model of nonalcoholic fatty liver disease. <b>2011</b> , 489, 329-48	21
1362	Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient - death of a dogma from analysis of therapeutic studies?. <b>2011</b> , 5, 279-89	48
1361	Estimation of hepatic proton-density fat fraction by using MR imaging at 3.0 T. <b>2011</b> , 258, 749-59	215
1360	Neonatal exposure to genistein ameliorates high-fat diet-induced non-alcoholic steatohepatitis in rats. <b>2011</b> , 106, 105-13	22
1359	Serotonin receptor type 3 antagonists improve obesity-associated fatty liver disease in mice. <b>2011</b> , 339, 790-8	44
1358	Is steatosis a risk factor for hepatic blunt force injury?. <b>2011</b> , 32, 263-5	4
1357	The role of hepatic liver X receptor $\beta$ and sterol regulatory element binding protein-1c-mediated lipid disorder in the pathogenesis of non-alcoholic steatohepatitis in rats. <b>2011</b> , 39, 1219-29	19
1356	Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. <b>2011</b> , 259, 749-56	320
1355	Disrupted fat distribution and composition due to medium-chain triglycerides in mice with a $\beta$ -oxidation defect. <b>2011</b> , 94, 439-49	28
1354	Hepatocellular ballooning in nonalcoholic steatohepatitis: the pathologist's perspective. <b>2011</b> , 5, 223-31	42
1353	Alcohol-Related Histopathology. <b>2011</b> , 137-147	
1352	Colorectal Oncogenesis and Inflammation in a Rat Model Based on Chronic Inflammation due to Cycling DSS Treatments. <b>2011</b> , 2011, 924045	5
1351	Insulin resistance, steatosis, and fibrosis in Egyptian patients with chronic Hepatitis C virus infection. <b>2011</b> , 17, 245-51	15

1350	Obesity, Visceral Fat, and NAFLD: Querying the Role of Adipokines in the Progression of Nonalcoholic Fatty Liver Disease. <b>2011</b> , 2011, 592404	89
1349	Non-invasive assessment of liver fibrosis: it is time for laboratory medicine. <b>2011</b> , 49, 13-32	16
1348	Nonalcoholic Fatty Liver Disease. <b>2011</b> , 435-440	1
1347	Effective therapy using voglibose for nonalcoholic steatohepatitis in a patient with insufficient dietary and exercise therapy: exploring other treatment possibilities. <b>2011</b> , 5, 336-43	6
1346	A common polymorphism in the ABCB11 gene is associated with advanced fibrosis in hepatitis C but not in non-alcoholic fatty liver disease. <b>2011</b> , 120, 287-96	37
1345	Foxp3 expression in liver correlates with the degree but not the cause of inflammation. <b>2011</b> , 2011, 827565	32
1344	Experimental evidence for therapeutic potential of taurine in the treatment of nonalcoholic fatty liver disease. <b>2011</b> , 301, R1710-22	75
1343	NCX 1000 Alone or in Combination with Vitamin E Reverses Experimental Nonalcoholic Steatohepatitis in the Rat Similarly to UDCA. <b>2011</b> , 2011, 136816	3
1342	Emodin, a Naturally Occurring Anthraquinone Derivative, Ameliorates Dyslipidemia by Activating AMP-Activated Protein Kinase in High-Fat-Diet-Fed Rats. <b>2012</b> , 2012, 781812	25
1341	The impact of host metabolic factors on treatment outcome in chronic hepatitis C. <b>2012</b> , 2012, 420156	
1340	Low clinical relevance of the nonalcoholic fatty liver disease activity score (NAS) in predicting fibrosis progression. <b>2012</b> , 47, 108-15	39
1339	Myricetin Increases Hepatic Peroxisome Proliferator-Activated Receptor $\beta$ Protein Expression and Decreases Plasma Lipids and Adiposity in Rats. <b>2012</b> , 2012, 787152	46
1338	Serum FGF21 and RBP4 levels in patients with chronic hepatitis C. <b>2012</b> , 47, 1037-47	11
1337	Vinegar-Baked Radix Bupleuri Regulates Lipid Disorders via a Pathway Dependent on Peroxisome-Proliferator-Activated Receptor $\alpha$ in High-Fat-Diet-Induced Obese Rats. <b>2012</b> , 2012, 827278	8
1336	A prospective evaluation of the role of transient elastography for the detection of hepatic fibrosis in type 2 diabetes without overt liver disease. <b>2012</b> , 47, 836-41	22
1335	MRI steatosis grading: development and initial validation of a color mapping system. <b>2012</b> , 198, 582-8	37
1334	Alcoholic hepatitis: diagnosis and management in 2012. <b>2012</b> , 6, 695-710	10
1333	Serum biomarkers in nonalcoholic steatohepatitis: value for assessing drug effects?. <b>2012</b> , 6, 743-57	7

1332	Effect of food restriction and leptin supplementation on fetal programming in mice. <b>2012</b> , 153, 4556-67	23
1331	Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma. <i>American Journal of Gastroenterology</i> , <b>2012</b> , 107, 253-61	0.7 173
1330	Docosahexaenoic acid and arachidonic acid prevent essential fatty acid deficiency and hepatic steatosis. <b>2012</b> , 36, 431-41	21
1329	Effect of liver fibrosis on long-term mortality in HIV/hepatitis C virus-coinfected individuals who are evaluated to receive interferon therapies in the highly active antiretroviral therapy era. <b>2012</b> , 28, 1235-43	7
1328	Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress. <b>2012</b> , 107, 202-10	124
1327	Apo-10'-lycopenoic acid, a lycopene metabolite, increases sirtuin 1 mRNA and protein levels and decreases hepatic fat accumulation in ob/ob mice. <b>2012</b> , 142, 405-10	58
1326	Liver Biopsy Interpretation. <b>2012</b> , 184-200	
1325	Liver morphologic analysis in perinatal autopsies with intrauterine stress liver morphology in perinatal autopsies. <b>2012</b> , 31, 240-7	3
1324	How normal is the liver in which the inflammatory type hepatocellular adenoma develops?. <b>2012</b> , 2012, 805621	13
1323	Antioxidant therapy in nonalcoholic steatohepatitis. <b>2012</b> , 2012, 947575	31
1322	Diagnosis and evaluation of nonalcoholic fatty liver disease. <b>2012</b> , 2012, 145754	145
1321	Resection of nonalcoholic steatohepatitis-associated hepatocellular carcinoma: a Western experience. <b>2012</b> , 2012, 915128	2
1320	Polydatin alleviates non-alcoholic fatty liver disease in rats by inhibiting the expression of TNF- $\alpha$ and SREBP-1c. <b>2012</b> , 6, 815-20	31
1319	Nonalcoholic steatohepatitis in bariatric patients with a diagnosis of obstructive sleep apnea. <b>2012</b> , 5, 587-96	10
1318	Liver fibrosis in patients with non-alcoholic fatty liver disease: diagnostic options in clinical practice. <b>2012</b> , 6, 381-94	8
1317	Fatty liver: a link to cardiovascular disease--its natural history, pathogenesis, and treatment. <b>2012</b> , 8, 21-5	11
1316	Safety and feasibility of diet-treated donors with steatotic livers at the initial consultation for living-donor liver transplantation. <b>2012</b> , 93, 1024-30	26
1315	Association of serum adipocytokines with insulin resistance and liver injury in patients with chronic hepatitis C genotype 4. <b>2012</b> , 46, 871-9	7



1314	Metformin prevents and reverses inflammation in a non-diabetic mouse model of nonalcoholic steatohepatitis. <b>2012</b> , 7, e43056	95
1313	Magnetic resonance for quantitative assessment of liver steatosis: a new potential tool to monitor antiretroviral-drug-related toxicities. <b>2012</b> , 17, 965-71	10
1312	Pediatric nonalcoholic fatty liver disease: a multidisciplinary approach. <b>2012</b> , 9, 152-61	79
1311	Piperine, an LXR antagonist, protects against hepatic steatosis and improves insulin signaling in mice fed a high-fat diet. <b>2012</b> , 84, 1501-10	32
1310	Genetic background effects of keratin 8 and 18 in a DDC-induced hepatotoxicity and Mallory-Denk body formation mouse model. <b>2012</b> , 92, 857-67	32
1309	Non-alcoholic fatty liver disease is associated with high prevalence of gastro-oesophageal reflux symptoms. <b>2012</b> , 44, 1032-6	13
1308	Clinical features of nonalcoholic fatty liver disease-associated hepatocellular carcinoma. <b>2012</b> , 11, 18-27	43
1307	Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events. <b>2012</b> , 56, 1741-50	154
1306	Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. <b>2012</b> , 56, 1751-9	438
1305	Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus. <b>2012</b> , 56, 2180-7	153
1304	Pathophysiological analysis of nonalcoholic fatty liver disease by evaluation of fatty liver changes and blood flow using xenon computed tomography: can early-stage nonalcoholic steatohepatitis be distinguished from simple steatosis?. <b>2012</b> , 47, 1238-47	19
1303	The effect of metformin on the efficacy of antiviral therapy in patients with genotype 1 chronic hepatitis C and insulin resistance. <b>2012</b> , 16, e436-41	23
1302	Nonalcoholic fatty liver in children and adolescents: an overview. <b>2012</b> , 51, 305-12	33
1301	Noninvasive assessment of nonalcoholic fatty liver disease in obese or overweight patients. <b>2012</b> , 10, 1162-8; quiz e87	52
1300	The effect of chronic intermittent hypoxia in the evolution of NASH. <b>2012</b> , 61, 197-202	
1299	A myriad of pathways to NASH. <b>2012</b> , 16, 525-48	33
1298	Treatment of NASH with ursodeoxycholic acid: cons. <b>2012</b> , 36 Suppl 1, S46-52	8
1297	Effect of multiplex spectral modeling of fat for liver iron and fat quantification: correlation of biopsy with MR imaging results. <b>2012</b> , 265, 133-42	141

1296	Development and validation of a new histological score for pediatric non-alcoholic fatty liver disease. <b>2012</b> , 57, 1312-8	60
1295	Pharmacologic ER stress induces non-alcoholic steatohepatitis in an animal model. <b>2012</b> , 211, 29-38	103
1294	Fatty liver disease. <b>2012</b> , 293-359	9
1293	Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD. <b>2012</b> , 32, 1242-52	124
1292	Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. <b>2012</b> , 32, 911-8	233
1291	<i>Populus balsamifera</i> L. (Salicaceae) mitigates the development of obesity and improves insulin sensitivity in a diet-induced obese mouse model. <b>2012</b> , 141, 1012-20	18
1290	Serum proteomic analysis revealed diagnostic value of hemoglobin for nonalcoholic fatty liver disease. <b>2012</b> , 56, 241-7	72
1289	The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies. <b>2012</b> , 56, 448-54	126
1288	Serum interleukin 1 receptor antagonist as an independent marker of non-alcoholic steatohepatitis in humans. <b>2012</b> , 56, 663-70	69
1287	Structural and inflammatory heterogeneity in subcutaneous adipose tissue: relation with liver histopathology in morbid obesity. <b>2012</b> , 56, 1152-1158	61
1286	Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C. <b>2012</b> , 57, 492-8	48
1285	Regular coffee but not espresso drinking is protective against fibrosis in a cohort mainly composed of morbidly obese European women with NAFLD undergoing bariatric surgery. <b>2012</b> , 57, 1090-6	106
1284	[Nonalcoholic fatty liver disease]. <b>2012</b> , 41, 169-89	4
1283	Progression of morphological changes after transplantation of a liver with heterozygous $\alpha_1$ -antitrypsin deficiency. <b>2012</b> , 43, 753-6	7
1282	<i>Agrimonia eupatoria</i> protects against chronic ethanol-induced liver injury in rats. <b>2012</b> , 50, 2335-41	45
1281	Histological assessment of nonalcoholic fatty liver disease in adults and children. <b>2012</b> , 1, 108-111	18
1280	Nonalcoholic fatty liver disease: Definitions, risk factors, and workup. <b>2012</b> , 1, 99-103	53
1279	Preventive Effects of Flavonoid Extracts from <i>Ilex hainanensis</i> Merr. on Rats with Hepatic Steatosis Induced by a High-Fat Diet. <b>2012</b> , 73, 308-316	6

1278	Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus-coinfected patients. <b>2012</b> , 56, 1261-70	30
1277	Accuracy of real-time shear wave elastography for assessing liver fibrosis in chronic hepatitis C: a pilot study. <b>2012</b> , 56, 2125-33	452
1276	Clinical relevance of antibodies to cardiolipin in patients with chronic hepatitis C. <b>2012</b> , 26, 342-8	7
1275	Hepatic steatosis in HIV-HCV coinfecting patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals. <b>2012</b> , 5, 180	3
1274	Fatty liver in men is associated with high serum levels of small, dense low-density lipoprotein cholesterol. <b>2012</b> , 4, 34	10
1273	Non-alcoholic fatty liver disease. <b>2012</b> , 4, 266-80	38
1272	The glycated albumin to glycated haemoglobin ratio increases along with the fibrosis stage in non-alcoholic steatohepatitis. <b>2012</b> , 49, 387-90	11
1271	Nonalcoholic fatty liver disease. <b>2012</b> , 16, 397-419	55
1270	The relevance of liver histology to predicting clinically meaningful outcomes in nonalcoholic steatohepatitis. <b>2012</b> , 16, 487-504	37
1269	Epidemiology and Natural History of Non-alcoholic Fatty Liver Disease. <b>2012</b> , 2, 135-44	51
1268	A Randomized Controlled Trial Comparing Efficacy of Pentoxifylline and Pioglitazone on Metabolic Factors and Liver Histology in Patients with Non-alcoholic Steatohepatitis. <b>2012</b> , 2, 333-7	24
1267	The controlled attenuation parameter (CAP): a novel tool for the non-invasive evaluation of steatosis using Fibroscan. <b>2012</b> , 36, 13-20	157
1266	Ursodeoxycholic acid with vitamin E in patients with nonalcoholic steatohepatitis: long-term results. <b>2012</b> , 36, 146-55	43
1265	Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling. <b>2012</b> , 16, 44-54	232
1264	Post-load insulin resistance does not predict virological response to treatment of chronic hepatitis C patients without the metabolic syndrome. <b>2012</b> , 44, 419-25	7
1263	Hepatic tumor necrosis factor- $\alpha$ , leptin and adiponectin expression in morbid obese patients: Clinicopathological correlations. <b>2012</b> , 6, e1-e90	1
1262	Features, diagnosis, and treatment of nonalcoholic fatty liver disease. <b>2012</b> , 10, 837-58	182
1261	Serologic predictors of nonalcoholic steatohepatitis in a population undergoing bariatric surgery. <b>2012</b> , 8, 416-22	10

1260	Detection of non-alcoholic steatohepatitis in patients with morbid obesity before bariatric surgery: preliminary evaluation with acoustic radiation force impulse imaging. <b>2012</b> , 22, 2525-32	43
1259	Fuzheng Huayu recipe prevents nutritional fibrosing steatohepatitis in mice. <b>2012</b> , 11, 45	20
1258	Discordance between liver biopsy and Fibroscan® in assessing liver fibrosis in chronic hepatitis b: risk factors and influence of necroinflammation. <b>2012</b> , 7, e32233	43
1257	Blueberry husks and probiotics attenuate colorectal inflammation and oncogenesis, and liver injuries in rats exposed to cycling DSS-treatment. <b>2012</b> , 7, e33510	28
1256	Quantification of hepatic iron concentration in chronic viral hepatitis: usefulness of T2-weighted single-shot spin-echo echo-planar MR imaging. <b>2012</b> , 7, e33868	6
1255	Relation of IL28B gene polymorphism with biochemical and histological features in hepatitis C virus-induced liver disease. <b>2012</b> , 7, e37998	42
1254	Neutrophil-derived myeloperoxidase aggravates non-alcoholic steatohepatitis in low-density lipoprotein receptor-deficient mice. <b>2012</b> , 7, e52411	83
1253	Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. <b>2012</b> , 18, 2300-8	369
1252	NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications. <b>2012</b> , 6, 149-71	278
1251	Serum lipids and chronic hepatitis C genotype 4: interaction and significance. <b>2012</b> , 11, 37-46	9
1250	Steatotic livers. Can we use them in OLTX? Outcome data from a prospective baseline liver biopsy study. <b>2012</b> , 11, 891-898	44
1249	Aging is a risk factor of nonalcoholic fatty liver disease in premenopausal women. <b>2012</b> , 18, 237-43	86
1248	Nonalcoholic Fatty Liver Disease. <b>2012</b> , 941-968	3
1247	Life style modification improves insulin resistance and liver histology in patients with non-alcoholic fatty liver disease. <b>2012</b> , 4, 209-17	38
1246	How many valid measurements are necessary to assess liver fibrosis using FibroScan® in patients with chronic viral hepatitis? An analysis of subjects with at least 10 valid measurements. <b>2012</b> , 53, 337-45	11
1245	The utility of Xenon-133 liver scan in the diagnosis and management of nonalcoholic fatty liver disease. <b>2012</b> , 26, 155-9	8
1244	The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans. <b>2012</b> , 122, 2176-94	254
1243	Risk factors for nonalcoholic steatohepatitis in cryptogenic cirrhosis. <b>2012</b> , 49, 245-9	1

1242	Regulation of obesity and lipid disorders by extracts from <i>Angelica acutiloba</i> root in high-fat diet-induced obese rats. <b>2012</b> , 26, 223-30	10
1241	Validation of MRI biomarkers of hepatic steatosis in the presence of iron overload in the ob/ob mouse. <b>2012</b> , 35, 844-51	34
1240	Liver-vessel cancellation artifact on in-phase and out-of-phase MRI imaging: a sign of ultra-high liver fat content. <b>2012</b> , 35, 1112-8	3
1239	Accuracy of MR elastography and anatomic MR imaging features in the diagnosis of severe hepatic fibrosis and cirrhosis. <b>2012</b> , 35, 1356-64	99
1238	The interleukin 28B rs12979860 C/T polymorphism and serum cholesterol as predictors of fibrosis progression in patients with chronic hepatitis C and persistently normal transaminases. <b>2012</b> , 84, 747-55	11
1237	Transient elastography identifies liver recipients with nonviral graft disease after transplantation: a guide for liver biopsy. <b>2012</b> , 18, 566-76	24
1236	ISMRM workshop on fat-water separation: insights, applications and progress in MRI. <b>2012</b> , 68, 378-88	117
1235	Hepatic ratio of phosphatidylcholine to phosphatidylethanolamine predicts survival after partial hepatectomy in mice. <b>2012</b> , 55, 1094-102	54
1234	Endoplasmic reticulum-tethered transcription factor cAMP responsive element-binding protein, hepatocyte specific, regulates hepatic lipogenesis, fatty acid oxidation, and lipolysis upon metabolic stress in mice. <b>2012</b> , 55, 1070-82	135
1233	Ursodeoxycholy l lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease. <b>2012</b> , 55, 1369-78	57
1232	Clinical cofactors and hepatic fibrosis in hereditary hemochromatosis: the role of diabetes mellitus. <b>2012</b> , 56, 904-11	31
1231	Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial. <b>2012</b> , 56, 922-32	181
1230	Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. <b>2012</b> , 56, 943-51	302
1229	Cirrhosis and portal hypertension. <b>2012</b> , 1079-1091.e2	
1228	Innate immune reactivity of the ileum-liver axis in nonalcoholic steatohepatitis. <b>2012</b> , 57, 1144-51	18
1227	The spontaneous course of liver enzymes and its correlation in nonalcoholic fatty liver disease. <b>2012</b> , 57, 1925-31	23
1226	The role of innate cells is coupled to a Th1-polarized immune response in pediatric nonalcoholic steatohepatitis. <b>2012</b> , 32, 611-21	39
1225	A case-control study on the effects of the apolipoprotein E genotypes in nonalcoholic fatty liver disease. <b>2012</b> , 39, 7381-8	18

1224	Antiobesity effect of <i>Tamarindus indica</i> L. pulp aqueous extract in high-fat diet-induced obese rats. <b>2012</b> , 66, 333-42	37
1223	An egg-enriched diet attenuates plasma lipids and mediates cholesterol metabolism of high-cholesterol fed rats. <b>2012</b> , 47, 269-77	13
1222	Development of novel rat model for high-fat and high-cholesterol diet-induced steatohepatitis and severe fibrosis progression in SHRSP5/Dmcr. <b>2012</b> , 17, 173-82	38
1221	Specificity of unenhanced CT for non-invasive diagnosis of hepatic steatosis: implications for the investigation of the natural history of incidental steatosis. <b>2012</b> , 22, 1075-82	110
1220	Growth hormone, dehydroepiandrosterone and adiponectin levels in non-alcoholic steatohepatitis: an endocrine signature for advanced fibrosis in obese patients. <b>2012</b> , 32, 279-86	36
1219	Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease. <b>2012</b> , 32, 297-302	161
1218	Transition from hepatic steatosis to steatohepatitis: unique microRNA patterns and potential downstream functions and pathways. <b>2012</b> , 27, 331-40	30
1217	Transitional features of histologic type of non-alcoholic fatty liver disease in Korean young men. <b>2012</b> , 27, 142-8	1
1216	Histological features of non-alcoholic fatty liver disease: what is important?. <b>2012</b> , 27, 5-7	15
1215	Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. <b>2012</b> , 35, 66-75	213
1214	The epidemiology, pathogenesis and histopathology of fatty liver disease. <b>2012</b> , 61, 141-52	125
1213	Regulation of lipid disorders by ethanol extracts from <i>Zingiber zerumbet</i> in high-fat diet-induced rats. <b>2012</b> , 132, 460-7	20
1212	Effect of omega-3 polyunsaturated fatty acids to reverse biopsy-proven parenteral nutrition-associated liver disease in adults. <b>2012</b> , 31, 217-23	61
1211	Spontaneously hypertensive rats develop pronounced hepatic steatosis induced by choline-deficient diet: Evidence for hypertension as a potential enhancer in non-alcoholic steatohepatitis. <b>2012</b> , 42, 310-20	10
1210	Usefulness of Technetium-99 m-2-methoxy-isobutyl-isonitrile liver scintigraphy for evaluating disease activity of non-alcoholic fatty liver disease. <b>2012</b> , 42, 273-9	9
1209	Recent trend of clinical features in patients with hepatocellular carcinoma. <b>2012</b> , 42, 368-75	68
1208	Clinical and pathological progression of non-alcoholic steatohepatitis to hepatocellular carcinoma. <b>2012</b> , 42, 767-73	45
1207	Efficacy of rosuvastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study. <b>2012</b> , 42, 1065-72	33

1206	Non-alcoholic fatty liver disease impairs hippocampal-dependent memory in male rats. <b>2012</b> , 106, 133-41	38
1205	Unconjugated hyperbilirubinemia is inversely associated with non-alcoholic steatohepatitis (NASH). <b>2012</b> , 35, 1416-23	31
1204	Characterization of nonalcoholic fatty liver disease unrelated to the metabolic syndrome. <b>2012</b> , 42, 411-8	31
1203	CD14 expression and Kupffer cell dysfunction in non-alcoholic steatohepatitis: superparamagnetic iron oxide-magnetic resonance image and pathologic correlation. <b>2012</b> , 27, 789-96	20
1202	Involvement of a periodontal pathogen, Porphyromonas gingivalis on the pathogenesis of non-alcoholic fatty liver disease. <b>2012</b> , 12, 16	160
1201	Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. <b>2012</b> , 55, 429-36	219
1200	Hepatic steatosis, fibrosis, and cancer in elderly cadavers. <b>2012</b> , 295, 40-50	18
1199	Non-alcoholic fatty liver disease: is iron relevant?. <b>2012</b> , 6, 332-41	31
1198	Clinical predictors of different grades of nonalcoholic fatty liver disease. <b>2012</b> , 22, 248-52	11
1197	Modulation of ammonium perfluorooctanoate-induced hepatic damage by genetically different PPAR $\alpha$ mice. <b>2012</b> , 86, 63-74	21
1196	Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. <b>2012</b> , 57, 545-53	290
1195	Autophagy may precede cellular senescence of bile ductular cells in ductular reaction in primary biliary cirrhosis. <b>2012</b> , 57, 660-6	34
1194	Rosiglitazone and bezafibrate modulate gene expression in a rat model of non-alcoholic fatty liver disease--a historical prospective. <b>2013</b> , 12, 41	8
1193	Rapid regression of atherosclerosis with MTP inhibitor treatment. <b>2013</b> , 227, 125-9	42
1192	Pediatric non alcoholic fatty liver disease: old and new concepts on development, progression, metabolic insight and potential treatment targets. <b>2013</b> , 13, 40	107
1191	Plasmatic higher levels of homocysteine in non-alcoholic fatty liver disease (NAFLD). <b>2013</b> , 12, 37	56
1190	Desmosterol in human nonalcoholic steatohepatitis. <b>2013</b> , 58, 976-82	34
1189	Lipid biomarkers and metabolic effects of lycopene from tomato juice on liver of rats with induced hepatic steatosis. <b>2013</b> , 24, 1870-81	38

1188	Current histological classification of NAFLD: strength and limitations. <b>2013</b> , 7 Suppl 2, 765-70	33
1187	Three-dimensional magnetic resonance imaging for stringent diagnosis of advanced fibrosis associated with nonalcoholic steatohepatitis. <b>2013</b> , 7, 850-8	6
1186	B cell-activating factor is associated with the histological severity of nonalcoholic fatty liver disease. <b>2013</b> , 7, 539-47	27
1185	Impact of combined therapy with alpha-lipoic and ursodeoxycolic acid on nonalcoholic fatty liver disease: double-blind, randomized clinical trial of efficacy and safety. <b>2013</b> , 7, 570-6	17
1184	Analysis of discordance between transient elastography and liver biopsy for assessing liver fibrosis in chronic hepatitis B virus infection. <b>2013</b> , 7, 134-43	9
1183	In the non-cirrhotic stage of nonalcoholic steatohepatitis, angioarchitecture of portal veins and lobular architecture are maintained. <b>2013</b> , 462, 533-40	5
1182	Serum metabolomic profile and potential biomarkers for severity of fibrosis in nonalcoholic fatty liver disease. <b>2013</b> , 48, 1392-400	48
1181	Increased hepatic oxidative DNA damage in patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. <b>2013</b> , 48, 1249-58	59
1180	Clinicopathological features of liver injury in patients with type 2 diabetes mellitus and comparative study of histologically proven nonalcoholic fatty liver diseases with or without type 2 diabetes mellitus. <b>2013</b> , 48, 515-25	19
1179	Curcumin and liver disease. <b>2013</b> , 39, 88-100	91
1178	Association between hepatic steatosis and hepatic expression of genes involved in innate immunity in patients with chronic hepatitis C. <b>2013</b> , 63, 145-50	3
1177	Liver fat volume fraction quantification with fat and water T1 and T2* estimation and accounting for NMR multiple components in patients with chronic liver disease at 1.5 and 3.0 T. <b>2013</b> , 23, 2175-86	26
1176	Association between novel MRI-estimated pancreatic fat and liver histology-determined steatosis and fibrosis in non-alcoholic fatty liver disease. <b>2013</b> , 37, 630-9	88
1175	Evaluation of the Liver Fibrosis Index calculated by using real-time tissue elastography for the non-invasive assessment of liver fibrosis in chronic liver diseases. <b>2013</b> , 43, 735-42	18
1174	Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. <b>2013</b> , 1281, 106-22	183
1173	Obstructive sleep apnea is associated with fatty liver and abnormal liver enzymes: a meta-analysis. <b>2013</b> , 23, 1815-25	64
1172	Is nonalcoholic steatohepatitis associated with a high-though-normal thyroid stimulating hormone level and lower cholesterol levels?. <b>2013</b> , 8, 297-305	57
1171	Association between anthropometric parameters and measurements of liver stiffness by transient elastography. <b>2013</b> , 11, 295-302.e1-3	48



1170	Non-alcoholic steatohepatitis: a non-invasive diagnosis by analysis of exhaled breath. <b>2013</b> , 58, 543-8	40
1169	[Fatty liver and metabolic syndrome]. <b>2013</b> , 141, 252-3	2
1168	Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. <b>2013</b> ,	
1167	Prognostic implication of liver histology in patients with nonalcoholic fatty liver disease in diabetes. <b>2013</b> , 27, 293-300	39
1166	Value of acoustic radiation force impulse imaging elastography for non-invasive evaluation of patients with nonalcoholic fatty liver disease. <b>2013</b> , 39, 1942-50	69
1165	Quercetin decreases liver damage in mice with non-alcoholic steatohepatitis. <b>2013</b> , 112, 385-91	39
1164	Gut microbiota and non-alcoholic fatty liver disease: new insights. <b>2013</b> , 19, 338-48	157
1163	Severity of non-alcoholic steatohepatitis is associated with substitution of adipose tissue in skeletal muscle. <b>2013</b> , 28, 1507-14	75
1162	Persistent fibrosis in the liver of choline-deficient and iron-supplemented L-amino acid-defined diet-induced nonalcoholic steatohepatitis rat due to continuing oxidative stress after choline supplementation. <b>2013</b> , 268, 264-77	30
1161	Nonalcoholic fatty liver disease and the metabolic syndrome: clinical implications and treatment. <b>2013</b> , 28, 40-51	46
1160	Investigation of the factors associated with circulating soluble CD36 levels in patients with HCV-related chronic liver disease. <b>2013</b> , 5, 51	8
1159	Influence of liver histopathology on transaminitis following total pancreatectomy and autologous islet transplantation. <b>2013</b> , 58, 1349-54	10
1158	Markers in nonalcoholic steatohepatitis. <b>2013</b> , 61, 67-125	12
1157	Heterogeneity of fibrosis patterns in non-alcoholic fatty liver disease supports the presence of multiple fibrogenic pathways. <b>2013</b> , 33, 624-32	40
1156	Controlled attenuation parameter for non-invasive assessment of hepatic steatosis: does etiology affect performance?. <b>2013</b> , 28, 1194-201	75
1155	Combining transient elastography with FIB4 enhances sensitivity in detecting advanced fibrosis of the liver. <b>2013</b> , 48, 93-100	14
1154	Cassia tora (Leguminosae) seed extract alleviates high-fat diet-induced nonalcoholic fatty liver. <b>2013</b> , 51, 194-201	15
1153	Animal models of chronic liver diseases. <b>2013</b> , 304, G449-68	137

1152	Antioxidant effect of apolipoprotein A-I on high-fat diet-induced non-alcoholic fatty liver disease in rabbits. <b>2013</b> , 45, 95-103	16
1151	Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease. <b>2013</b> , 62, 1356-63	235
1150	High dietary salt decreases antioxidant defenses in the liver of fructose-fed insulin-resistant rats. <b>2013</b> , 24, 2016-22	16
1149	The ratio of insulin-like growth factor-I/insulin-like growth factor-binding protein-3 in sera of patients with hepatitis C virus-related chronic liver disease as a predictive marker of insulin resistance. <b>2013</b> , 33, 27-33	11
1148	Nonalcoholic Steatohepatitis: Diagnostic Challenges. <b>2013</b> , 6, 227-57	2
1147	Hepatic fibrosis and serum alpha-fetoprotein (AFP) as predictors of response to HCV treatment and factors associated with serum AFP normalisation after treatment. <b>2013</b> , 14, 94-8	10
1146	Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment. <b>2013</b> , 305, G483-95	153
1145	Bariatric surgery in patients with liver cirrhosis. <b>2013</b> , 9, 1-6	100
1144	Focal fat deposition at liver MRI with gadobenate dimeglumine and gadoxetic acid: Quantitative and qualitative analysis. <b>2013</b> , 31, 911-7	10
1143	Non-alcoholic fatty liver disease. <b>2013</b> , 23, 529-534	3
1142	Marked 25-hydroxyvitamin D deficiency is associated with poor prognosis in patients with alcoholic liver disease. <b>2013</b> , 59, 344-50	81
1141	The pro-inflammatory action of tumour necrosis factor- $\alpha$ in non-alcoholic steatohepatitis is independent of the NSMAF gene product. <b>2013</b> , 45, 147-54	6
1140	Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods. <b>2013</b> , 37, 392-400	126
1139	Intestinal microbiota in patients with nonalcoholic fatty liver disease. <b>2013</b> , 58, 120-7	461
1138	Hepatic and extrahepatic malignancies in cirrhosis caused by nonalcoholic steatohepatitis and alcoholic liver disease. <b>2013</b> , 37 Suppl 1, E247-52	31
1137	The performance of transient elastography compared to clinical acumen and routine tests - what is the incremental diagnostic value?. <b>2013</b> , 33, 172-9	5
1136	Dental infection of Porphyromonas gingivalis exacerbates high fat diet-induced steatohepatitis in mice. <b>2013</b> , 48, 1259-70	77
1135	Non-alcoholic fatty liver disease contributes to hepatocarcinogenesis in non-cirrhotic liver: a clinical and pathological study. <b>2013</b> , 28, 848-54	86

1134	Patients with Nonalcoholic Fatty Liver Disease (NAFLD) have Higher Oxidative Stress in Comparison to Chronic Viral Hepatitis. <b>2013</b> , 3, 12-8	40
1133	Liver steatosis assessment: correlations among pathology, radiology, clinical data and automated image analysis software. <b>2013</b> , 209, 371-9	47
1132	Angiotensin 1-7 as means to prevent the metabolic syndrome: lessons from the fructose-fed rat model. <b>2013</b> , 62, 1121-30	55
1131	Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. <b>2013</b> , 267, 422-31	306
1130	The role of transient elastography in the detection of liver disease in patients with chronic pancreatitis. <b>2013</b> , 33, 1121-7	4
1129	Effects of sitagliptin on nonalcoholic fatty liver disease in diet-induced obese rats. <b>2013</b> , 11, 243-50	25
1128	Amelioration of hepatic inflammation in a mouse model of NASH using a dithiocarbamate derivative. <b>2013</b> , 7, 600-9	4
1127	Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. <b>2013</b> ,	
1126	The relationship between copper and steatosis in Wilson's disease. <b>2013</b> , 37, 36-40	25
1125	Plant-based foods as a source of lipotropes for human nutrition: a survey of in vivo studies. <b>2013</b> , 53, 535-90	32
1124	Association of peroxisome proliferator activated receptor- $\alpha$ gene with non-alcoholic fatty liver disease in Asian Indians residing in north India. <b>2013</b> , 512, 143-7	23
1123	Clinical implications of chronic hepatitis E virus infection in heart transplant recipients. <b>2013</b> , 32, 78-85	58
1122	Maternal high-fat intake during pregnancy programs metabolic-syndrome-related phenotypes through liver mitochondrial DNA copy number and transcriptional activity of liver PPARGC1A. <b>2013</b> , 24, 6-13	82
1121	Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. <b>2013</b> , CD008623	57
1120	Circulating levels of FGF-21 in obese youth: associations with liver fat content and markers of liver damage. <b>2013</b> , 98, 2993-3000	69
1119	Inhibitory effect of a <i>Cirsium setidens</i> extract on hepatic fat accumulation in mice fed a high-fat diet via the induction of fatty acid $\beta$ oxidation. <b>2013</b> , 77, 1424-9	15
1118	Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). <b>2013</b> , 33, 1398-405	173
1117	Lycopene metabolite, apo-10'-lycopenoic acid, inhibits diethylnitrosamine-initiated, high fat diet-promoted hepatic inflammation and tumorigenesis in mice. <b>2013</b> , 6, 1304-16	73

1116	Higher hepatic gene expression and serum levels of matrix metalloproteinase-2 are associated with steatohepatitis in non-alcoholic fatty liver diseases. <b>2013</b> , 18, 82-7	17
1115	Influence of age and gender before and after liver transplantation. <b>2013</b> , 19, 122-34	39
1114	Genetic variation at NCAN locus is associated with inflammation and fibrosis in non-alcoholic fatty liver disease in morbid obesity. <b>2013</b> , 75, 34-43	66
1113	Diabetes and nonalcoholic Fatty liver disease: a pathogenic duo. <b>2013</b> , 34, 84-129	157
1112	Association of Adiponectin rs1501299 and rs266729 Gene Polymorphisms With Nonalcoholic Fatty Liver Disease. <b>2013</b> , 13, e9527	54
1111	Cardiovascular disease is associated with high-fat-diet-induced liver damage and up-regulation of the hepatic expression of hypoxia-inducible factor 1 in a rat model. <b>2013</b> , 124, 53-63	23
1110	Increased thickness of abdominal subcutaneous adipose tissue occurs more frequently in steatohepatitis than in simple steatosis. <b>2013</b> , 137, 642-6	1
1109	Sonographic evaluation for predicting the presence and severity of coronary artery disease. <b>2013</b> , 29, 125-30	13
1108	Hepatic fat loss in advanced nonalcoholic steatohepatitis: are alterations in serum adiponectin the cause?. <b>2013</b> , 57, 2180-8	95
1107	Predictive value of the adiponectin to leptin ratio for diagnosis of steatohepatitis in patients with nonalcoholic fatty liver disease. <b>2013</b> , 3, 47-53	
1106	Assessment of liver biopsies in obese patients. <b>2013</b> , 36, 285-291	
1105	Stepwise combination of simple noninvasive fibrosis scoring systems increases diagnostic accuracy in nonalcoholic fatty liver disease. <b>2013</b> , 47, 719-26	23
1104	Revisiting the topic of histochemically detectable copper in various liver diseases with special focus on venous outflow impairment. <b>2013</b> , 139, 79-86	17
1103	Hepatic steatosis: quantification by proton density fat fraction with MR imaging versus liver biopsy. <b>2013</b> , 267, 767-75	251
1102	The expanding role of fish models in understanding non-alcoholic fatty liver disease. <b>2013</b> , 6, 905-14	63
1101	Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial. <b>2013</b> , 6, 249-59	87
1100	Immunological and molecular basis of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease. <b>2013</b> , 9, 727-38	7
1099	Clinical usefulness of non-protein respiratory quotient measurement in non-alcoholic fatty liver disease. <b>2013</b> , 43, 1284-94	4

1098	Fatty liver Shionogi-ob/ob mouse: A new candidate for a non-alcoholic steatohepatitis model. <b>2013</b> , 43, 547-56	12
1097	Serum biomarkers in type 2 diabetic patients with non-alcoholic steatohepatitis and advanced fibrosis. <b>2013</b> , 43, 508-15	22
1096	A Reappraisal of Chemotherapy-Induced Liver Injury in Colorectal Liver Metastases before the Era of Antiangiogenics. <b>2013</b> , 2013, 314868	15
1095	Definiciones, factores de riesgo y pruebas diagn�sticas en la enfermedad por h�gado Graso No Alcoh�lico. <b>2013</b> , 2, S48-S52	78
1094	Retinol binding protein-4 circulating levels were higher in nonalcoholic fatty liver disease vs. histologically normal liver from morbidly obese women. <b>2013</b> , 21, 170-7	43
1093	Association of nicotinamide-N-methyltransferase gene rs694539 variant with patients with nonalcoholic steatohepatitis. <b>2013</b> , 17, 849-53	22
1092	Circulating MicroRNAs as potential biomarkers for alcoholic steatohepatitis. <b>2013</b> , 33, 1257-65	35
1091	Alterations in adipocytokines and cGMP homeostasis in morbid obesity patients reverse after bariatric surgery. <b>2013</b> , 21, 229-37	17
1090	Toxicant-associated steatohepatitis. <b>2013</b> , 41, 343-60	122
1089	Incidence and risk factors for new-onset diabetes in living-donor liver transplant recipients. <b>2013</b> , 27, 426-35	38
1088	Hepatic steatosis estimated microscopically versus digital image analysis. <b>2013</b> , 33, 926-35	29
1087	Reproducibility of hepatic fat fraction measurement by magnetic resonance imaging. <b>2013</b> , 37, 1359-70	58
1086	Nonalcoholic fatty liver disease in severely obese adolescent and adult patients. <b>2013</b> , 21, 591-7	52
1085	Ginsenoside Rb1 reduces fatty liver by activating AMP-activated protein kinase in obese rats. <b>2013</b> , 54, 1430-8	91
1084	Pathology of NAFLD. <b>2013</b> , 27-36	2
1083	Steatosis in the liver. <b>2013</b> , 3, 1493-532	27
1082	Current management of patients with nonalcoholic fatty liver disease. <b>2013</b> , 8, 549-558	1
1081	Characteristics and diagnosis of NAFLD/NASH. <b>2013</b> , 28 Suppl 4, 64-70	141

1080	Electron Therapy Attenuated Elevated Alanine Aminotransferase and Oxidative Stress Values in Type 2 Diabetes-Induced Nonalcoholic Steatohepatitis of Rats. <b>2013</b> , 6, 63-73	2
1079	Application and validation of a new histologic staging and grading system for primary biliary cirrhosis. <b>2013</b> , 47, 174-81	27
1078	Abusive drinking after liver transplantation is associated with allograft loss and advanced allograft fibrosis. <b>2013</b> , 19, 1377-86	107
1077	Adiponectin, bile acids, and burnt-out nonalcoholic steatohepatitis: new light on an old paradox. <b>2013</b> , 57, 2106-9	9
1076	Emerging quantitative magnetic resonance imaging biomarkers of hepatic steatosis. <b>2013</b> , 58, 1877-80	35
1075	Solute carrier family 2 member 1 is involved in the development of nonalcoholic fatty liver disease. <b>2013</b> , 57, 505-14	18
1074	Interobserver concordance in controlled attenuation parameter measurement, a novel tool for the assessment of hepatic steatosis on the basis of transient elastography. <b>2013</b> , 25, 905-11	29
1073	Transient elastography for diagnosis of hepatic fibrosis in people with alcoholic liver disease. <b>2013</b> ,	1
1072	Treatment of nonalcoholic steatohepatitis with vitamins E and C: a pilot study. <b>2013</b> , 5, 11-6	16
1071	Nonalcoholic steatohepatitis in nonalcoholic fatty liver disease patients of Bangladesh. <b>2013</b> , 5, 281-7	26
1070	Performance of liver stiffness measurements by transient elastography in chronic hepatitis. <b>2013</b> , 19, 49-56	33
1069	The spectrum of non alcoholic fatty liver disease in morbidly obese patients: prevalence and associate risk factors. <b>2013</b> , 28, 788-93	20
1068	Nonalcoholic steatohepatitis on preoperative period of gastric bypass: lack of correlation with degree of obesity. <b>2013</b> , 26 Suppl 1, 39-42	5
1067	Is increased red cell distribution width an indicating marker of nonalcoholic steatohepatitis and fibrotic stage?. <b>2013</b> , 19, 7412-8	27
1066	Melatonin attenuates high fat diet-induced fatty liver disease in rats. <b>2013</b> , 5, 160-9	44
1065	Curcumin attenuated paracetamol overdose induced hepatitis. <b>2013</b> , 19, 1962-7	27
1064	Diagnostic performance of a rapid magnetic resonance imaging method of measuring hepatic steatosis. <b>2013</b> , 8, e59287	10
1063	Peroxisome proliferator-activated receptors-alpha and gamma are targets to treat offspring from maternal diet-induced obesity in mice. <b>2013</b> , 8, e64258	54

1062	Fatty liver is associated with transcriptional downregulation of stearyl-CoA desaturase and impaired protein dimerization. <b>2013</b> , 8, e76912	17
1061	Nonalcoholic fatty liver disease in severe obese patients, subjected to bariatric surgery. <b>2013</b> , 50, 285-9	15
1060	Murine Models of Nonalcoholic Fatty Liver Disease and Steatohepatitis. <b>2013</b> , 2013, 237870	3
1059	Non-invasive assessment of liver fibrosis with transient elastography (FibroScan <sup>®</sup> ): applying the cut-offs of M probe to XL probe. <b>2013</b> , 12, 402-412	15
1058	Prevalence of insulin resistance in chronic hepatitis C genotype 1 and 3 patients. <b>2013</b> , 12, 871-875	8
1057	Prevalence and Predictors of Nonalcoholic Steatohepatitis in Obese Patients Undergoing Bariatric Surgery: A Department of Defense Experience. <b>2014</b> , 80, 595-599	19
1056	Non-alcoholic fatty liver disease and diabetes: from physiopathological interplay to diagnosis and treatment. <b>2014</b> , 20, 8377-92	53
1055	Viscoelastic parameters for quantifying liver fibrosis: three-dimensional multifrequency MR elastography study on thin liver rat slices. <b>2014</b> , 9, e94679	17
1054	Distinct patterns of the lipid alterations between genotype 1 and 2 chronic hepatitis C patients after viral clearance. <b>2014</b> , 9, e104783	21
1053	Protective role of plant sterol and stanol esters in liver inflammation: insights from mice and humans. <b>2014</b> , 9, e110758	37
1052	Transcriptome analysis on the inflammatory cell infiltration of nonalcoholic steatohepatitis in bama minipigs induced by a long-term high-fat, high-sucrose diet. <b>2014</b> , 9, e113724	24
1051	Establishment of a general NAFLD scoring system for rodent models and comparison to human liver pathology. <b>2014</b> , 9, e115922	215
1050	Nonalcoholic fatty liver disease: different classifications concordance and relationship between degrees of morphological features and spectrum of the disease. <b>2014</b> , 2014, 526979	10
1049	Biomarkers in nonalcoholic fatty liver disease. <b>2014</b> , 28, 607-18	91
1048	Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. <b>2014</b> , 20, 15539-48	192
1047	Surgical treatment of nonalcoholic fatty liver disease in severely obese patients. <b>2014</b> , 6, 103-12	8
1046	Pathology of alcoholic liver disease, can it be differentiated from nonalcoholic steatohepatitis?. <b>2014</b> , 20, 16474-9	58
1045	The role of interleukin-6 and interleukin-8 gene polymorphisms in non-alcoholic steatohepatitis. <b>2014</b> , 14, e24635	9

1044	Questionnaire survey on lifestyle of patients with nonalcoholic steatohepatitis. <b>2014</b> , 55, 191-5	4
1043	Clinical differences between alcoholic liver disease and nonalcoholic fatty liver disease. <b>2014</b> , 20, 8393-406	71
1042	Can serum pin1 level be regarded as an indicative marker of nonalcoholic steatohepatitis and fibrotic stages?. <b>2014</b> , 90, 35-41	12
1041	Non-alcoholic fatty liver disease: diagnosis and investigation. <b>2014</b> , 32, 586-96	8
1040	Clinical usage of serum ferritin to assess liver fibrosis in patients with non-alcoholic fatty liver disease: Proceed with caution. <b>2014</b> , 44, E499-502	17
1039	Impaired autophagic flux is associated with increased endoplasmic reticulum stress during the development of NAFLD. <b>2014</b> , 5, e1179	325
1038	Gene polymorphisms of cellular senescence marker p21 and disease progression in non-alcohol-related fatty liver disease. <b>2014</b> , 13, 1489-94	44
1037	Non-alcoholic fatty liver disease in obese adults: clinical aspects and current management strategies. <b>2014</b> , 4, 243-53	20
1036	Autophagy and non-alcoholic fatty liver disease. <b>2014</b> , 2014, 120179	81
1035	Evaluation of hepatic tissue blood flow using xenon computed tomography with fibrosis progression in nonalcoholic fatty liver disease: comparison with chronic hepatitis C. <b>2014</b> , 15, 1026-39	7
1034	Reducing Liver Fat by Low Carbohydrate Caloric Restriction Targets Hepatic Glucose Production in Non-Diabetic Obese Adults with Non-Alcoholic Fatty Liver Disease. <b>2014</b> , 3, 1050-63	21
1033	Hepatic chemerin and chemokine-like receptor 1 expression in patients with chronic hepatitis C. <b>2014</b> , 2014, 517820	10
1032	Lingonberry ( <i>Vaccinium vitis-idaea</i> L.) Exhibits Antidiabetic Activities in a Mouse Model of Diet-Induced Obesity. <b>2014</b> , 2014, 645812	28
1031	Nonalcoholic Fatty liver disease/non-alcoholic steatohepatitis in childhood: endocrine-metabolic "mal-programming". <b>2014</b> , 14, e17641	13
1030	Fibrosis progression in interferon treatment-naïve Chinese plasma donors with chronic hepatitis C for 20 years: a cohort study. <b>2014</b> , 27, 49-53	11
1029	Endocannabinoid receptors gene expression in morbidly obese women with nonalcoholic fatty liver disease. <b>2014</b> , 2014, 502542	21
1028	Treatment of Nonalcoholic Fatty Liver Disease with Total Alkaloids in <i>Rubus aleaefolius</i> Poir through Regulation of Fat Metabolism. <b>2014</b> , 2014, 768540	7
1027	Rice Bran Oil and Pumpkin Seed Oil Alleviate Oxidative Injury and Fatty Liver in Rats Fed High Fructose Diet. <b>2014</b> , 64, 127-133	21



1026	Altered fatty acid metabolism-related gene expression in liver from morbidly obese women with non-alcoholic fatty liver disease. <b>2014</b> , 15, 22173-87	37
1025	Fatty Liver, NASH, and Alcoholic Liver Disease. <b>2014</b> , 1817-1824	1
1024	Silencing of microRNA-122 is an early event during hepatocarcinogenesis from non-alcoholic steatohepatitis. <b>2014</b> , 105, 1254-60	60
1023	Hepatic inflammation scores correlate with common carotid intima-media thickness in rats with NAFLD induced by a high-fat diet. <b>2014</b> , 10, 162	22
1022	The use of guideline images to improve histological estimation of hepatic steatosis. <b>2014</b> , 34, 1414-27	12
1021	Efficacy of probucol for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label pilot study. <b>2014</b> , 44, 429-35	8
1020	The role of fibroblast growth factor 21 in the pathogenesis of liver disease: a novel predictor and therapeutic target. <b>2014</b> , 18, 1305-13	21
1019	Feasibility of liver weight estimation by postmortem computed tomography images: an autopsy study. <b>2014</b> , 64, 315-24	11
1018	Histopathological aspects of liver under variable food restriction: has the intense one-week food restriction a protective effect on non-alcoholic-fatty-liver-disease (NAFLD) development?. <b>2014</b> , 210, 855-62	5
1017	Prevalence and natural history of histologically proven chronic liver disease in a longitudinal cohort of patients with type 1 diabetes. <b>2014</b> , 60, 158-68	27
1016	Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfecting adults: prospective analysis of 435 liver biopsy pairs. <b>2014</b> , 59, 767-75	70
1015	Determination of normal hepatic elasticity by using real-time shear-wave elastography. <b>2014</b> , 271, 895-900	53
1014	Liver fat quantification using a multi-step adaptive fitting approach with multi-echo GRE imaging. <b>2014</b> , 72, 1353-65	138
1013	Lipoprotein subclass metabolism in nonalcoholic steatohepatitis. <b>2014</b> , 55, 2676-84	51
1012	Chemoprevention of nonalcoholic fatty liver disease by dietary natural compounds. <b>2014</b> , 58, 147-71	63
1011	Extracellular matrix and cytochrome P450 gene expression can distinguish steatohepatitis from steatosis in mice. <b>2014</b> , 18, 1762-72	15
1010	Progression of liver fibrosis in HIV/hepatitis C virus-coinfecting individuals on antiretroviral therapy with early stages of liver fibrosis at baseline. <b>2014</b> , 15, 203-12	16
1009	A pilot study estimating liver fibrosis with ultrasound shear-wave elastography: does the cause of liver disease or location of measurement affect performance?. <b>2014</b> , 203, W267-73	28

1008	Clinical, anthropometric, biochemical, and histological characteristics of nonobese nonalcoholic fatty liver disease patients of Bangladesh. <b>2014</b> , 33, 452-7	40
1007	Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C. <b>2014</b> , 60, 521-30	115
1006	The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease. <b>2014</b> , 59, 1393-405	235
1005	Choline supplementation protects against liver damage by normalizing cholesterol metabolism in Pemt/Ldlr knockout mice fed a high-fat diet. <b>2014</b> , 144, 252-7	35
1004	Long-term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease. <b>2014</b> , 14, 166	61
1003	Prediction of response to pegylated interferon and ribavirin in Egyptian patients with chronic hepatitis C using serum neopterin. <b>2014</b> , 4, 63-68	
1002	Pentoxifylline for the treatment of nonalcoholic fatty liver disease: a meta-analysis of randomized double-blind, placebo-controlled studies. <b>2014</b> , 26, 646-53	33
1001	Hematocrit is associated with fibrosis in patients with nonalcoholic steatohepatitis. <b>2014</b> , 26, 332-8	10
1000	Fat and iron quantification in the liver: past, present, and future. <b>2014</b> , 23, 73-94	33
999	Shear wave elastography in the evaluation of liver fibrosis in children. <b>2014</b> , 58, 750-5	53
998	Simple non-invasive biomarkers of advanced fibrosis in the evaluation of non-alcoholic fatty liver disease. <b>2014</b> , 2, 276-80	37
997	Evidence of endoplasmic reticulum stress and liver inflammation in the American mink Neovison vison with benign hepatic steatosis. <b>2014</b> , 184, 913-27	2
996	Long-term intake of soyabean phytosterols lowers serum TAG and NEFA concentrations, increases bile acid synthesis and protects against fatty liver development in dyslipidaemic hamsters. <b>2014</b> , 112, 663-73	20
995	Physiology of Morbid Obese Patients. <b>2014</b> , 3-9	
994	The Interaction between Diabetes, Body Mass Index, Hepatic Steatosis, and Risk of Liver Resection: Insulin Dependent Diabetes Is the Greatest Risk for Major Complications. <b>2014</b> , 2014, 586159	9
993	Hepatic molecular effects of rosiglitazone in human non-alcoholic steatohepatitis suggest long-term pro-inflammatory damage. <b>2014</b> , 44, 1241-1247	13
992	Lycopene attenuated hepatic tumorigenesis via differential mechanisms depending on carotenoid cleavage enzyme in mice. <b>2014</b> , 7, 1219-27	43
991	Non-invasive assessment of liver steatosis in non-alcoholic fatty liver disease. <b>2014</b> , 44, E420-7	16

990	Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population. <b>2014</b> , 34, 102-9	113
989	Inflammatory hepatocellular adenomatosis, metabolic syndrome, polycystic ovary syndrome and non-alcoholic steatohepatitis: chance tetrad or association by necessity?. <b>2014</b> , 46, 288-9	15
988	Simple steatosis is a more relevant source of serum inflammatory markers than omental adipose tissue. <b>2014</b> , 38, 46-54	16
987	Effects of <i>Xylopia aromatica</i> (Lam.) Mart. fruit on metabolic and inflammatory dysfunction induced by high refined carbohydrate-containing-diet in mice. <b>2014</b> , 62, 541-550	13
986	Metadoxine Versus Placebo for the Treatment of Non-alcoholic Steatohepatitis: A Randomized Controlled Trial. <b>2014</b> , 4, 94-100	12
985	Association of glucokinase regulatory gene polymorphisms with risk and severity of non-alcoholic fatty liver disease: an interaction study with adiponutrin gene. <b>2014</b> , 49, 1056-64	45
984	Oral choline tolerance test as a novel noninvasive method for predicting nonalcoholic steatohepatitis. <b>2014</b> , 49, 295-304	6
983	The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial. <b>2014</b> , 57, 878-90	86
982	Association between liver vitamin A reserves and severity of nonalcoholic fatty liver disease in the class III obese following bariatric surgery. <b>2014</b> , 24, 219-24	28
981	Genetic risk score does not predict the outcome of obesity surgery. <b>2014</b> , 24, 128-33	16
980	Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. <b>2014</b> , 49, 1477-84	87
979	Paediatric ultrasonography of the liver, hepatobiliary tract and pancreas. <b>2014</b> , 83, 1570-81	8
978	Pediatric non-alcoholic fatty liver disease: an increasing public health issue. <b>2014</b> , 173, 131-9	84
977	Nonalcoholic fatty liver disease and bariatric surgery in adolescents. <b>2014</b> , 23, 49-57	18
976	The role of histopathology in forensic practice: an overview. <b>2014</b> , 10, 401-12	16
975	Recommendations of a group of experts for the pathological assessment of tumour regression of liver metastases of colorectal cancer and damage of non-tumour liver tissue after neoadjuvant therapy. <b>2014</b> , 16, 234-42	6
974	New and Improved Imaging Modalities for NAFLD. <b>2014</b> , 13, 88-96	1
973	New Paradigms in the Histopathology of NAFLD. <b>2014</b> , 13, 81-87	

972	OxNASH score correlates with histologic features and severity of nonalcoholic fatty liver disease. <b>2014</b> , 59, 1617-24	33
971	Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia. <b>2014</b> , 60, 554-64	103
970	The impact of cereal grain consumption on the development and severity of non-alcoholic fatty liver disease. <b>2014</b> , 53, 1727-35	28
969	A cross-sectional study assessing dietary intake and physical activity in Canadian patients with nonalcoholic fatty liver disease vs healthy controls. <b>2014</b> , 114, 1181-94	60
968	Diets enriched in trans-11 vaccenic acid alleviate ectopic lipid accumulation in a rat model of NAFLD and metabolic syndrome. <b>2014</b> , 25, 692-701	50
967	Antioxidant properties of proanthocyanidins attenuate carbon tetrachloride (CCl <sub>4</sub> )-induced steatosis and liver injury in rats via CYP2E1 regulation. <b>2014</b> , 17, 663-9	50
966	Serum proteome of nonalcoholic fatty liver disease: a multimodal approach to discovery of biomarkers of nonalcoholic steatohepatitis. <b>2014</b> , 29, 1839-47	29
965	Are oxidative stress mechanisms the common denominator in the progression from hepatic steatosis towards non-alcoholic steatohepatitis (NASH)?. <b>2014</b> , 34, e180-90	73
964	Non-viral causes of liver cancer: does obesity led inflammation play a role?. <b>2014</b> , 345, 223-9	44
963	Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. <b>2014</b> , 60, 565-75	329
962	Nonalcoholic Fatty Liver Disease. <b>2014</b> , 145-169	1
961	Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease. <b>2014</b> , 60, 69-77	272
960	Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations. <b>2014</b> , 60, 1026-31	241
959	The role of renin-angiotensin system modulation on treatment and prevention of liver diseases. <b>2014</b> , 62, 189-96	68
958	Review article: The prevention and reversal of hepatic fibrosis in autoimmune hepatitis. <b>2014</b> , 39, 385-406	50
957	Chemotherapy-associated steatohepatitis induced by irinotecan: a novel animal model. <b>2014</b> , 74, 711-20	13
956	Mesenchymal stem cell therapy ameliorates diabetic hepatocyte damage in mice by inhibiting infiltration of bone marrow-derived cells. <b>2014</b> , 59, 1816-29	38
955	Wolfberries potentiate mitophagy and enhance mitochondrial biogenesis leading to prevention of hepatic steatosis in obese mice: the role of AMP-activated protein kinase $\alpha$ subunit. <b>2014</b> , 58, 1005-15	17

954	Role of FDFT1 polymorphism for fibrosis progression in patients with chronic hepatitis C. <b>2014</b> , 34, 388-95	14
953	Increased soluble CD36 is linked to advanced steatosis in nonalcoholic fatty liver disease. <b>2014</b> , 44, 65-73	31
952	Clinical but not histological factors predict long-term prognosis in patients with histologically advanced non-decompensated alcoholic liver disease. <b>2014</b> , 34, 235-42	22
951	Formylchromone exhibits salubrious effects against nitrosodiethylamine mediated early hepatocellular carcinogenesis in rats. <b>2014</b> , 219, 175-83	3
950	Limited correlation between conventional pathologist and automatic computer-assisted quantification of hepatic steatosis due to difference between event-based and surface-based analysis. <b>2014</b> , 18, 1473-7	10
949	Genetic variants in the PNPLA3 gene are associated with nonalcoholic steatohepatitis. <b>2014</b> , 18, 489-96	3
948	Maternal fat supplementation during late pregnancy and lactation influences the development of hepatic steatosis in offspring depending on the fat source. <b>2014</b> , 62, 1590-601	11
947	N-3 long-chain PUFA supplementation prevents high fat diet induced mouse liver steatosis and inflammation in relation to PPAR- $\alpha$ upregulation and NF- $\kappa$ B DNA binding abrogation. <b>2014</b> , 58, 1333-41	62
946	Quantification of hepatic fat and iron with magnetic resonance imaging. <b>2014</b> , 22, 397-416	12
945	Reversion to a control balanced diet is able to restore body weight and to recover altered metabolic parameters in adult rats long-term fed on a cafeteria diet. <b>2014</b> , 64, 839-848	17
944	Pathological features of fatty liver disease. <b>2014</b> , 147, 754-64	226
943	Aloe vera attenuated liver injury in mice with acetaminophen-induced hepatitis. <b>2014</b> , 14, 229	16
942	Novel equation to determine the hepatic triglyceride concentration in humans by MRI: diagnosis and monitoring of NAFLD in obese patients before and after bariatric surgery. <b>2014</b> , 12, 137	15
941	Comparative proteomic study reveals 17 $\beta$ HSD13 as a pathogenic protein in nonalcoholic fatty liver disease. <b>2014</b> , 111, 11437-42	116
940	Application of localized $^{31}$ P MRS saturation transfer at 7 T for measurement of ATP metabolism in the liver: reproducibility and initial clinical application in patients with non-alcoholic fatty liver disease. <b>2014</b> , 24, 1602-9	21
939	The association of insomnia with gastroesophageal reflux symptoms in biopsy-proven nonalcoholic fatty liver disease. <b>2014</b> , 49, 1163-74	4
938	Elevated plasma sphingomyelin (d18:1/22:0) is closely related to hepatic steatosis in patients with chronic hepatitis C virus infection. <b>2014</b> , 33, 1725-32	20
937	Segmental atrophy of the liver: an uncommon and often unrecognized pseudotumor. <b>2014</b> , 59, 3122-5	6

936	Natural history of hepatic steatosis: observed outcomes for subsequent liver and cardiovascular complications. <b>2014</b> , 202, 752-8	49
935	The relationship between hepatic resistin overexpression and inflammation in patients with nonalcoholic steatohepatitis. <b>2014</b> , 14, 39	44
934	Methotrexate and liver fibrosis in people with psoriasis: a systematic review of observational studies. <b>2014</b> , 171, 17-29	48
933	Adherence to the Mediterranean diet is associated with the severity of non-alcoholic fatty liver disease. <b>2014</b> , 33, 678-83	135
932	Cirrhosis and end-stage chronic liver disease: The changing scenes on etiopathogenesis. <b>2014</b> , 4, 62-77	
931	Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments. <b>2014</b> , 39, 254-69	249
930	Obstructive sleep apnea and hypoxemia are associated with advanced liver histology in pediatric nonalcoholic fatty liver disease. <b>2014</b> , 164, 699-706.e1	67
929	Apoptotic and anti-apoptotic seromarkers for assessment of disease severity of non-alcoholic steatohepatitis. <b>2014</b> , 15, 6-11	10
928	Procoagulant imbalance in patients with non-alcoholic fatty liver disease. <b>2014</b> , 61, 148-54	113
927	Recomendaciones para el estudio patológico de las metástasis hepáticas de cáncer colorrectal tras neoadyuvancia. Consenso Nacional de la Sociedad Española de Anatomía Patológica. <b>2014</b> , 47, 90-98	1
926	Assessment of liver fat in an obese patient population using noncontrast CT fat percent index. <b>2014</b> , 38, 259-64	2
925	Ultrasound in chronic liver disease. <b>2014</b> , 5, 441-55	59
924	Comparative effects of the renin-angiotensin system blockers on nonalcoholic fatty liver disease and insulin resistance in C57BL/6 mice. <b>2014</b> , 12, 191-201	17
923	Hematopoietic stem cells and liver regeneration: differentially acting hematopoietic stem cell mobilization agents reverse induced chronic liver injury. <b>2014</b> , 53, 124-32	33
922	Reversal of high-fat diet-induced hepatic steatosis by n-3 LCPUFA: role of PPAR- $\alpha$ and SREBP-1c. <b>2014</b> , 25, 977-84	44
921	Visceral fat predominance is associated with non-alcoholic fatty liver disease in Japanese women with metabolic syndrome. <b>2014</b> , 44, 515-22	16
920	Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. <b>2014</b> , 20, 475-85	296
919	Evaluation of fatty liver fibrosis in rabbits using real-time shear wave elastography. <b>2014</b> , 8, 355-362	10

918	Auricularia polytricha aqueous extract supplementation decreases hepatic lipid accumulation and improves antioxidative status in animal model of nonalcoholic fatty liver. <b>2014</b> , 4, 12	27
917	Adipokines, insulin resistance, hepatic steatosis, and necroinflammation in patients with chronic viral hepatitis. <b>2014</b> , 8, 557-564	
916	A potential link between endothelial function, cardiovascular risk, and metabolic syndrome in patients with Non-alcoholic fatty liver disease. <b>2014</b> , 6, 109	8
915	Prothrombotic factors in histologically proven nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. <b>2014</b> , 59, 121-9	112
914	Hepatic Steatosis as a Predictive Factor of Antiviral Effect of Pegylated Interferon Therapy in Patients With Hepatitis B. <b>2015</b> , 47, 2886-91	11
913	Liver histology and clinical trials for nonalcoholic steatohepatitis-perspectives from 2 pathologists. <b>2015</b> , 149, 1305-8	36
912	Visceral Obesity Predicts Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <b>2015</b> , 94, e2159	56
911	Ultrasonography for diagnosis of cirrhosis in people with alcoholic liver disease. <b>2015</b> ,	10
910	Serum alanine aminotransferase predicts the histological course of non-alcoholic steatohepatitis in Japanese patients. <b>2015</b> , 45, E53-61	32
909	Liver steatosis is associated with insulin resistance in skeletal muscle rather than in the liver in Japanese patients with non-alcoholic fatty liver disease. <b>2015</b> , 6, 158-63	31
908	Pathological evidence of the cause of spontaneous regression in a case of resected hepatocellular carcinoma. <b>2015</b> , 54, 25-30	8
907	Obesity Leads to Tissue, but not Serum Vitamin A Deficiency. <b>2015</b> , 5, 15893	53
906	Beneficial impact of GpnmB and its significance as a biomarker in nonalcoholic steatohepatitis. <b>2015</b> , 5, 16920	31
905	Systematic review of genetic association studies involving histologically confirmed non-alcoholic fatty liver disease. <b>2015</b> , 2, e000019	19
904	The effects of onion consumption on treatment of metabolic, histologic, and inflammatory features of nonalcoholic fatty liver disease. <b>2015</b> , 15, 25	23
903	Persistent organic pollutants and non-alcoholic fatty liver disease in morbidly obese patients: a cohort study. <b>2015</b> , 14, 79	39
902	Quantification of liver fat with respiratory-gated quantitative chemical shift encoded MRI. <b>2015</b> , 42, 1241-8	23
901	Influence of lifestyle-related diseases and age on the development and progression of non-alcoholic fatty liver disease. <b>2015</b> , 45, 548-59	19

900	Nonalcoholic fatty liver disease: a potential consequence of tumor necrosis factor-inhibitor therapy. <b>2015</b> , 27, 1154-60	17
899	Melatonin reduces hepatic mitochondrial dysfunction in diabetic obese rats. <b>2015</b> , 59, 70-9	60
898	Serum fibrosis biomarkers predict death and graft loss in liver transplantation recipients. <b>2015</b> , 21, 1383-94	15
897	Predictors of malignancies and overall mortality in Japanese patients with biopsy-proven non-alcoholic fatty liver disease. <b>2015</b> , 45, 728-38	24
896	Human placental extract treatment for non-alcoholic steatohepatitis non-responsive to lifestyle intervention: A pilot study. <b>2015</b> , 45, 1034-1040	10
895	Quantitative magnetic resonance imaging of hepatic steatosis: Validation in ex vivo human livers. <b>2015</b> , 62, 1444-55	91
894	Identification of compounds from high-fat and extra virgin olive oil-supplemented diets in whole mouse liver extracts and isolated mitochondria using mass spectrometry. <b>2015</b> , 50, 951-8	7
893	Prevalence and risk factors for biopsy-proven non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in a prospective cohort of adult patients with gallstones. <b>2015</b> , 35, 1983-91	17
892	Comparative diagnostic accuracy of red cell distribution width-to-platelet ratio versus noninvasive fibrosis scores for the diagnosis of liver fibrosis in biopsy-proven nonalcoholic fatty liver disease. <b>2015</b> , 27, 1293-9	7
891	Sitagliptin can inhibit the development of hepatic steatosis in high-fructose diet-fed ob/ob mice. <b>2015</b> , 57, 244-53	11
890	Genistein Attenuates Nonalcoholic Steatohepatitis and Increases Hepatic PPAR $\alpha$ in a Rat Model. <b>2015</b> , 2015, 509057	15
889	Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance. <b>2015</b> , 21, 11077-87	82
888	Correlation of Histopathologic Findings of Non-Graft Threatening Preservation/Reperfusion Injury in Time-Zero Liver Needle Biopsies With Short-Term Post-transplantation Laboratory Alterations. <b>2015</b> , 15, e30008	1
887	Comparison of magnetic resonance elastography and diffusion-weighted imaging for staging hepatic fibrosis. <b>2015</b> , 128, 620-5	9
886	Non-Alcoholic Steatohepatitis (NASH): Risk Factors in Morbidly Obese Patients. <b>2015</b> , 16, 25552-9	20
885	Normal range of hepatic fat fraction on dual- and triple-echo fat quantification MR in children. <b>2015</b> , 10, e0117480	13
884	Hyperuricemia Inversely Correlates with Disease Severity in Taiwanese Nonalcoholic Steatohepatitis Patients. <b>2015</b> , 10, e0139796	12
883	Peripheral and Hepatic Vein Cytokine Levels in Correlation with Non-Alcoholic Fatty Liver Disease (NAFLD)-Related Metabolic, Histological, and Haemodynamic Features. <b>2015</b> , 10, e0143380	43



882	Prognostic Value of Non-Invasive Fibrosis and Steatosis Tools, Hepatic Venous Pressure Gradient (HVPG) and Histology in Nonalcoholic Steatohepatitis. <b>2015</b> , 10, e0128774	46
881	Fish Oil Lipid Emulsion-Associated Sea-Blue Histiocyte Syndrome in a Pediatric Patient. <b>2015</b> , 20, 217-21	1
880	Nonalcoholic Fatty Liver Disease Relationship with Metabolic Syndrome in Class III Obesity Individuals. <b>2015</b> , 2015, 839253	9
879	Nonalcoholic Steatohepatitis: Involvement of the Telomerase and Proinflammatory Mediators. <b>2015</b> , 2015, 850246	7
878	Drug Induced Steatohepatitis: An Uncommon Culprit of a Common Disease. <b>2015</b> , 2015, 168905	68
877	To Biopsy or not to Biopsy: A Review of Guidelines on the use of Methotrexate. <b>2015</b> , 1, 31-37	
876	CD4+ROR $\gamma$ t++ and Tregs in a Mouse Model of Diet-Induced Nonalcoholic Steatohepatitis. <b>2015</b> , 2015, 239623	19
875	Chronic hepatitis B associated with hepatic steatosis, insulin resistance, necroinflammation and fibrosis. <b>2015</b> , 15, 714-8	17
874	Development of steatohepatitis in Ob/Ob mice is dependent on Toll-like receptor 4. <b>2015</b> , 14, 735-743	17
873	Histopathological differences utilizing the nonalcoholic fatty liver disease activity score criteria in diabetic (type 2 diabetes mellitus) and non-diabetic patients with nonalcoholic fatty liver disease. <b>2015</b> , 7, 2610-8	16
872	Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease. <b>2015</b> , 21, 1189-96	82
871	PTPRO-mediated autophagy prevents hepatosteatosis and tumorigenesis. <b>2015</b> , 6, 9420-33	20
870	Hepatic steatosis is prevalent in stillborns delivered to women with diabetes mellitus. <b>2015</b> , 60, 152-8	41
869	Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J). <b>2015</b> , 45, 269-78	108
868	Model to predict survival after surgical resection of intrahepatic cholangiocarcinoma: the Mayo Clinic experience. <b>2015</b> , 17, 244-50	40
867	EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. <b>2015</b> , 63, 237-64	1082
866	Non-invasive diagnostic approach to non-alcoholic fatty liver disease: current evidence and future perspectives. <b>2015</b> , 9, 1039-53	9
865	NADPH Oxidase-Derived Peroxynitrite Drives Inflammation in Mice and Human Nonalcoholic Steatohepatitis via TLR4-Lipid Raft Recruitment. <b>2015</b> , 185, 1944-57	31

864	The effect of surgically induced weight loss on nonalcoholic fatty liver disease in morbidly obese Indians: "NASHOST" prospective observational trial. <b>2015</b> , 11, 1315-22	59
863	Comparison between modified Dixon MRI techniques, MR spectroscopic relaxometry, and different histologic quantification methods in the assessment of hepatic steatosis. <b>2015</b> , 25, 2869-79	85
862	Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications. <b>2015</b> , 9, 603-27	79
861	Utility of Ultrasound, Transaminases, and Visual Inspection to Assess Nonalcoholic Fatty Liver Disease in Bariatric Surgery Patients. <b>2015</b> , 25, 2368-75	31
860	Increased abdominal fat levels measured by bioelectrical impedance are associated with histological lesions of nonalcoholic steatohepatitis. <b>2015</b> , 27, 907-13	7
859	Epigenetic Alterations in Human Liver From Subjects With Type 2 Diabetes in Parallel With Reduced Folate Levels. <b>2015</b> , 100, E1491-501	109
858	Association between nonalcoholic fatty liver disease and coronary artery calcification in postmenopausal women. <b>2015</b> , 22, 1323-7	24
857	Transient Elastography (FibroScan) Is Not Correlated With Liver Fibrosis but With Cholestasis in Patients With Long-Term Home Parenteral Nutrition. <b>2015</b> , 39, 719-24	41
856	Effects of 4-nonylphenol on oxidant/antioxidant balance system inducing hepatic steatosis in male rat. <b>2015</b> , 2, 1423-1433	24
855	Polydatin supplementation ameliorates diet-induced development of insulin resistance and hepatic steatosis in rats. <b>2015</b> , 11, 603-10	27
854	Fast and accurate identification of fat droplets in histological images. <b>2015</b> , 121, 59-65	7
853	PNPLA3 genotype increases susceptibility of nonalcoholic steatohepatitis among obese patients with nonalcoholic fatty liver disease. <b>2015</b> , 11, 888-94	12
852	Blood redox status is associated with the likelihood of nonalcoholic fatty liver disease irrespectively of diet's total antioxidant capacity. <b>2015</b> , 35, 41-8	18
851	Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop. <b>2015</b> , 61, 1392-405	223
850	Beneficial effects of neomangiferin on high fat diet-induced nonalcoholic fatty liver disease in rats. <b>2015</b> , 25, 218-28	22
849	Association Between Quantity of Liver Fat and Cardiovascular Risk in Patients With Nonalcoholic Fatty Liver Disease Independent of Nonalcoholic Steatohepatitis. <b>2015</b> , 13, 1513-20.e1	69
848	The association between retinal microvascular changes, metabolic risk factors, and liver histology in pediatric patients with non-alcoholic fatty liver disease (NAFLD). <b>2015</b> , 50, 903-12	13
847	Occult cirrhosis diagnosed by transient elastography is a frequent and under-monitored clinical entity. <b>2015</b> , 35, 2285-93	7

846	Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort). <b>2015</b> , 62, 737-50	69
845	Non-alcoholic fatty liver disease comorbid with major depressive disorder: The pathological features and poor therapeutic efficacy. <b>2015</b> , 30, 1009-14	40
844	Oral exposure to the anti-pyridoxine compound 1-amino D-proline further perturbs homocysteine metabolism through the transsulfuration pathway in moderately vitamin B12 deficient rats. <b>2015</b> , 26, 241-9	10
843	Role of serum toll-like receptors 2 and 4 in non-alcoholic steatohepatitis and liver fibrosis. <b>2015</b> , 30, 1190-6	28
842	Helicobacter pylori infection might have a potential role in hepatocyte ballooning in nonalcoholic fatty liver disease. <b>2015</b> , 50, 996-1004	41
841	Bariatric surgery improves histological features of nonalcoholic fatty liver disease and liver fibrosis. <b>2015</b> , 19, 429-36; discussion 436-7	85
840	Altered hepatic gene expression in nonalcoholic fatty liver disease is associated with lower hepatic n-3 and n-6 polyunsaturated fatty acids. <b>2015</b> , 61, 1565-78	141
839	Nonalcoholic fatty liver disease: Fibrosis portends a worse prognosis. <b>2015</b> , 61, 1462-4	12
838	Magnetic resonance imaging and liver histology as biomarkers of hepatic steatosis in children with nonalcoholic fatty liver disease. <b>2015</b> , 61, 1887-95	107
837	Nonalcoholic fatty liver disease: portal hypertension due to outflow block in patients without cirrhosis. <b>2015</b> , 274, 597-604	19
836	Vagus nerve contributes to the development of steatohepatitis and obesity in phosphatidylethanolamine N-methyltransferase deficient mice. <b>2015</b> , 62, 913-20	11
835	Utility of real-time shear wave elastography for assessing liver fibrosis in patients with chronic hepatitis C infection without cirrhosis: Comparison of liver fibrosis indices. <b>2015</b> , 45, E122-9	37
834	Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats. <b>2015</b> , 754, 19-24	76
833	Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. <b>2015</b> , 50, 364-77	138
832	Singular effects of PPAR agonists on nonalcoholic fatty liver disease of diet-induced obese mice. <b>2015</b> , 127, 73-81	31
831	New discriminant score to predict the fibrotic stage of non-alcoholic steatohepatitis in Japan. <b>2015</b> , 9, 269-77	7
830	Magnetic resonance elastography can discriminate normal vs. abnormal liver biopsy in candidates for live liver donation. <b>2015</b> , 40, 795-802	10
829	Hepatic steatosis in Wilson disease--Role of copper and PNPLA3 mutations. <b>2015</b> , 63, 156-63	74

828	The common marmoset as a model for the study of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. <b>2015</b> , 52, 404-13	16
827	Non-alcoholic fatty liver disease in 2015. <b>2015</b> , 7, 1450-9	124
826	Prevalence of Non-alcoholic Fatty Liver Disease and Steatohepatitis Risk Factors in Patients Undergoing Bariatric Surgery. <b>2015</b> , 25, 2335-43	21
825	Portal inflammation during NAFLD is frequent and associated with the early phases of putative hepatic progenitor cell activation. <b>2015</b> , 68, 883-90	12
824	Impact of Steatosis on Prognosis of Patients with Early-Stage Hepatocellular Carcinoma After Hepatic Resection. <b>2015</b> , 22, 2253-61	24
823	Liver fat quantification: Comparison of dual-echo and triple-echo chemical shift MRI to MR spectroscopy. <b>2015</b> , 84, 1452-1458	18
822	Dietary Rosa mosqueta (Rosa rubiginosa) oil prevents high diet-induced hepatic steatosis in mice. <b>2015</b> , 6, 3109-16	8
821	Autoimmune Markers Do Not Impact Clinical Presentation or Natural History of Steatohepatitis-Related Liver Disease. <b>2015</b> , 60, 3788-93	29
820	Differences and similarities in hepatic lipogenesis, gluconeogenesis and oxidative imbalance in mice fed diets rich in fructose or sucrose. <b>2015</b> , 6, 1684-91	29
819	Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease. <b>2015</b> , 1, CD010542	43
818	Current efforts and trends in the treatment of NASH. <b>2015</b> , 62, S65-75	185
817	Pathology of NonNeoplastic Disease After Transplantation. <b>2015</b> , 1171-1190	
816	Sexual dimorphism of lipid metabolism in very long-chain acyl-CoA dehydrogenase deficient (VLCAD <sup>-/-</sup> ) mice in response to medium-chain triglycerides (MCT). <b>2015</b> , 1852, 1442-50	15
815	Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD. <b>2015</b> , 38, 1347-55	121
814	Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease. <b>2015</b> , 50, 776-84	117
813	Raloxifene Ameliorates Liver Fibrosis of Nonalcoholic Steatohepatitis Induced by Choline-Deficient High-Fat Diet in Ovariectomized Mice. <b>2015</b> , 60, 2730-9	20
812	Laparoscopic Adjustable Gastric Banding In Patients with Unexpected Cirrhosis: Safety and Outcomes. <b>2015</b> , 25, 1858-62	19
811	Exacerbation of insulin resistance and hepatic steatosis deriving from zinc deficiency in patients with HCV-related chronic liver disease. <b>2015</b> , 163, 81-8	21

810	Monascus purpureus-fermented Thai glutinous rice reduces blood and hepatic cholesterol and hepatic steatosis concentrations in diet-induced hypercholesterolemic rats. <b>2015</b> , 15, 88	12
809	High-salt in addition to high-fat diet may enhance inflammation and fibrosis in liver steatosis induced by oxidative stress and dyslipidemia in mice. <b>2015</b> , 14, 6	27
808	Enhanced hepatic targeting, biodistribution and antifibrotic efficacy of tanshinone IIA loaded globin nanoparticles. <b>2015</b> , 73, 35-43	28
807	Non-alcoholic fatty liver disease: The diagnosis and management. <b>2015</b> , 7, 846-58	195
806	Non-Alcoholic Fatty Liver Disease (NAFLD): The Lipid Disease of the Liver and the Effect of Statins. <b>2015</b> , 149-173	1
805	Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients. <b>2015</b> , 149, 379-88; quiz e15-6	450
804	Effects of ursodeoxycholic acid therapy on carotid intima media thickness, apolipoprotein A1, apolipoprotein B, and apolipoprotein B/A1 ratio in nonalcoholic steatohepatitis. <b>2015</b> , 27, 142-9	11
803	How to Identify the Patient with Nonalcoholic Steatohepatitis Who Will Progress to Cirrhosis. <b>2020</b> , 49, 45-62	2
802	High rates of ineligibility for participation in trials of new therapies in non-alcoholic steatohepatitis: a systematic review. <b>2020</b> , 32, 1023-1029	2
801	Point shear wave elastography predicts fibrosis severity and steatohepatitis in alcohol-related liver disease. <b>2020</b> , 14, 270-280	5
800	Loss of ELK1 has differential effects on age-dependent organ fibrosis. <b>2020</b> , 120, 105668	7
799	Genecriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design. <b>2020</b> , 89, 105922	49
798	High-Throughput, Machine Learning-Based Quantification of Steatosis, Inflammation, Ballooning, and Fibrosis in Biopsies From Patients With Nonalcoholic Fatty Liver Disease. <b>2020</b> , 18, 2081-2090.e9	35
797	Performance of noninvasive scores for the diagnosis of advanced liver fibrosis in morbidly obese with nonalcoholic fatty liver disease. <b>2020</b> , 32, 420-425	14
796	Cd36 gene expression in adipose and hepatic tissue mediates the lipids accumulation in liver of obese rats with sucrose-induced hepatic steatosis. <b>2020</b> , 147, 106404	5
795	CD8 T cells regulate liver injury in obesity-related nonalcoholic fatty liver disease. <b>2020</b> , 318, G211-G224	27
794	Circulating MicroRNA-122 and Fibrosis Stage Predict Mortality of Japanese Patients With Histopathologically Confirmed NAFLD. <b>2020</b> , 4, 66-76	7
793	Risk factors for histological progression of non-alcoholic steatohepatitis analyzed from repeated biopsy cases. <b>2020</b> , 35, 1412-1419	4

792	Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease. <b>2020</b> , 72, 828-838	22
791	Homeostatic model assessment of insulin resistance closely related to lobular inflammation in nonalcoholic fatty liver disease. <b>2020</b> , 32, 80-86	5
790	Serum soluble sialic acid-binding immunoglobulin-like lectin-7 concentration as an indicator of liver macrophage activation and advanced fibrosis in patients with non-alcoholic fatty liver disease. <b>2020</b> , 50, 466-477	4
789	Quantification of hepatic steatosis with ultrasound: promising role of attenuation imaging coefficient in a biopsy-proven cohort. <b>2020</b> , 30, 2293-2301	29
788	The effects of crocus sativus extract on serum lipid profile and liver enzymes in patients with non-alcoholic fatty liver disease: A randomized placebo-controlled study. <b>2020</b> , 17, 100165	6
787	STING expression in monocyte-derived macrophages is associated with the progression of liver inflammation and fibrosis in patients with nonalcoholic fatty liver disease. <b>2020</b> , 100, 542-552	22
786	Quantification of hepatic steatosis in histologic images by deep learning method. <b>2019</b> , 27, 1033-1045	3
785	Higher liver stiffness scores are associated with early kidney dysfunction in patients with histologically proven non-cirrhotic NAFLD. <b>2020</b> , 46, 288-295	9
784	MiR-155 and other microRNAs downregulate drug metabolizing cytochromes P450 in inflammation. <b>2020</b> , 171, 113725	20
783	Performance of B-mode ratio and 2D shear wave elastography for the detection and quantification of hepatic steatosis and fibrosis after liver transplantation. <b>2020</b> , 32, 222-230	5
782	Correlation of serum zinc levels with pathological and laboratory findings in patients with nonalcoholic fatty liver disease. <b>2020</b> , 32, 748-753	8
781	Vitamin E is an effective treatment for nonalcoholic steatohepatitis in HIV mono-infected patients. <b>2020</b> , 34, 237-244	12
780	FIB-4 Index and Diabetes Mellitus Are Associated with Chronic Kidney Disease in Japanese Patients with Non-Alcoholic Fatty Liver Disease. <b>2019</b> , 21,	8
779	Alcohol and Liver Clock Disruption Increase Small Droplet Macrosteatosis, Alter Lipid Metabolism and Clock Gene mRNA Rhythms, and Remodel the Triglyceride Lipidome in Mouse Liver. <b>2020</b> , 11, 1048	3
778	Clinical Value of Information Entropy Compared with Deep Learning for Ultrasound Grading of Hepatic Steatosis. <b>2020</b> , 22,	4
777	Circulating lipidomic alterations in obese and non-obese subjects with non-alcoholic fatty liver disease. <b>2020</b> , 52, 1603-1614	8
776	Digital pathology: accurate technique for quantitative assessment of histological features in metabolic-associated fatty liver disease. <b>2021</b> , 53, 160-171	4
775	Liver fat quantification: where do we stand?. <b>2020</b> , 45, 3386-3399	14

774	Fortified vegetarian milk for prevention of metabolic syndrome in rats: impact on hepatic and vascular complications. <b>2020</b> , 6, e04593	1
773	The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. <b>2020</b> , 14, 889-919	142
772	Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial. <b>2020</b> , 5, 996-1007	7
771	Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD. <b>2020</b> , 11, 4982	67
770	Knockout of sulfatase 2 is associated with decreased steatohepatitis and fibrosis in a mouse model of nonalcoholic fatty liver disease. <b>2020</b> , 319, G333-G344	3
769	Current Trends of Essential Trace Elements in Patients with Chronic Liver Diseases. <b>2020</b> , 12,	15
768	Influence of LGALS3 and PNPLA3 genes in non-alcoholic steatohepatitis (NASH) in patients undergone bariatric surgery. <b>2020</b> , 14, 326-332	2
767	Aberrant DNA methylation results in altered gene expression in non-alcoholic steatohepatitis-related hepatocellular carcinomas. <b>2020</b> , 146, 2461-2477	8
766	MR elastography-based liver fibrosis correlates with liver events in nonalcoholic fatty liver patients: A multicenter study. <b>2020</b> , 40, 2242-2251	20
765	Decrease in fasting insulin secretory function correlates with significant liver fibrosis in Japanese non-alcoholic fatty liver disease patients. <b>2020</b> , 4, 929-936	1
764	PPAR $\alpha$ agonist and metformin co-treatment ameliorates NASH in mice induced by a choline-deficient, amino acid-defined diet with 45% fat. <b>2020</b> , 10, 19578	1
763	Metabolic and Genetic Risk Factors Are the Strongest Predictors of Severity of Alcohol-Related Liver Fibrosis. <b>2020</b> ,	9
762	polymorphism influences the association between sarcopenia and liver fibrosis in adults with biopsy-proven non-alcoholic fatty liver disease. <b>2021</b> , 126, 813-824	5
761	Hepatoprotective Effects of a Novel Trihoney against Nonalcoholic Fatty Liver Disease: A Comparative Study with Atorvastatin. <b>2020</b> , 2020, 4503253	0
760	Multiparametric MR mapping in clinical decision-making for diffuse liver disease. <b>2020</b> , 45, 3507-3522	13
759	NAFLD and NASH in Postmenopausal Women: Implications for Diagnosis and Treatment. <b>2020</b> , 161,	23
758	Dual-energy CT in diffuse liver disease: is there a role?. <b>2020</b> , 45, 3413-3424	8
757	Lipophagy Impairment Is Associated With Disease Progression in NAFLD. <b>2020</b> , 11, 850	29



756	Improvement in histological endpoints of MAFLD following a 12-week aerobic exercise intervention. <b>2020</b> , 52, 1387-1398	15
755	Capparis spinosa improves the high fat diet-induced non-alcoholic steatohepatitis in rats: the possible role of FGF21. <b>2020</b> , 13, 356	1
754	Noninvasive diagnostic tools for pediatric NAFLD: where are we now?. <b>2020</b> , 14, 1035-1046	3
753	Fatty change of the liver microenvironment influences the metastatic potential of colorectal cancer. <b>2020</b> , 101, 162-170	4
752	The common variant of rs6214 in insulin like growth factor 1 ( ) gene: a potential protective factor for non-alcoholic fatty liver disease. <b>2020</b> , 1-6	5
751	Consumption of Spinach and Tomato Modifies Lipid Metabolism, Reducing Hepatic Steatosis in Rats. <b>2020</b> , 9,	5
750	Linagliptin Ameliorates Hepatic Steatosis via Non-Canonical Mechanisms in Mice Treated with a Dual Inhibitor of Insulin Receptor and IGF-1 Receptor. <b>2020</b> , 21,	3
749	Maternal exercise conveys protection against NAFLD in the offspring via hepatic metabolic programming. <b>2020</b> , 10, 15424	7
748	High fat worsens olanzapine induced metabolic abnormalities in rats. <b>2020</b> , 122, 3065-3075	
747	Increased Body Mass Index and Type 2 Diabetes Are the Main Predictors of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in Liver Biopsies of Patients With Human Immunodeficiency Virus Monoinfection. <b>2021</b> , 73, e2184-e2193	5
746	Nonalcoholic Fatty Liver Disease (NAFLD) and Hepatic Cytochrome P450 (CYP) Enzymes. <b>2020</b> , 13,	8
745	An Improved qFibrosis Algorithm for Precise Screening and Enrollment into Non-Alcoholic Steatohepatitis (NASH) Clinical Trials. <b>2020</b> , 10,	5
744	Ultrasound Assessment of Hepatic Steatosis by Using the Double Nakagami Distribution: A Feasibility Study. <b>2020</b> , 10,	4
743	Dual-Energy Computed Tomography for Fat Quantification in the Liver and Bone Marrow: A Literature Review. <b>2020</b> , 192, 1137-1153	5
742	Transient elastography with controlled attenuation parameter (CAP) for diagnosis of moderate or severe steatosis in people with suspected non-alcoholic fatty liver disease. <b>2020</b> ,	1
741	Therapeutic Targeting of Myeloperoxidase Attenuates NASH in Mice. <b>2020</b> , 4, 1441-1458	8
740	Identifying High-Risk NASH Patients: What We Know so Far. <b>2020</b> , 12, 125-138	11
739	History of Nonalcoholic Fatty Liver Disease. <b>2020</b> , 21,	30



738	Portal flow dynamics after total pancreatectomy and autologous islet cell transplantation. <b>2020</b> , 34, e14112	2
737	Renal and Hepatic Disease: as Diet Therapy Proposal for Prevention and Treatment. <b>2021</b> , 40, 646-664	
736	Postmortem determination of hepatic steatosis. Comparing Rho/Z and fat fraction measurements on dual-energy CT for histological grading: A retrospective analysis. <b>2020</b> , 23, 200422	
735	A trans fatty acid substitute enhanced development of liver proliferative lesions induced in mice by feeding a choline-deficient, methionine-lowered, L-amino acid-defined, high-fat diet. <b>2020</b> , 19, 251	3
734	The effect of hepatic steatosis and fibrosis on liver weight and dimensions. <b>2020</b> , 47, 101781	5
733	Non-invasive predictors of prognosis of Asian patients with histopathologically-confirmed lean nonalcoholic fatty liver disease. <b>2020</b> , 20, 368	2
732	Characteristics of NAFLD Based on Hypopituitarism. <b>2020</b> , 2020, 8814435	3
731	Histopathological findings of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. <b>2020</b> , 47, 549-554	3
730	Low-Density Lipoprotein (LDL)-Triglyceride and Its Ratio to LDL-Cholesterol as Diagnostic Biomarkers for Nonalcoholic Steatohepatitis. <b>2020</b> , 5, 1206-1215	2
729	Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. <b>2020</b> , 5, 739-752	156
728	Review article: the signalling and functional role of the extracellular matrix in the development of liver fibrosis. <b>2020</b> , 52, 85-97	14
727	Targeted Nutrient Modifications in Purified Diets Differentially Affect Nonalcoholic Fatty Liver Disease and Metabolic Disease Development in Rodent Models. <b>2020</b> , 4, nzaa078	5
726	The PNPLA3-I148M variant increases polyunsaturated triglycerides in human adipose tissue. <b>2020</b> , 40, 2128-2138	13
725	HLA-G liver expression and HLA-G extended haplotypes are associated with chronic hepatitis C in HIV-negative and HIV-coinfected patients. <b>2020</b> , 217, 108482	2
724	Elastography Techniques for the Assessment of Liver Fibrosis in Non-Alcoholic Fatty Liver Disease. <b>2020</b> , 21,	20
723	Development of insulin resistance preceded major changes in iron homeostasis in mice fed a high-fat diet. <b>2020</b> , 84, 108441	6
722	Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis. <b>2020</b> , 159, 1290-1301.e5	118
721	Non-invasive monitoring of chronic liver disease via near-infrared and shortwave-infrared imaging of endogenous lipofuscin. <b>2020</b> , 4, 801-813	14

720	Genistein and exercise modulated lipid peroxidation and improved steatohepatitis in ovariectomized rats. <b>2020</b> , 20, 162	3
719	Farnesoid X receptor mediates hepatic steatosis induced by PM. <b>2020</b> , 27, 34412-34420	3
718	PPAR $\gamma$ gene Pro12Ala variants reduce the risk of obese individuals to non-alcoholic fatty liver: A study in Uyghur Chinese population residing in Northwestern China. <b>2020</b> , 44, 894-904	
717	The NLRP3 Inflammasome in Alcoholic and Nonalcoholic Steatohepatitis. <b>2020</b> , 40, 298-306	21
716	Chemotherapy-associated liver injury in colorectal cancer. <b>2020</b> , 13, 1756284820924194	11
715	Relationship between hepatic and systemic angiopoietin-like 3, hepatic Vitamin D receptor expression and NAFLD in obesity. <b>2020</b> , 40, 2139-2147	8
714	Advanced fibrosis of non-alcoholic steatohepatitis affects the significance of lipoprotein(a) as a cardiovascular risk factor. <b>2020</b> , 299, 32-37	10
713	The Novel Adipokine Gremlin 1 Antagonizes Insulin Action and Is Increased in Type 2 Diabetes and NAFLD/NASH. <b>2020</b> , 69, 331-341	14
712	Type 2 diabetes influences bacterial tissue compartmentalisation in human obesity. <b>2020</b> , 2, 233-242	78
711	Gut Microbiota Dysbiosis in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study in Taiwan. <b>2020</b> , 12,	21
710	Obstructive Sleep Apnea and Non-alcoholic Fatty Liver Disease in Obese Patients Undergoing Bariatric Surgery. <b>2020</b> , 30, 2572-2578	4
709	Effects of Laparoscopic Sleeve Gastrectomy on Non-Alcoholic Steatohepatitis and Liver Fibrosis in Japanese Patients with Severe Obesity. <b>2020</b> , 30, 2579-2587	8
708	Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials. <b>2020</b> , 73, 1322-1332	87
707	Allogenic Fecal Microbiota Transplantation in Patients With Nonalcoholic Fatty Liver Disease Improves Abnormal Small Intestinal Permeability: A Randomized Control Trial. <i>American Journal of Gastroenterology</i> , <b>2020</b> , 115, 1055-1065	0.7 72
706	Relationship between IL-8 Circulating Levels and TLR2 Hepatic Expression in Women with Morbid Obesity and Nonalcoholic Steatohepatitis. <b>2020</b> , 21,	9
705	Suppression of high-fat diet-induced obesity-associated liver mitochondrial dysfunction by docosahexaenoic acid and hydroxytyrosol co-administration. <b>2020</b> , 52, 895-904	43
704	Computer-aided classification of hepatocellular ballooning in liver biopsies from patients with NASH using persistent homology. <b>2020</b> , 195, 105614	6
703	Non-invasive diagnosis: non-alcoholic fatty liver disease and alcoholic liver disease. <b>2020</b> , 5, 31	13

702	rs7903146 (C/T) polymorphism of Transcription factor 7 like 2 (TCF7L-2) gene is independently associated with non-alcoholic fatty liver disease in Asian Indians. <b>2020</b> , 14, 175-180	6
701	Accuracy of the Enhanced Liver Fibrosis test, and combination of the Enhanced Liver Fibrosis and non-invasive tests for the diagnosis of advanced liver fibrosis in patients with non-alcoholic fatty liver disease. <b>2020</b> , 50, 682-692	22
700	Serum Golgi Protein 73 as a Potential Biomarker for Hepatic Necroinflammation in Population with Nonalcoholic Steatohepatitis. <b>2020</b> , 2020, 6036904	7
699	Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma. <b>2020</b> , 21,	31
698	Proposal of a liver histology-based scoring system for bile salt export pump deficiency. <b>2020</b> , 50, 754-762	
697	Serum miR-379 expression is related to the development and progression of hypercholesterolemia in non-alcoholic fatty liver disease. <b>2020</b> , 15, e0219412	10
696	Neutralizing antibody against osteopontin attenuates non-alcoholic steatohepatitis in mice. <b>2020</b> , 14, 223-232	8
695	Impact of the Co-Administration of N-3 Fatty Acids and Olive Oil Components in Preclinical Nonalcoholic Fatty Liver Disease Models: A Mechanistic View. <b>2020</b> , 12,	45
694	Pharmacologic Treatment Strategies for Nonalcoholic Steatohepatitis. <b>2020</b> , 49, 105-121	1
693	Defects in long-chain 3-hydroxy acyl-CoA dehydrogenase lead to hepatocellular carcinoma: A novel etiology of hepatocellular carcinoma. <b>2020</b> , 147, 1461-1473	6
692	PNPLA3 polymorphism influences the association between high-normal TSH level and NASH in euthyroid adults with biopsy-proven NAFLD. <b>2020</b> , 46, 496-503	3
691	Adipose Tissue-Liver Cross Talk in the Control of Whole-Body Metabolism: Implications in Nonalcoholic Fatty Liver Disease. <b>2020</b> , 158, 1899-1912	53
690	and ameliorate progression of non-alcoholic fatty liver disease through modulation of the gut microbiome. <b>2020</b> , 11, 882-899	28
689	Long-term outcomes of non-alcoholic fatty liver disease and the risk factors for mortality and hepatocellular carcinoma in a Japanese population. <b>2020</b> , 35, 1579-1589	14
688	Iron-induced derangement in hepatic $\Delta^5$ and $\Delta^6$ desaturation capacity and fatty acid profile leading to steatosis: Impact on extrahepatic tissues and prevention by antioxidant-rich extra virgin olive oil. <b>2020</b> , 153, 102058	9
687	Tri-antennary tri-sialylated mono-fucosylated glycan of alpha-1 antitrypsin as a non-invasive biomarker for non-alcoholic steatohepatitis: a novel glycobiomarker for non-alcoholic steatohepatitis. <b>2020</b> , 10, 321	11
686	Smad Phospho-Isoforms for Hepatocellular Carcinoma Risk Assessment in Patients with Nonalcoholic Steatohepatitis. <b>2020</b> , 12,	4
685	The effect of steatosis and fibrosis on blunt force vulnerability of the liver. <b>2020</b> , 134, 1067-1072	2

684	Study Protocol for Pleiotropic Effects and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Versus Sulfonylurea in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. <b>2020</b> , 11, 549-560	3
683	Diagnostic Accuracy of Shear Wave Elastography as a Non-invasive Biomarker of High-Risk Non-alcoholic Steatohepatitis in Patients with Non-alcoholic Fatty Liver Disease. <b>2020</b> , 46, 972-980	6
682	Attenuated effect of PNPLA3 on hepatic fibrosis by HSD17B13 in Japanese patients with non-alcoholic fatty liver disease. <b>2020</b> , 40, 1686-1692	10
681	Correlation between insulin resistance and liver histology in patients with nonalcoholic steatohepatitis with and without obesity. <b>2020</b> , 39, 42-49	4
680	Sleeve Gastroplasty Combined with the NLRP3 Inflammasome Inhibitor CY-09 Reduces Body Weight, Improves Insulin Resistance and Alleviates Hepatic Steatosis in Mouse Model. <b>2020</b> , 30, 3435-3443	5
679	Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis. <b>2020</b> , 73, 252-262	65
678	Combined and sequential non-invasive approach to diagnosing non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease and persistently normal alanine aminotransferase levels. <b>2020</b> , 8,	11
677	Diagnostic accuracy of FibroScan-AST score to identify non-alcoholic steatohepatitis with significant activity and fibrosis in Japanese patients with non-alcoholic fatty liver disease: Comparison between M and XL probes. <b>2020</b> , 50, 831-839	21
676	Anti-steatotic linagliptin pleiotropic effects encompasses suppression of de novo lipogenesis and ER stress in high-fat-fed mice. <b>2020</b> , 509, 110804	2
675	Outcome for Pediatric Recipients of Macrosteatotic Liver Grafts From Living Donors. <b>2020</b> , 26, 899-905	
674	Automated quantification and architectural pattern detection of hepatic fibrosis in NAFLD. <b>2020</b> , 47, 151518	17
673	Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. <b>2020</b> , 73, 505-515	113
672	21st Century Advances in Multimodality Imaging of Obesity for Care of the Cardiovascular Patient. <b>2021</b> , 14, 482-494	10
671	Women Have a Lower Risk of Nonalcoholic Fatty Liver Disease but a Higher Risk of Progression vs Men: A Systematic Review and Meta-analysis. <b>2021</b> , 19, 61-71.e15	58
670	The histologic presentation of hepatitis E reflects patients' immune status and pre-existing liver condition. <b>2021</b> , 34, 233-248	4
669	Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis. <b>2021</b> , 44, 133-165	4
668	Can Dasatinib Ameliorate the Hepatic changes, Induced by Long Term Western Diet, in Mice?. <b>2021</b> , 234, 151626	3
667	Muscle alterations are independently associated with significant fibrosis in patients with nonalcoholic fatty liver disease. <b>2021</b> , 41, 494-504	6

- 666 Accuracy of non-invasive methods/models for predicting esophageal varices in patients with compensated advanced chronic liver disease secondary to nonalcoholic fatty liver disease. **2021**, 20, 100229 2
- 665 Steatosis, Steatohepatitis and Related Conditions. **2021**, 108-135
- 664 Non-alcoholic fatty liver disease: A review with clinical and pathological correlation. **2021**, 120, 68-77 7
- 663 Systematic review on the prevalence of nonalcoholic fatty liver disease in South Korea. **2021**, 45, 101526 9
- 662 Outcomes of Japanese patients with non-alcoholic fatty liver disease according to genetic background and lifestyle-related diseases. **2021**, 21, 100260
- 661 Role of CC chemokine receptor 9 in the progression of murine and human non-alcoholic steatohepatitis. **2021**, 74, 511-521 8
- 660 TERT Promoter Mutation in Serum Cell-Free DNA Is a Diagnostic Marker of Primary Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. **2021**, 99, 114-123 8
- 659 Association between positivity of serum autoantibodies and liver disease severity in patients with biopsy-proven NAFLD. **2021**, 31, 552-560 2
- 658 Prevalence of anti-Hepatitis E antibodies and impact on disease severity in non-alcoholic fatty liver disease. **2021**, 51, 69-79 1
- 657 NLRP3 inflammasome inhibitor CY-09 reduces hepatic steatosis in experimental NAFLD mice. **2021**, 534, 734-739 8
- 656 Insulin Resistance Is Central to Long-Term Reversal of Histologic Nonalcoholic Steatohepatitis After Metabolic Surgery. **2021**, 106, 750-761 1
- 655 Type IV Collagen 7S Is the Most Accurate Test For Identifying Advanced Fibrosis in NAFLD With Type 2 Diabetes. **2021**, 5, 559-572 7
- 654 Synthesis, physicochemical characterization, antifungal activity and toxicological features of cerium oxide nanoparticles. **2021**, 14, 102888 6
- 653 Fully automated prediction of liver fibrosis using deep learning analysis of gadoxetic acid-enhanced MRI. **2021**, 31, 3805-3814 12
- 652 Development and course of diabetes according to genetic factors and diabetes treatment among patients with nonalcoholic fatty liver disease. **2021**, 83, 111080 3
- 651 Glycogenesis is common in nonalcoholic fatty liver disease and is independently associated with ballooning, but lower steatosis and lower fibrosis. **2021**, 41, 996-1011 6
- 650 Functional food mixtures: Inhibition of lipid peroxidation, HMGCoA reductase, and ACAT2 in hypercholesterolemia-induced rats. **2021**, 9, 875-887 1
- 649 Protein Phosphatase 1 Regulatory Subunit 3B Genotype at rs4240624 Has a Major Effect on Gallbladder Bile Composition. **2021**, 5, 244-257 1

648	Ultrasound Detection of Liver Fibrosis in Individuals with Hepatic Steatosis Using the Homodyned K Distribution. <b>2021</b> , 47, 84-94	3
647	NAFLD: Reporting Histologic Findings in Clinical Practice. <b>2021</b> , 73, 2028-2038	31
646	Effects of alcohol consumption on multiple hepatocarcinogenesis in patients with fatty liver disease. <b>2021</b> , 51, 62-68	3
645	Liver biopsy findings in patients on immune checkpoint inhibitors. <b>2021</b> , 34, 426-437	15
644	Transcriptomic and Proteomic Analysis of Steatohepatic Hepatocellular Carcinoma Reveals Novel Distinct Biologic Features. <b>2021</b> , 155, 87-96	2
643	A tool to predict progression of non-alcoholic fatty liver disease in severely obese patients. <b>2021</b> , 41, 91-100	1
642	Applicability and Results of Liver Stiffness Measurement and Controlled Attenuation Parameter Using XL Probe for Metabolic-Associated Fatty Liver Disease in Candidates to Bariatric Surgery. A Single-Center Observational Study. <b>2021</b> , 31, 702-711	2
641	Circulating dipeptidyl peptidase-4 is independently associated with the presence and severity of NAFLD/NASH in individuals with and without obesity and metabolic disease. <b>2021</b> , 44, 979-988	9
640	Liver biopsy in the quantitative assessment of liver fibrosis in nonalcoholic fatty liver disease. <b>2021</b> , 64, S104-S111	0
639	Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver Disease. <b>2021</b> , 11,	22
638	Novel insulin sensitizer MSDC-0602K improves insulinemia and fatty liver disease in mice, alone and in combination with liraglutide. <b>2021</b> , 296, 100807	9
637	A novel radiomics signature based on T2-weighted imaging accurately predicts hepatic inflammation in individuals with biopsy-proven nonalcoholic fatty liver disease: a derivation and independent validation study.. <b>2022</b> , 11, 212-226	0
636	Pterostilbene modifies triglyceride metabolism in hepatic steatosis induced by high-fat high-fructose feeding: a comparison with its analog resveratrol. <b>2021</b> , 12, 3266-3279	5
635	Severe Phenotype of Non-alcoholic Fatty Liver Disease in Pediatric Patients with Subclinical Hypothyroidism: a Retrospective Multicenter Study from Korea. <b>2021</b> , 36, e137	1
634	Development of a Scoring System to Differentiate Amiodarone-Induced Liver Injury From Alcoholic Steatohepatitis. <b>2021</b> ,	
633	Obésité foie. <b>2021</b> , 269-273	
632	Hepcidin Levels and Pathological Characteristics in Children with Fatty Liver Disease. <b>2021</b> , 24, 295-305	1
631	A case of acute steatosis induced by chemotherapy for colon cancer. <b>2021</b> , 62, 1-7	1

630 Nonalcoholic Fatty Liver Disease. **2021**, 812-818.e2

629 Temporal effect of fructose supplementation at different concentrations on hepatic metabolism of Wistar rats. **2021**, 38, 1089-1100

628 Distinct Cause of Death Profiles of Hospitalized Non-alcoholic Fatty Liver Disease: A 10 Years' Cross-Sectional Multicenter Study in China. **2020**, 7, 584396 3

627 Noninvasive diagnosis of portal hypertension using gadoxetate DCE-MRI of the liver and spleen. **2021**, 31, 4804-4812 1

626 Sodium-Glucose Cotransporter 2 Inhibitor Versus Sulfonylurea in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized, Open-Label Trial Study.

625 Dynamic Shifts in the Composition of Resident and Recruited Macrophages Influence Tissue Remodeling in NASH. **2021**, 34, 108626 39

624 Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective. **2021**, 27, 44-57 7

623 Natural Progression of Non-Alcoholic Steatohepatitis to Hepatocellular Carcinoma. **2021**, 9, 7

622 A STUDY OF PREVALENCE OF NON ALCOHOLIC FATTY LIVER IN TYPE 2 DIABETES MELLITUS PATIENTS. **2021**, 21-23

621 Protection of Fatty Liver by the Intake of Fermented Soybean Paste, , and Its Pre-Fermented Mixture. **2021**, 10, 1

620 Accuracy comparison of MR elastography and biological markers in detecting liver fibrosis and predicting postoperative ascites. **2021**, 23, 1383-1391 1

619 Comprehensive lipidomics reveals reduced hepatic lipid turnover in NAFLD during alcohol intoxication.

618 Valoración bioquímica en la enfermedad hepática grasa asociada a la disfunción metabólica. **2021**, 2, 209-219

617 From the origin of NASH to the future of metabolic fatty liver disease. **2021**, 14

616 Transient Elastography Accurately Screens for Compensated Advanced Chronic Liver Disease in Patients With Ongoing or Recent Alcohol Withdrawal. **2021**, 3

615 Use of noninvasive scores for advanced liver fibrosis can guide the need for hepatic biopsy during bariatric procedures. **2021**, 17, 292-298 1

614 Increased Frequency of Dysfunctional Siglec-7CD57PD-1 Natural Killer Cells in Patients With Non-alcoholic Fatty Liver Disease. **2021**, 12, 603133 3

613 FIB-4 First in the Diagnostic Algorithm of Metabolic-Dysfunction-Associated Fatty Liver Disease in the Era of the Global Metabodemic. **2021**, 11, 6



612	Triglycerides in Nonalcoholic Fatty Liver Disease: Guilty Until Proven Innocent. <b>2021</b> , 42, 183-190	5
611	Non-Alcoholic Fatty Liver Disease in Children. <b>2021</b> , 653-670	
610	HLA-E gene polymorphisms in chronic hepatitis C: Impact on HLA-E liver expression and disease severity. <b>2021</b> , 82, 177-185	1
609	Abnormal fucosylation of alpha-fetoprotein in patients with nonalcoholic steatohepatitis. <b>2021</b> , 51, 548-553	1
608	Cholesterol Accumulation as a Driver of Hepatic Inflammation Under Translational Dietary Conditions Can Be Attenuated by a Multicomponent Medicine. <b>2021</b> , 12, 601160	3
607	Microscope-Based Automated Quantification of Liver Fibrosis in Mice Using a Deep Learning Algorithm. <b>2021</b> , 49, 1126-1133	2
606	Quantitative, noninvasive MRI characterization of disease progression in a mouse model of non-alcoholic steatohepatitis. <b>2021</b> , 11, 6105	0
605	Biochemical assessment of metabolic associated fatty liver disease. <b>2021</b> , 2, 199-208	1
604	Telomerase: a key player in the pathogenesis of non-alcoholic fatty liver disease?. <b>2021</b> , 15, 811-819	1
603	Simple non-invasive scoring systems and histological scores in predicting mortality in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. <b>2021</b> , 36, 1754-1768	2
602	The Effect of Chronic Alcohol Intoxication on the Daily Rhythm of Some Micromorphometric Parameters of Rat Hepatocytes. <b>2021</b> , 11, 01-12	
601	Fructo-Oligosaccharides and Pectins Enhance Beneficial Effects of Raspberry Polyphenols in Rats with Nonalcoholic Fatty Liver. <b>2021</b> , 13,	2
600	Individualized Polygenic Risk Score Identifies NASH in the Eastern Asia Region: A Derivation and Validation Study. <b>2021</b> , 12, e00321	0
599	STE20-Type Protein Kinase MST4 Controls NAFLD Progression by Regulating Lipid Droplet Dynamics and Metabolic Stress in Hepatocytes. <b>2021</b> , 5, 1183-1200	4
598	Intrahepatic distribution of nerve fibers and alterations due to fibrosis in diseased liver. <b>2021</b> , 16, e0249556	0
597	Elastography A Bona Fide Non-Invasive Method for Assessing Non-Alcoholic Fatty Liver Disease in Children. <b>2021</b> , 11, 3240	
596	A dietary ketone ester mitigates histological outcomes of NAFLD and markers of fibrosis in high-fat diet fed mice. <b>2021</b> , 320, G564-G572	3
595	Impact of combined long-term fructose and prednisolone intake on glucose and lipid homeostasis in rats: benefits of intake interruption or fish oil administration. <b>2021</b> , 90, 108572	3



594	Animal Evidence for Synergistic Induction of Hepatic Injury by Dietary Fat and Alcohol Consumption and Its Potential Mechanisms. <b>2021</b> , 11,	0
593	Evolution of Non-alcoholic Fatty Liver Disease (NAFLD) Biomarkers in Response to Weight Loss 1 Year After Bariatric Surgery-a Post Hoc Analysis of the FibroTest Prospective Study. <b>2021</b> , 31, 3548-3556	1
592	Silencing of STE20-type kinase MST3 in mice with antisense oligonucleotide treatment ameliorates diet-induced nonalcoholic fatty liver disease. <b>2021</b> , 35, e21567	5
591	The Effect of Genetic Polymorphism in Response to Body Weight Reduction in Japanese Patients with Nonalcoholic Fatty Liver Disease. <b>2021</b> , 12,	1
590	Protocatechuic acid improves hepatic insulin resistance and restores vascular oxidative status in type-2 diabetic rats. <b>2021</b> , 83, 103577	11
589	Portal Vein Thrombosis in Non-Cirrhotic Non-Alcoholic Fatty Liver Disease: A 9-Year Prospective Cohort Study. <b>2021</b> , 8, 650818	1
588	The usefulness of noninvasive liver stiffness assessment using shear-wave elastography for predicting liver fibrosis in children. <b>2021</b> , 21, 68	3
587	Fatty liver evaluation with double-Nakagami model under low-resolution conditions. <b>2021</b> , 60, SDDE06	2
586	Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: Pathophysiological Links, Diagnosis, and Therapeutic Management. <b>2021</b> , 11,	6
585	Predictive scoring system for advanced liver fibrosis in Japanese patients with severe obesity. <b>2021</b> , 51, 1513-1520	0
584	Non-alcoholic fatty liver disease in mice with hepatocyte-specific deletion of mitochondrial fission factor. <b>2021</b> , 64, 2092-2107	5
583	LI-RADS v2018 major criteria: Do hepatocellular carcinomas in non-alcoholic steatohepatitis differ from those in virus-induced chronic liver disease on MRI?. <b>2021</b> , 138, 109651	3
582	Metabolic Complementation between Glucose and Amino Acid Drives Hepatic De Novo Lipogenesis and Steatosis.	0
581	The Impact of the NLRP3 Pathway in the Pathogenesis of Non-Alcoholic Fatty Liver Disease and Alcohol-Related Liver Disease. <b>2021</b> , 1, 68-81	
580	Dietary alpha- and gamma-tocopherol (1:5 ratio) supplementation attenuates adipose tissue expansion, hepatic steatosis, and expression of inflammatory markers in a high-fat-diet-fed murine model. <b>2021</b> , 85, 111139	3
579	Effect of Ileal Transposition (IT) on Angiopoietin-Like Protein-8 (ANGPTL8) and Pentraxin (PTX3) Plasma Level in Sprague-Dawley Rats Fed High-Fat Diet (HFD). <b>2021</b> , 2021, 6699923	0
578	Validity of routine biochemical and ultrasound scores for prediction of hepatic fibrosis and steatosis in NAFLD. <b>2021</b> , 11,	0
577	FibroTest for Evaluating Fibrosis in Non-Alcoholic Fatty Liver Disease Patients: A Systematic Review and Meta-Analysis. <b>2021</b> , 10,	5

576	Danthron ameliorates obesity and MAFLD through activating the interplay between PPAR $\alpha$ /RXR $\beta$ heterodimer and adiponectin receptor 2. <b>2021</b> , 137, 111344	4
575	Performance of shear wave elastography: A single centre pilot study of mixed etiology liver disease patients with normal BMI. <b>2021</b> , 24, 120-136	0
574	Genistein and exercise treatment reduced NASH related HDAC3, IL-13 and MMP-12 expressions in ovariectomized rats fed with high fat high fructose diet. <b>2021</b> , 11, 503-512	1
573	Maternal Exercise Mediates Hepatic Metabolic Programming via Activation of AMPK-PGC1 $\beta$ Axis in the Offspring of Obese Mothers. <b>2021</b> , 10,	6
572	Green Tea from the Far East to the Drug Store: Focus on the Beneficial Cardiovascular Effects. <b>2021</b> , 27, 1931-1940	2
571	Grape-Seed Proanthocyanidin Extract Reverts Obesity-Related Metabolic Derangements in Aged Female Rats. <b>2021</b> , 13,	1
570	A Study on Association between Neutrophil to Lymphocyte Ratio and Steatohepatitis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease. <b>2021</b> , 10, 1876-1882	2
569	The Placebo Response in Randomized Trials in Nonalcoholic Steatohepatitis Simply Explained. <b>2021</b> , ,	2
568	Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD. <b>2021</b> ,	9
567	Deregulation of Secreted Frizzled-Related Protein 5 in Nonalcoholic Fatty Liver Disease Associated with Obesity. <b>2021</b> , 22,	1
566	Accuracy of the ultrasound attenuation coefficient for the evaluation of hepatic steatosis: a systematic review and meta-analysis of prospective studies. <b>2021</b> ,	0
565	Sex influences the association between appendicular skeletal muscle mass to visceral fat area ratio and non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease. <b>2021</b> , 1-8	4
564	Historical narrative from fatty liver in the nineteenth century to contemporary NAFLD - Reconciling the present with the past. <b>2021</b> , 3, 100261	4
563	Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease. <b>2021</b> , 15, 922-933	6
562	The HSD17B13 rs72613567 variant is associated with lower levels of albuminuria in patients with biopsy-proven nonalcoholic fatty liver disease. <b>2021</b> , 31, 1822-1831	2
561	Hepatic miR-20b promotes nonalcoholic fatty liver disease by suppressing PPAR $\beta$	
560	Pathology of non-alcoholic fatty liver disease. <b>2021</b> , 113, 194-202	5
559	Predictors of early and sustained virological response of viral hepatitis C. <b>2020</b> , 61, 1185-1192	1

558	EVALUATION OF REST ENERGY EXPENDITURE IN PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE. <b>2021</b> , 58, 157-163	0
557	Pediatric nonalcoholic fatty liver disease - a changing diagnostic paradigm. <b>2020</b> , 61, 1023-1031	2
556	Noninvasive measure of treatment response in non-alcoholic steatohepatitis: Insights from EMMINENCE and meta-analysis. <b>2021</b> , 5, 740-749	1
555	Ultrasonographic grayscale findings related to fibrosis in patients with non-alcoholic fatty liver disease: comparison with transient elastography and Fib-4 index. <b>2021</b> , 48, 323-333	0
554	Circulating Levels of Pro-Neurotensin and Its Relationship with Nonalcoholic Steatohepatitis and Hepatic Lipid Metabolism. <b>2021</b> , 11,	0
553	Suppression of insulin-induced gene 1 (INSIG1) function promotes hepatic lipid remodelling and restrains NASH progression. <b>2021</b> , 48, 101210	6
552	Evaluation of the fibrosis-4 index for detection of advanced fibrosis among individuals at risk for intestinal failure-associated liver disease. <b>2021</b> ,	0
551	A Decreased Response to Resistin in Mononuclear Leukocytes Contributes to Oxidative Stress in Nonalcoholic Fatty Liver Disease. <b>2021</b> , 1	2
550	Therapeutic effects of sleeve gastrectomy for non-alcoholic steatohepatitis estimated by paired liver biopsy in morbidly obese Japanese patients. <b>2021</b> , 100, e26436	0
549	Circulating tumor necrosis factor- $\alpha$ levels in non-alcoholic fatty liver disease: A systematic review and a meta-analysis. <b>2021</b> , 36, 3002-3014	2
548	Expression of Jejunal Taste Receptors in Women with Morbid Obesity. <b>2021</b> , 13,	0
547	Nonalcoholic Fatty Liver Disease, Liver Fibrosis and Cardiovascular Disease in the Adult US Population. <b>2021</b> , 12, 711484	1
546	Iron depletion attenuates steatosis in a mouse model of non-alcoholic fatty liver disease: Role of iron-dependent pathways. <b>2021</b> , 1867, 166142	0
545	Metabolic-associated fatty liver disease and autoimmune hepatitis: an overlooked interaction. <b>2021</b> , 15, 1181-1189	0
544	A rapid juvenile murine model of nonalcoholic steatohepatitis (NASH): Chronic intermittent hypoxia exacerbates Western diet-induced NASH. <b>2021</b> , 276, 119403	3
543	CYP2E1 in Alcoholic and Non-Alcoholic Liver Injury. Roles of ROS, Reactive Intermediates and Lipid Overload. <b>2021</b> , 22,	13
542	KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. <b>2021</b> , 27, 363-401	21
541	Increasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma: single-institution 20-year study. <b>2021</b> , 21, 306	5

540	The ultrasound-guided attenuation parameter is useful in quantification of hepatic steatosis in non-alcoholic fatty liver disease. <b>2021</b> , 5, 947-952	0
539	Modulation and bioinformatics screening of hepatic mRNA-lncRNAs (HML) network associated with insulin resistance in prediabetic and exercised mice. <b>2021</b> , 18, 75	1
538	Interaction of , and Increases Susceptibility to Nonalcoholic Steatohepatitis.. <b>2022</b> , 10, 219-229	0
537	Aspectos relevantes de la enfermedad por hígado graso no alcohólico. <b>2021</b> , 310-324	0
536	Predictive value of cytokeratin-18 fragment levels for diagnosing steatohepatitis in patients with nonalcoholic fatty liver disease. <b>2021</b> , 33, 1451-1458	0
535	Decline in serum albumin concentration is a predictor of serious events in nonalcoholic fatty liver disease. <b>2021</b> , 100, e26835	3
534	The Role of Innate Immune Cells in Nonalcoholic Fatty Liver Disease. <b>2021</b> , 1-11	3
533	The Prophylactic Effects of Glutamine on Muscle Protein Synthesis and Degradation in Rats with Ethanol-Induced Liver Damage. <b>2021</b> , 13,	3
532	Periodontal disease-related nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: An emerging concept of oral-liver axis. <b>2021</b> , 87, 204-240	10
531	Independent of Calorie Intake, Short-term Alternate-day Fasting Alleviates NASH, With Modulation of Markers of Lipogenesis, Autophagy, Apoptosis, and Inflammation in Rats. <b>2021</b> , 69, 575-596	3
530	Liver Fibrosis Assessment. <b>2021</b> , 42, 381-389	2
529	Effect of skin-capsular distance on controlled attenuation parameter for diagnosing liver steatosis in patients with nonalcoholic fatty liver disease. <b>2021</b> , 11, 15641	0
528	Phenotypic Changes in Macrophage Activation in a Model of Nonalcoholic Fatty Liver Disease using Microminipigs. <b>2021</b> , 28, 844-851	3
527	Association between circulating bile acid alterations and nonalcoholic steatohepatitis independent of obesity and diabetes mellitus. <b>2021</b> ,	4
526	Virgin coconut oil complements with its polyphenol components mitigate sodium fluoride toxicity and. <b>2021</b> , 1-7	0
525	Therapeutic and diagnostic targeting of fibrosis in metabolic, proliferative and viral disorders. <b>2021</b> , 175, 113831	4
524	Liver enhancer signature and regulatory network of non-alcoholic steatohepatitis resistance in humans with obesity.	0
523	The "GG" genotype of rs26802 variant in the ghrelin gene is a potential protective factor against nonalcoholic fatty liver disease. <b>2021</b> , 108, 342-352	0

522	Quantification of Liver Fat Content with CT and MRI: State of the Art. <b>2021</b> , 301, 250-262	10
521	The transcription factors CREBH, PPAR $\alpha$ , and FOXO1 as critical hepatic mediators of diet-induced metabolic dysregulation. <b>2021</b> , 95, 108633	4
520	The feasibility of T2 mapping in the assessment of hepatic steatosis, inflammation, and fibrosis in patients with non-alcoholic fatty liver disease: a preliminary study. <b>2021</b> , 76, 709.e13-709.e18	1
519	Ferulic acid attenuates non-alcoholic steatohepatitis by reducing oxidative stress and inflammation through inhibition of the ROCK/NF- $\kappa$ B signaling pathways. <b>2021</b> , 147, 72-80	2
518	Effects of $\beta$ -glucan, probiotics, and synbiotics on obesity-associated colitis and hepatic manifestations in C57BL/6J mice. <b>2021</b> , 1	2
517	Association between telomere length and hepatic fibrosis in non-alcoholic fatty liver disease. <b>2021</b> , 11, 18004	0
516	Elevated levels of circulating mitochondrial DNA predict early allograft dysfunction in patients following liver transplantation. <b>2021</b> ,	1
515	High-intensity interval training with probiotic supplementation decreases gene expression of NF- $\kappa$ B and CXCL2 in small intestine of rats with steatosis. 1	
514	Non-alcoholic fatty liver disease: A patient guideline. <b>2021</b> , 3, 100322	17
513	Comparison of bioelectrical impedance analysis, mass index, and waist circumference in assessing risk for non-alcoholic steatohepatitis. <b>2022</b> , 93, 111491	0
512	Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B. <b>2021</b> , 3, 100350	7
511	Comprehensive lipidomics reveals phenotypic differences in hepatic lipid turnover in ALD and NAFLD during alcohol intoxication. <b>2021</b> , 3, 100325	3
510	Fecal Fungi Dysbiosis in Nonalcoholic Fatty Liver Disease. <b>2021</b> , 29, 350-358	1
509	Sleeve Gastrectomy in Non-alcoholic Steatohepatitis (NASH) and Liver Cirrhosis. <b>2021</b> , 115-137	
508	Abnormalities of Carbohydrate Metabolism and the Liver. <b>2021</b> , 804-811.e3	
507	Effect of breath holding at the end of the inspiration and expiration phases on liver stiffness measured by 2D-MR elastography. <b>2021</b> , 46, 2516-2526	1
506	Assessment of Lifestyle Factors Helps to Identify Liver Fibrosis Due to Non-Alcoholic Fatty Liver Disease in Obesity. <b>2021</b> , 13,	3
505	Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis. <b>2021</b> , 17, 12	16

504	Autophagy in liver diseases. <b>2021</b> , 13, 6-65	12
503	Management of non-alcoholic fatty liver disease. <b>2021</b> , 372, m4747	31
502	Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis.	0
501	Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. <b>2004</b> , 40, 820-6	368
500	PPARalpha in the pathogenesis of fatty liver disease. <b>2004</b> , 40, 783-6	75
499	Clinical Applications of Liver Magnetic Resonance Elastography: Chronic Liver Disease. <b>2014</b> , 39-60	1
498	Nonalcoholic steatohepatitis, animal models, and biomarkers: what is new?. <b>2010</b> , 593, 109-36	20
497	Fatty Liver Disease. <b>2010</b> , 201-222	1
496	Alteration of Liver MMP-9/TIMP-1 and Plasma Type IV Collagen in the Development of Rat Insulin Resistance. <b>2014</b> , 531-543	1
495	Histological Biomarkers of Nonalcoholic Fatty Liver Disease. <b>2017</b> , 693-705	1
494	Liver. <b>2011</b> , 857-980	3
493	Steatosis, Steatohepatitis and Related Conditions. <b>2010</b> , 93-114	1
492	Hepatitis C. <b>2006</b> , 665-686	2
491	Liver Disease Caused by Drugs. <b>2010</b> , 1413-1446.e8	2
490	Tissue Changes in the Development of Fatty Liver by Chronic Ingestion of Sucrose Associated with Obesity and Dyslipidemia in Rats. <b>2018</b> , 88, 117-125	2
489	Hepatoprotective Activity of Linalool in Rats Against Liver Injury Induced by Carbon Tetrachloride. <b>2020</b> , 90, 302-308	8
488	Retinol Binding Protein-4 Circulating Levels Were Higher in Nonalcoholic Fatty Liver Disease Vs. Histologically Normal Liver From Morbidly Obese Women.	4
487	Kupffer cell activation by ambient air particulate matter exposure may exacerbate non-alcoholic fatty liver disease. <b>2009</b> , 00, 090924084432057-10	41

486	Liver Cancer. <b>2006</b> , 763-786	57
485	Effect of ischemia-reperfusion injury on the microcirculation of the steatotic liver of the Zucker rat. <b>2001</b> , 72, 1625-31	82
484	Polymorphisms of Interleukin-1?? and ??3-Adrenergic Receptor in Japanese Patients With Nonalcoholic Steatohepatitis. <b>2004</b> , 28, 106S-110S	3
483	The severity of histologic liver lesions is independent of body mass index in patients with nonalcoholic fatty liver disease. <b>2013</b> , 47, 280-6	28
482	Rapid progression of NASH in childhood. <b>2010</b> , 50, 453-6	30
481	Steatohepatic Variant of Hepatocellular Carcinoma Is Associated With Both Alcoholic Steatohepatitis and Nonalcoholic Steatohepatitis: A Study of 2 Cohorts With Molecular Insights. <b>2020</b> , 44, 1406-1412	7
480	Therapeutic Potential of Peroxisome Proliferator-Activated Receptor Modulation in Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis. <b>2017</b> , 4,	10
479	The role of serum bile acid profile in differentiation between nonalcoholic fatty liver disease and chronic viral hepatitis. <b>2020</b> , 10,	2
478	Prediction of liver-related events using fibroscan in chronic hepatitis B patients showing advanced liver fibrosis. <b>2012</b> , 7, e36676	76
477	Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. <b>2012</b> , 7, e38322	194
476	Regular exercise is associated with a reduction in the risk of NAFLD and decreased liver enzymes in individuals with NAFLD independent of obesity in Korean adults. <b>2012</b> , 7, e46819	128
475	NIKEI: a new inexpensive and non-invasive scoring system to exclude advanced fibrosis in patients with NAFLD. <b>2013</b> , 8, e58360	26
474	Incidence of liver damage of uncertain origin in HIV patients not co-infected with HCV/HBV. <b>2013</b> , 8, e68953	27
473	Ectopic fat accumulation and distant organ-specific insulin resistance in Japanese people with nonalcoholic fatty liver disease. <b>2014</b> , 9, e92170	30
472	Factors affecting the accuracy of controlled attenuation parameter (CAP) in assessing hepatic steatosis in patients with chronic liver disease. <b>2014</b> , 9, e98689	30
471	Complement alternative pathway activation in human nonalcoholic steatohepatitis. <b>2014</b> , 9, e110053	21
470	Use of non-invasive parameters of non-alcoholic steatohepatitis and liver fibrosis in daily practice--an exploratory case-control study. <b>2014</b> , 9, e111551	28
469	Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis. <b>2015</b> , 10, e0134302	9

468	A Series of microRNA in the Chromosome 14q32.2 Maternally Imprinted Region Related to Progression of Non-Alcoholic Fatty Liver Disease in a Mouse Model. <b>2016</b> , 11, e0154676	11
467	An Animal Model for the Juvenile Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis. <b>2016</b> , 11, e0158817	34
466	The Role of Morbid Obesity in the Promotion of Metabolic Disruptions and Non-Alcoholic Steatohepatitis by Helicobacter Pylori. <b>2016</b> , 11, e0166741	9
465	Liver biopsy in type 2 diabetes mellitus: Steatohepatitis represents the sole feature of liver damage. <b>2017</b> , 12, e0178473	42
464	Second harmonic generation microscopy provides accurate automated staging of liver fibrosis in patients with non-alcoholic fatty liver disease. <b>2018</b> , 13, e0199166	15
463	Pathology of Alcoholic Liver Disease. <b>2014</b> , 2, 103-9	27
462	Diabetes Mellitus Predicts Occurrence of Cirrhosis and Hepatocellular Cancer in Alcoholic Liver and Non-alcoholic Fatty Liver Diseases. <b>2015</b> , 3, 9-16	60
461	Current Modalities of Fibrosis Assessment in Non-alcoholic Fatty Liver Disease. <b>2017</b> , 5, 261-271	30
460	Liver Stiffness Measurement Can Reflect the Active Liver Necroinflammation in Population with Chronic Liver Disease: A Real-world Evidence Study. <b>2019</b> , 7, 313-321	2
459	The Apelin Receptor APJ in Hematopoietic Stem Cells/Progenitor Cells in the Early Stage of Non-Alcoholic Steatohepatitis. <b>2017</b> , 9, 809-811	4
458	Statin use and histopathological change in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. <b>2018</b> , 12, 3-13	2
457	An Accessible and Pragmatic Experimental Model of Nonalcoholic Fatty Liver Disease. <b>2016</b> , 8, 109-15	16
456	Correlation between Serum Ferritin Level and Histopathological Disease Severity in Non-alcoholic Fatty Liver Disease. <b>2018</b> , 10, 90-95	8
455	Fighting liver fat. <b>2020</b> , 9, R173-R186	4
454	The Role of Non-alcoholic Fatty Liver Disease in Cardiovascular Disease. <b>2014</b> , 9, 10-15	6
453	Effects of grape juice, red wine and resveratrol on liver parameters of rat submitted high-fat diet. <b>2020</b> , 92, e20191230	4
452	INSULIN AND INSULIN RECEPTOR GENE POLYMORPHISMS AND SUSCEPTIBILITY TO NONALCOHOLIC FATTY LIVER DISEASE. <b>2020</b> , 57, 203-208	4
451	Prevalence of the hemochromatosis gene mutation in patients with nonalcoholic steatohepatitis and correlation with degree of liver fibrosis. <b>2006</b> , 43, 224-8	10



450	Increased hepatic CD36 expression with age is associated with enhanced susceptibility to nonalcoholic fatty liver disease. <b>2014</b> , 6, 281-95	64
449	Resistance of ground glass hepatocytes to oral antivirals in chronic hepatitis B patients and implication for the development of hepatocellular carcinoma. <b>2016</b> , 7, 27724-34	17
448	Evaluation of liver fibrosis: "Something old, something new" <b>2016</b> , 29, 445-453	31
447	Serum levels of vascular endothelial growth factor in non-alcoholic fatty liver disease. <b>2017</b> , 30, 209-216	2
446	Liver test abnormalities in patients with HIV mono-infection: assessment with simple noninvasive fibrosis markers. <b>2017</b> , 30, 349-356	10
445	SGLT2 Inhibitor Treatment Outcome in Nonalcoholic Fatty Liver Disease Complicated with Diabetes Mellitus: The Long-term Effects on Clinical Features and Liver Histopathology. <b>2020</b> , 59, 1931-1937	14
444	Combined Amelioration of Ginsenoside (Rg1, Rb1, and Rg3)-enriched Korean Red Ginseng and Probiotic Lactobacillus on Non-alcoholic Fatty Liver Disease. <b>2019</b> , 20, 222-231	11
443	Non-alcoholic fatty liver disease: a survey of involvement of primary care physicians. <b>2019</b> , 65, 255-258	4
442	Effects of intense exercise on biochemical and histological changes in rat liver and pancreas. <b>2010</b> , 4, 619-625	17
441	Effect of Weight Reduction on Histological Activity and Fibrosis of Lean Nonalcoholic Steatohepatitis Patient. <b>2019</b> , 7, 106-114	10
440	Biochemical and molecular-genetic indicators of inflammation and apoptosis in liver cirrhosis as an outcome of the progression of non-alcoholic steatohepatitis. <b>2019</b> , 91, 21-27	2
439	EFFECTS OF HIGH FAT DIET INDUCED OBESITY ON FEMALE RAT LIVERS (A HISTOCHEMICAL STUDY). <b>2005</b> , 2,	20
438	Angiotensin Converting Enzyme Gene (I/D) Polymorphism and Nonalcoholic Fatty Liver Disease. <b>2010</b> , 7,	1
437	Comparison of TGF- $\beta$ 1, PDGF, and CTGF in hepatic fibrosis models using DMN, CCl4, and TAA. <b>2016</b> , 39, 111-8	11
436	Clinical significance of serum alanine aminotransferase and lifestyle intervention in children with nonalcoholic fatty liver disease. <b>2016</b> , 59, 362-367	4
435	Noninvasive predictors of nonalcoholic steatohepatitis in Korean patients with histologically proven nonalcoholic fatty liver disease. <b>2013</b> , 19, 120-30	19
434	Serum matrix metalloproteinase-1 level represents disease activity as opposed to fibrosis in patients with histologically proven nonalcoholic steatohepatitis. <b>2018</b> , 24, 61-76	19
433	The Association of leptin with severity of non-alcoholic fatty liver disease: A population-based study. <b>2018</b> , 24, 392-401	21

432	Recent research trends and updates on nonalcoholic fatty liver disease. <b>2019</b> , 25, 1-11	47
431	Limited expression of TLR9 on T cells and its functional consequences in patients with nonalcoholic fatty liver disease. <b>2020</b> , 26, 216-226	6
430	[Pathology of nonalcoholic steatohepatitis]. <b>2009</b> , 15, 122-30	3
429	[Validity and reliability of the nonalcoholic fatty liver diseases activity score (NAS) in Korean NAFLD patients and its correlation with clinical factors]. <b>2010</b> , 16, 29-37	3
428	Apoptosis and diagnosis of nonalcoholic steatohepatitis. <b>2011</b> , 17, 247-9	1
427	A study on molecular mechanisms of adiposis induced by long-term treatment of high-fat and high-sucrose in C57BL/6J mice. <b>2019</b> , 68, 75-87	2
426	Genistein Modulated Lipid Metabolism, Hepatic PPAR $\alpha$ and Adiponectin Expression in Bilateral Ovariectomized Rats with Nonalcoholic Steatohepatitis (NASH). <b>2020</b> , 10,	4
425	Angiotensin-Like Protein 4 Overexpression in Visceral Adipose Tissue from Obese Subjects with Impaired Glucose Metabolism and Relationship with Lipoprotein Lipase. <b>2020</b> , 21,	8
424	Perspectives of nonalcoholic fatty liver disease research: a personal point of view. <b>2020</b> , 1, 85-107	10
423	Effect of Hog Millet Supplementation on Hepatic Steatosis and Insulin Resistance in Mice Fed a High-fat Diet. <b>2012</b> , 41, 501-509	4
422	Innate immune reactivity of the liver in rats fed a choline-deficient L-amino-acid-defined diet. <b>2008</b> , 14, 6655-61	28
421	Inhibition of hepatic interleukin-18 production by rosiglitazone in a rat model of nonalcoholic fatty liver disease. <b>2008</b> , 14, 7240-6	25
420	Liver histology according to the presence of metabolic syndrome in nonalcoholic fatty liver disease cases. <b>2009</b> , 15, 1093-8	6
419	Immunotherapy for nonalcoholic steatohepatitis using the multiple cytokine production modulator Y-40138. <b>2009</b> , 15, 5533-40	8
418	A rabbit model of pediatric nonalcoholic steatohepatitis: the role of adiponectin. <b>2009</b> , 15, 912-8	22
417	Effects of ursodeoxycholic acid and/or low-calorie diet on steatohepatitis in rats with obesity and hyperlipidemia. <b>2005</b> , 11, 2346-50	14
416	Nonalcoholic steatohepatitis in Asian Indians is neither associated with iron overload nor with HFE gene mutations. <b>2005</b> , 11, 393-5	52
415	Severity of ultrasonographic liver steatosis and metabolic syndrome in Korean men and women. <b>2005</b> , 11, 5314-21	38

414	Association between thrombotic risk factors and extent of fibrosis in patients with non-alcoholic fatty liver diseases. <b>2005</b> , 11, 5834-9	48
413	Fatty liver in H63D homozygotes with hyperferritinemia. <b>2006</b> , 12, 1788-92	7
412	Non-alcoholic fatty liver disease may not be a severe disease at presentation among Asian Indians. <b>2006</b> , 12, 3400-5	53
411	Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease. <b>2006</b> , 12, 4369-76	42
410	Fatty liver, carotid disease and gallstones: a study of age-related associations. <b>2006</b> , 12, 5826-33	46
409	Increased intestinal permeability in pathogenesis and progress of nonalcoholic steatohepatitis in rats. <b>2007</b> , 13, 1732-6	31
408	Assessment of hepatic fibrosis in pediatric cases with hepatitis C virus in Egypt. <b>2007</b> , 13, 2846-51	19
407	Common genetic variations in CLOCK transcription factor are associated with nonalcoholic fatty liver disease. <b>2007</b> , 13, 4242-8	88
406	Pathogenesis and management issues for non-alcoholic fatty liver disease. <b>2007</b> , 13, 4539-50	187
405	N-acetylcysteine attenuates oxidative stress and liver pathology in rats with non-alcoholic steatohepatitis. <b>2007</b> , 13, 5127-32	55
404	Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C. <b>2007</b> , 13, 5180-7	66
403	Indian patients with nonalcoholic fatty liver disease presenting with raised transaminases are different at presentation. <b>2007</b> , 13, 649-50	28
402	Biochemical determination of lipid content in hepatic steatosis by the Soxtec method. <b>2010</b> , 16, 1495-9	13
401	Steatosis and steatohepatitis in postmortem material from Northwestern Greece. <b>2010</b> , 16, 3944-9	46
400	Non-alcoholic steatohepatitis and influence of age and gender on histopathologic findings. <b>2010</b> , 16, 4169-75	11
399	Hepatic lipogranulomas in patients with chronic liver disease: association with hepatitis C and fatty liver disease. <b>2010</b> , 16, 5065-9	19
398	Betaine and nonalcoholic steatohepatitis: back to the future?. <b>2011</b> , 17, 3663-4	9
397	Multi-modality treatment of colorectal liver metastases. <b>2012</b> , 18, 16-24	16

396	Identification of individuals with non-alcoholic fatty liver disease by the diagnostic criteria for the metabolic syndrome. <b>2012</b> , 18, 1508-16	67
395	Noninvasive parameters and hepatic fibrosis scores in children with nonalcoholic fatty liver disease. <b>2012</b> , 18, 1525-30	65
394	Potential role of Helicobacter pylori infection in nonalcoholic fatty liver disease. <b>2013</b> , 19, 7024-31	34
393	Pediatric non-alcoholic steatohepatitis: the first report on the ultrastructure of hepatocyte mitochondria. <b>2014</b> , 20, 4335-40	29
392	Role of liver biopsy in nonalcoholic fatty liver disease. <b>2014</b> , 20, 9026-37	104
391	Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic. <b>2014</b> , 20, 12082-101	122
390	Noninvasive imaging assessment of non-alcoholic fatty liver disease: focus on liver scintigraphy. <b>2015</b> , 21, 4432-9	6
389	Acoustic radiation force impulse imaging for assessing liver fibrosis in alcoholic liver disease. <b>2016</b> , 22, 4926-35	25
388	Fibrosis in nonalcoholic fatty liver disease: Noninvasive assessment using computed tomography volumetry. <b>2016</b> , 22, 8949-8955	5
387	Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease. <b>2020</b> , 26, 5919-5943	8
386	Effects of low-calorie diet on steatohepatitis in rats with obesity and hyperlipidemia. <b>2003</b> , 9, 2045-9	35
385	Combined Adiponectin Deficiency and Resistance in Obese Patients: Can It Solve Part of the Puzzle in Nonalcoholic Steatohepatitis. <b>2015</b> , 3, 298-302	2
384	Relationship between the production of autoantibodies to oxidized low-density lipoprotein and hepatic steatosis in patients with chronic hepatitis C. <b>2010</b> , 1, 663-668	6
383	Factors associated or related to with pathological severity of nonalcoholic fatty liver disease. <b>2004</b> , 19, 19-26	24
382	The effect of intermittent hypoxia on bodyweight, serum glucose and cholesterol in obesity mice. <b>2008</b> , 11, 869-75	19
381	Immunoregulation by lipids during the development of non-alcoholic steatohepatitis. <b>2015</b> , 4, 11-23	18
380	Comparative accuracy of CT, dual-echo MRI and MR spectroscopy for preoperative liver fat quantification in living related liver donors. <b>2016</b> , 26, 5-14	9
379	Validation of Remote Digital Frozen Sections for Cancer and Transplant Intraoperative Services. <b>2018</b> , 9, 34	26

378	Interobserver Agreement on Pathologic Features of Liver Biopsy Tissue in Patients with Nonalcoholic Fatty Liver Disease. <b>2016</b> , 50, 190-6	17
377	The Histologic Cut-off Point for Adjacent and Remote Non-neoplastic Liver Parenchyma of Hepatocellular Carcinoma in Chronic Hepatitis B Patients. <b>2012</b> , 46, 349-58	5
376	Folic acid supplementation prevents high fructose-induced non-alcoholic fatty liver disease by activating the AMPK and LKB1 signaling pathways. <b>2020</b> , 14, 309-321	3
375	VITAMIN D DEFICIENCY, A NONINVASIVE MARKER OF STEATOHEPATITIS IN PATIENTS WITH OBESITY AND BIOPSY PROVEN NONALCOHOLIC FATTY LIVER DISEASE. <b>2018</b> , 14, 76-84	2
374	Clinical Evaluation of Hepatic Fibrosis in Chinese Patients with Nonalcoholic Fatty Liver Disease with FibroScan. <b>2015</b> , 06, 115-123	1
373	Nonalcoholic steatohepatitis and insulin resistance in children. <b>2014</b> , 5, 917-23	12
372	Vitamin D levels do not predict the stage of hepatic fibrosis in patients with non-alcoholic fatty liver disease: A PRISMA compliant systematic review and meta-analysis of pooled data. <b>2018</b> , 10, 142-154	13
371	Anti-inflammatory and anti-oxidant effects of aloe vera in rats with non-alcoholic steatohepatitis. <b>2020</b> , 12, 363-377	10
370	Multicentric occurrence of hepatocellular carcinoma with nonalcoholic steatohepatitis. <b>2011</b> , 3, 15-23	11
369	Noninvasive predictors for liver fibrosis in patients with nonalcoholic steatohepatitis. <b>2011</b> , 3, 219-27	13
368	Surgically induced weight loss by gastric bypass improves non alcoholic fatty liver disease in morbid obese patients. <b>2012</b> , 4, 382-8	47
367	Increased bone mineral density in patients with non-alcoholic steatohepatitis. <b>2013</b> , 5, 627-34	7
366	Significance of serum leptin and adiponectin levels in Egyptian patients with chronic hepatitis C virus associated hepatic steatosis and fibrosis. <b>2013</b> , 5, 74-81	18
365	Transitions of histopathologic criteria for diagnosis of nonalcoholic fatty liver disease during the last three decades. <b>2014</b> , 6, 894-900	12
364	Vitamin E reduces liver stiffness in nonalcoholic fatty liver disease. <b>2015</b> , 7, 2749-56	9
363	Lack of hepcidin expression attenuates steatosis and causes fibrosis in the liver. <b>2016</b> , 8, 211-25	10
362	Infection Augments the Severity of Nonalcoholic Fatty Liver Disease in High-Fat/High-Fructose Diet-Fed Hamsters. <b>2019</b> , 101, 1161-1169	3
361	Combination curcumin and vitamin E treatment attenuates diet-induced steatosis in mice. <b>2017</b> , 8, 67-76	6

360	Fatty liver without a large "belly": Magnified review of non-alcoholic fatty liver disease in non-obese patients. <b>2017</b> , 8, 100-107	18
359	Prediction of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: An Enhanced Model of BARD Score. <b>2013</b> , 7, 323-8	20
358	Relationships between Genetic Variations of PNPLA3, TM6SF2 and Histological Features of Nonalcoholic Fatty Liver Disease in Japan. <b>2016</b> , 10, 437-45	20
357	Effects of Moderate Alcohol Drinking in Patients with Nonalcoholic Fatty Liver Disease. <b>2019</b> , 13, 308-314	6
356	Role of Tumor Necrosis Factor- $\beta$ Promoter Polymorphism and Insulin Resistance in the Development of Non-alcoholic Fatty Liver Disease in Obese Children. <b>2012</b> , 15, 44	5
355	Pre-and-post transplant considerations in patients with nonalcoholic fatty liver disease. <b>2014</b> , 4, 81-92	19
354	Non-alcoholic fatty liver disease (NAFLD)--a novel common aspect of the metabolic syndrome. <b>2006</b> , 150, 101-4	17
353	Dietary sucrose regulates the expression of the Cd36 gene in hepatic tissue of rats with obesity and Non Alcoholic Fatty Liver Disease (NAFLD). <b>2018</b> , 162, 99-106	3
352	Model for Non-Invasive Diagnosis of NAFLD Incorporating Caspase 3-Cleaved Cytokeratin-18: A Clinical, Serological, and Immunohistochemical Analysis. <b>2018</b> , 18,	1
351	Autopsy findings following gastric bypass surgery for morbid obesity. <b>2002</b> , 126, 1091-5	111
350	Assessment of the relationship between non-alcoholic fatty liver disease and CAD using MSCT. <b>2014</b> , 102, 10-8	4
349	Radiomics based on fluoro-deoxyglucose positron emission tomography predicts liver fibrosis in biopsy-proven MAFLD: a pilot study. <b>2021</b> , 18, 3624-3630	1
348	Exposure to environmental contaminants is associated with altered hepatic lipid metabolism in non-alcoholic fatty liver disease. <b>2021</b> ,	12
347	Nonalcoholic Fatty Liver Disease. <b>2022</b> , 295-323	
346	Liver biopsy in the real world-reporting, expert concordance and correlation with a pragmatic clinical diagnosis. <b>2021</b> , 54, 1472-1480	2
345	Capillin protects against non-alcoholic steatohepatitis through suppressing NLRP3 inflammasome activation and oxidative stress. <b>2021</b> , 43, 778-789	0
344	ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials. <b>2021</b> , 27, 1836-1848	14
343	2D-shear wave elastography: number of acquisitions can be reduced according to clinical setting. <b>2021</b> , 12, 145	0

- 342 Indole-3-Propionic Acid, a Gut-Derived Tryptophan Metabolite, Associates with Hepatic Fibrosis. **2021**, 13, 6
- 341 Adenosine deaminase 2 produced by infiltrative monocytes promotes liver fibrosis in nonalcoholic fatty liver disease. **2021**, 37, 109897 1
- 340 Non-alcoholic fatty liver disease as a medical and social problem. **2012**, 3, 71-80
- 339 Decompensation in Advanced Nonalcoholic Fatty Liver Disease May Occur at Lower Hepatic Venous Pressure Gradient Levels Than in Patients With Viral Disease. **2021**, 11
- 338 STE20-type kinase TAOK3 regulates hepatic lipid partitioning. **2021**, 54, 101353 1
- 337 PNPLA3 rs738409 C>G Variant Influences the Association Between Visceral Fat and Significant Fibrosis in Biopsy-proven Nonalcoholic Fatty Liver Disease. **2021**, 000, 000-000
- 336 MRI-based fat quantification of the liver: Is it time for commercially available products?. **2021**, 144, 109993 1
- 335 Metabolic disorders and storage diseases. **2002**, 519-574
- 334 Nichtalkoholische Leberverfettungen und Steatohepatitiden. **2003**, 659-671
- 333 Gender-Specific Issues in Liver Diseases. **2004**, 463-476
- 332 Pathology of Recurrence of Non-Neoplastic Disease After Liver Transplantation. **2005**, 1129-1148
- 331 Nutraceutical and Functional Food Application to Nonalcoholic Steatohepatitis. **2006**, 485-502
- 330 Cirrhosis and Portal Hypertension: Pathologic Aspects. **2007**, 1527-1540
- 329 Nonalcoholic Fatty Liver Disease and Diabetes Mellitus. **2007**, 553-560
- 328 Association of Lipid Profiles With Hepatitis C Viral Load in Chronic Hepatitis C Patients With Genotype 1 or 2 Infection. *American Journal of Gastroenterology*, **2009**, 104, 598-604 0.7 3
- 327 A case of nonalcoholic steatohepatitis associated with sicca syndrome in that autoimmune hepatitis was initially suspected but was correctly diagnosed by means of liver biopsy under laparoscopy. **2010**, 51, 65-70
- 326 ??????????????????????(NASH)??????????????. **2010**, 35, 216-220 2
- 325 Histopathological Scoring Systems. **2010**, 271-288

- 324 A Pathological Study of Chemotherapy-associated Liver Injury in Colorectal Hepatic Metastases. **2010**, 43, 20-26 3
- 323 Hepatic Fibrosis and Cirrhosis. **2011**, 449-466
- 322 Hemochromatosis. **2011**, 177-189 0
- 321 Alcoholic and Non-Alcoholic Fatty Liver Diseases. **2011**, 71-92 2
- 320 TWO CASES OF MULTICENTRIC HEPATOCELLULAR CARCINOMA ARISING FROM NONALCOHOLIC STEATOHEPATITIS (NASH) WITHOUT ADVANCED FIBROSIS. **2011**, 72, 1508-1515
- 319 Elevated Levels of Serum Ferritin May be Related to Non-Alcoholic Steatohepatitis. **2011**, 1, 13-20
- 318 A case of hepatocellular carcinoma arising from chronic hepatitis B caused by HBV genotype Ae and NASH without perisinusoidal fibrosis. **2012**, 53, 90-100
- 317 The Role of Inflammatory Mediators in the Pathogenesis of Nonalcoholic Fatty Liver Disease. **2012**, 15, 74 1
- 316 Obesity and its Hepatic Complications in Adults and Children. 244-262
- 315 Olmesartan for non-alcoholic steatohepatitis complicated with hypertension: An open-label study. **2013**, 03, 128-133 1
- 314 The Analysis of Non-pharmacological Intervention Study for Nonalcoholic Fatty Liver Disease: Intervention Types and Measurement Parameters. **2013**, 15, 43-53 1
- 313 [Non-alcoholic fatty liver disease and steatohepatitis]. **2013**, 154, 1124-34
- 312 The Liver in Metabolic Syndrome. **2014**, 27-61 0
- 311 A Case of Hepatocellular Carcinoma with Non-Alcoholic Steatohepatitis Complicated by Wernicke's Encephalopathy After Hepatectomy. **2014**, 39, 1161-1168
- 310 Exocyclic DNA Adducts in a Murine Model of Non-alcoholic Steatohepatitis. **2013**, 2013,
- 309 New Histological Staging and Grading System for Primary Biliary Cirrhosis. **2014**, 215-232
- 308 Diffuse hepatic steatosis (grading).
- 307 The Association of Low Free Testosterone with Histological Severity of Nonalcoholic Fatty Liver Disease in Japanese Men. **2015**, 2, 1



- 306 Liver Biopsy and Histopathological Diagnosis. 2950-2979
- 305 Nonalcoholic Fatty Liver Disease. 2056-2069
- 304 Clinicopathological Study of Hepatectomy for Non-B Non-C Hepatocellular Carcinoma. **2016**, 77, 2405-2410
- 303 Steatosis, Steatohepatitis and Related Conditions. **2016**, 101-125 2
- 302 [Clinical Importance of Non-alcoholic Fatty Liver Diseases. Topics: VI. Diagnostic procedures: when referring to specialists]. **2016**, 105, 47-55
- 301 n-3 LCPUFA in the reversal of hepatic steatosis: the role of ACOX and CAT-1. **2016**, 67, e134 1
- 300 Disruption of Hepatocyte Jak2 leads to Spontaneous NASH in Aged Mice and Uncouples Metabolic Liver Disease from Insulin Resistance.
- 299 Pediatric Nonalcoholic Fatty Liver Disease. **2016**, 293-307
- 298 Do I Need a Liver Biopsy?. **2017**, 27-39
- 297 Nonalcoholic Steatohepatitis. **2017**, 176-179
- 296 Dyslipidemic Effect of Pravastatin and Herbal Medicine in Rats. **2017**, 38, 327-335 1
- 295 Alcohol-Related Histopathology. **2018**, 171-185
- 294 Incidence of nonalcoholic fatty liver disease in patients undergoing laparoscopic cholecystectomy. **2018**, 7, 1375-1378 2
- 293 Expansion of intrahepatic lymphocytes expressing PD-1 and bcl-2 in chronic hepatitis C. **2018**, 38, 105-109
- 292 Recipient But Not Donor Adiponectin Polymorphisms Are Associated With Early Posttransplant Hepatic Steatosis in Patients Transplanted for Non-Nonalcoholic Fatty Liver Disease Indications. **2018**, 16, 439-445 5
- 291 Cryptogenic Cirrhosis. **2019**, 331-349
- 290 Alcoholic Liver Disease and Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. **2019**, 75-84 1
- 289 Predictive Performance of Ultrasound-Determined Non-Alcoholic Fatty Pancreas Disease Severity for Intermediate and High Risk of Coronary Heart Disease. **2019**, 80, 1190 0

- 288 Liver Cirrhosis with Steatohepatitis: Nonalcoholic Steatohepatitis and Alcoholic Steatohepatitis. **2019**, 1-21
- 287 Potential Toxic Effects of Olanzapine on Metabolic Parameters in &#x26;de Novo&/i>; Paranoid Schizophrenic Patients. The Role of Adjunctive Aripiprazole: Clinical and Experimental Study. **2019**, 07, 91-113
- 286 Association between Helicobacter pylori Infection and Nonalcoholic Fatty Liver Disease. **2019**, 9, 5-9
- 285 Electrocardiographic and echocardiographic changes in nonalcoholic fatty liver disease. **2019**, 31, 191-198 ○
- 284 Acceleration of chemical shift encoding-based water fat MRI for liver proton density fat fraction and T2\* mapping using compressed sensing. ○
- 283 Serum miR-379 expression is related to the development and progression of hypercholesterolemia in non-alcoholic fatty liver disease.
- 282 FICK-3 Score Combining Fibrosis-4, Insulin Resistance and Cytokeratin-18 in Predicting Non-alcoholic Steatohepatitis in NAFLD Egyptian Patients. **2019**, 22, 457-466 2
- 281 Loss of ELK1 has differential effects on age-dependent organ fibrosis and integrin expression.
- 280 Fibrosis Assessment via Liver Stiffness Measurements: How Many Patients Are Spared from a Liver Biopsy?. **2020**, 563-588
- 279 Low real-world eligibility rates for nonalcoholic steatohepatitis patients for phase 3 clinical trial criteria application in a large academic health system. **2021**, 33, 424-429
- 278 A scoring system for the diagnosis of non-alcoholic steatohepatitis from liver biopsy. **2020**, 54, 228-236 ○
- 277 Cirrhosis in a Young Child Due to Fatty Liver; Importance of Early Screening: A Case Report and Review of the Literature. **2020**, 21, e923250 ○
- 276 PENGARUH PEMBERIAN PROPOLIS LEBAH TERHADAP GAMBARAN HISTOPATOLOGI HEPAR MENCIT (*Mus musculus*) BETINA YANG DIPAPAR LOGAM BERAT PB ASETAT [Pb(C<sub>2</sub>H<sub>3</sub>O<sub>2</sub>)<sub>2</sub>]. **2020**, 8, 21
- 275 Anti-inflammatory and anti-oxidant effects of aloe vera in rats with non-alcoholic steatohepatitis. **2020**, 12, 364-378
- 274 Gut microbiome signatures distinguish type 2 diabetes mellitus from non-alcoholic fatty liver disease. **2021**, 19, 5920-5930 1
- 273 Effects of Sodium-Glucose Cotransporter 2 Inhibition on Glucose Metabolism, Liver Function, Ascites, and Hemodynamics in a Mouse Model of Nonalcoholic Steatohepatitis and Type 2 Diabetes. **2020**, 2020, 1682904 3
- 272 Use of Ultrasound Microscopy for Ex Vivo Analysis of Acoustic Impedance in Mouse Liver with Steatohepatitis. **2021**, 3, 3-10
- 271 MSDC-0602K, A Novel Insulin-Sensitizer Improves Insulinemia and Fatty Liver Disease Alone and in Addition to Liraglutide in Mice.

270	Ultrasound Sample Entropy Imaging: A New Approach for Evaluating Hepatic Steatosis and Fibrosis. <b>2021</b> , 9, 1800612	0
269	Relationships between severity of steatosis with glycemic control and carotid intima-media thickness among diabetic patients with ischemic heart disease. <b>2020</b> , 25, 64	2
268	The role of non-invasive scores in determining the liver fibrosis in NAFLD and psoriatic patients. <b>2020</b> , 61, 503-511	1
267	Medikamentö-toxischer Leberschaden (DILI). <b>2020</b> , 117-157	
266	Biomarkers in Pediatric NAFLD. <b>2020</b> , 69-88	
265	Histopathology of Nonalcoholic Fatty Liver Disease. <b>2020</b> , 25-47	
264	Current status and prospects for quantitative analysis of digital image of pathological specimen using image processing software including artificial intelligence. <b>2020</b> , 2, 72-79	1
263	Type 2 diabetes mellitus-related non-alcoholic steatohepatitis in the Zucker Diabetic Sprague Dawley rat. <b>2020</b> , 2, 89-95	
262	Issues regarding NAFLD~From the changes and problems in the pathological diagnosis of NASH to the confusion of nomenclature change. <b>2021</b> , 62, 681-689	
261	The Role of Gut-Derived Lipopolysaccharides and the Intestinal Barrier in Fatty Liver Diseases. <b>2021</b> , 1	5
260	Comparative pathology. <b>2008</b> , 47-73	
259	Metabolic disorders and storage diseases. <b>2006</b> , 577-635	
258	Predictive value of perfusion CT for blood loss in liver resection. <b>2020</b> , 14, 384-389	
257	Frequency of nonalcoholic fatty liver disease and degree of hepatic steatosis in African-American patients. <b>2006</b> , 98, 1613-5	19
256	Regulation of oxidative stress and inflammation by hepatic adiponectin receptor 2 in an animal model of nonalcoholic steatohepatitis. <b>2010</b> , 3, 472-81	25
255	Non-alcoholic fatty liver disease and correlation of serum alanin aminotransferase level with histopathologic findings. <b>2011</b> , 11, 452-8	19
254	Effects of increased dietary cholesterol with carbohydrate restriction on hepatic lipid metabolism in Guinea pigs. <b>2012</b> , 62, 109-15	16
253	Association of pro-inflammatory cytokines, adipokines & oxidative stress with insulin resistance & non-alcoholic fatty liver disease. <b>2012</b> , 136, 229-36	33

252	Serum leptin levels correlate with body mass index but not with histologic disease severity in Indian patients with non-alcoholic steatohepatitis: a pilot study. <b>2013</b> , 137, 986-7	4
251	The de ritis ratio: the test of time. <b>2013</b> , 34, 117-30	182
250	Non-alcoholic steatohepatitis: the therapeutic challenge of a global epidemic. <b>2012</b> , 25, 207-217	11
249	Probiotics and Nonalcoholic Fatty liver Disease. <b>2013</b> , 5, 129-36	37
248	Metformin in nonalcoholic steatohepatitis: a randomized controlled trial. <b>2012</b> , 4, 16-22	4
247	The relationship between resistin and ghrelin levels with fibrosis in nonalcoholic fatty liver disease. <b>2014</b> , 19, 1058-61	8
246	Curcumin prevents the non-alcoholic fatty hepatitis via mitochondria protection and apoptosis reduction. <b>2015</b> , 8, 11503-9	12
245	A Comparison of Brunt's Criteria, the Non-Alcoholic Fatty Liver Disease Activity Score (NAS), and a Proposed NAS Scoring that Includes Fibrosis in Non-Alcoholic Fatty Liver Disease Staging. <b>2015</b> , 34, 189-94	17
244	Prevalence of hepatic steatosis and associated factors in Iranian patients with chronic hepatitis C. <b>2016</b> , 30, 322	2
243	Nonalcoholic Fatty Liver Disease: Clinical Features and Pathogenesis. <b>2006</b> , 2, 282-291	8
242	Liver biopsy diagnosis of hepatitis: clues to clinically-meaningful reporting. <b>2010</b> , 107, 113-8	4
241	Diagnosis of steatohepatitis and fibrosis in biopsy-proven nonalcoholic fatty liver diseases: including two-dimension real-time shear wave elastography and noninvasive fibrotic biomarker scores.. <b>2022</b> , 12, 1800-1814	0
240	Effect of vanillic acid and exercise training on fatty liver and insulin resistance in rats: Possible role of fibroblast growth factor 21 and autophagy. <b>2021</b> ,	0
239	PNPLA3 genotype and fibrosis-4 index predict cardiovascular diseases of Japanese patients with histopathologically-confirmed NAFLD. <b>2021</b> , 21, 434	1
238	Molecular and histological traits of reduced lysosomal acid lipase activity in the fatty liver. <b>2021</b> , 12, 1092	1
237	Hepatic retinaldehyde dehydrogenases are modulated by tocopherol supplementation in mice with hepatic steatosis.. <b>2021</b> , 94, 111539	
236	Nitric oxide facilitates the targeting Kupffer cells of a nano-antioxidant for the treatment of NASH. <b>2021</b> ,	0
235	Accumulation of Genetic and Epigenetic Alterations in the Background Liver and Emergence of Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease. <b>2021</b> , 10,	2

- 234 Selenotranscriptome Network in Non-alcoholic Fatty Liver Disease. **2021**, 8, 744825 2
- 233 Dynamics of Circulating miR-122 Predict Liver Cancer and Mortality in Japanese Patients with Histopathologically Confirmed NAFLD and Severe Fibrosis Stage. **2021**, 1-8 0
- 232 Mendelian randomization analysis identifies blood tyrosine levels as a biomarker of non-alcoholic fatty liver disease.
- 231 Diabetes and hypercholesterolemia experimental study on inhibition of liver fibrosis by angiotensin converting enzymes. **2021**, 14, 107-112
- 230 An Overview on Non-invasive Assessment of Cirrhosis. **2021**, 12, 42-48
- 229 Pathologic Diagnosis of Nonalcoholic Fatty Liver Disease. **2021**, 1
- 228 Assessment of hepatic steatosis based on virtual non-contrast computed tomography: Initial experiences with a photon counting scanner approved for clinical use.. **2022**, 149, 110185 2
- 227 T- and B-Cells in the Inner Invasive Margin of Hepatocellular Carcinoma after Resection Associate with Favorable Prognosis.. **2022**, 14, 0
- 226 Plasma sgp130 is an independent predictor of non-alcoholic fatty liver disease severity.
- 225 Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO).. **2021**, 1
- 224 The egyptian clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.. **2022**, 0
- 223 Noninvasive estimation of local speed of sound by pulse-echo ultrasound in a rat model of nonalcoholic fatty liver.. **2021**, 1
- 222 Clinical Outcomes in Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients: A Multicenter Registry-Based Cohort Study.. **2022**, 2
- 221 Vibration controlled transient elastography for non-invasive evaluation of liver steatosis.. **2022**, 0
- 220 Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO).. **2021**, 1
- 219 Prevalence of fatty liver disease after liver transplantation and risk factors for recipients and donors.. **2022**, 100670 0
- 218 Advances in fibrosis biomarkers in nonalcoholic fatty liver disease.. **2022**, 106, 33-65 0
- 217 J-shaped relationship between serum zinc levels and the severity of hepatic necro-inflammation in patients with MAFLD.. **2022**, 2

216	The potential of soluble CD14 in discriminating nonalcoholic steatohepatitis from nonalcoholic fatty liver disease.. <b>2022,</b>	
215	Liver Decompensation after Bariatric Surgery in the Absence of Cirrhosis.. <b>2022, 32, 1227</b>	0
214	Altered branched-chain keto acid metabolism is a feature of NAFLD in individuals with severe obesity.	
213	The Translational Bridge between Inflammation and Hepatocarcinogenesis.. <b>2022, 11,</b>	3
212	Resveratrol ameliorates nutritional steatohepatitis through the mmu-miR-599/PXR pathway.. <b>2022, 49,</b>	0
211	Histopathological Diagnosis of Nonalcoholic Steatohepatitis (NASH).. <b>2022, 2455, 1-18</b>	0
210	OUP accepted manuscript.	
209	Hepatic PRMT1 ameliorates diet-induced hepatic steatosis via induction of PGC1 $\beta$ <b>2022, 12, 2502-2518</b>	0
208	The Concept of Indeterminable NASH Inducted by Preoperative Diet and Metabolic Surgery: Analyses of Histopathological and Clinical Features.. <b>2022, 10,</b>	0
207	Histological assessment based on liver biopsy: the value and challenges in NASH drug development.. <b>2022,</b>	0
206	Liver biopsy for assessment of chronic liver diseases: a synopsis.. <b>2022, 1</b>	1
205	Methanolic L. Extract Ameliorates Cisplatin-Induced Hepatic Injury in Male Rats.. <b>2022, 14,</b>	2
204	The Utility and Diagnostic Accuracy of Transient Elastography in Adults with Morbid Obesity: A Prospective Study.. <b>2022, 11,</b>	0
203	Bone morphogenetic protein 2 is a new molecular target linked to nonalcoholic fatty liver disease with potential value as non-invasive screening tool.	
202	Biochemical and Histopathological Investigation of Liver Tissues on High Fat Diet Fed Rats. <b>2022, 23, 101-107</b>	
201	Expanding donor pool for live donor liver transplantation: utilization of donors with non-alcoholic steatohepatitis after optimization.. <b>2022, 1</b>	1
200	Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (NAFLD).. <b>2022,</b>	0
199	Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population.. <b>2022,</b>	0

198	Chia seeds and chemical-elicited sprouts supplementation ameliorates insulin resistance, dyslipidemia, and hepatic steatosis in obese rats.. <b>2022</b> , e14136	0
197	Utility of sonic hedgehog and keratin 8/18 immunohistochemistry for detecting ballooned hepatocytes.. <b>2022</b> ,	0
196	Anti-nuclear antibody and a granuloma could be biomarkers for iCIs-related hepatitis by anti-PD-1 treatment.. <b>2022</b> , 12, 3669	0
195	Reliability of Histologic Assessment for NAFLD and Development of an Expanded NAFLD Activity Score.. <b>2022</b> ,	0
194	Hepatic promotes nonalcoholic fatty liver disease by suppressing .. <b>2021</b> , 10,	1
193	Lactoferrin Prevents Hepatic Injury and Fibrosis via the Inhibition of NF- $\kappa$ B Signaling in a Rat Non-Alcoholic Steatohepatitis Model.. <b>2021</b> , 14,	0
192	Human Genetics to Identify Therapeutic Targets for NAFLD: Challenges and Opportunities.. <b>2021</b> , 12, 777075	1
191	Quantitative evaluation of hepatic steatosis using novel ultrasound technology normalized local variance (NLV) and its standard deviation with different ROIs in patients with metabolic-associated fatty liver disease: a pilot study.. <b>2021</b> , 47, 693	0
190	Accuracy of Controlled Attenuation Parameter for Assessing Liver Steatosis in Individuals With Morbid Obesity Before Bariatric Surgery. <b>2021</b> ,	0
189	Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO).. <b>2021</b> , 1	1
188	The impact of health status, diet and lifestyle on non-alcoholic fatty liver disease: Narrative review.. <b>2022</b> , e12525	0
187	The Chromatin Accessibility Landscape of Nonalcoholic Fatty Liver Disease Progression.. <b>2022</b> ,	0
186	Paediatric non-alcoholic fatty liver disease: an approach to pathological evaluation.. <b>2022</b> ,	0
185	Non-alcoholic Fatty Liver Disease prevalence in Latin America: A systematic review and meta-analysis.. <b>2022</b> , 100706	0
184	Development and Validation of a Score for Fibrotic Non-Alcoholic Steatohepatitis.. <b>2022</b> ,	0
183	Pairing 3D-Printing with Nanotechnology to Manage Metabolic Syndrome.. <b>2022</b> , 17, 1783-1801	
182	Image_1.PDF. <b>2018</b> ,	
181	Image_2.PDF. <b>2018</b> ,	

180	Table_1.DOCX. 2018,	
179	Table_2.DOCX. 2018,	
178	Data_Sheet_1.pdf. 2020,	
177	A review of hepatic fibrosis-associated histopathology in aged cadavers.. 2022,	1
176	Prevalence of Nonalcoholic Fatty Liver Disease in Children with Renal Failure Underwent Treatment with Dialysis.. 2022, 13, 35	
175	Gastrointestinal Imaging: Liver Fat and Iron Quantification. 2022, 235-244	
174	Higher hepatic advanced glycation end products and liver damage markers are associated with non-alcoholic steatohepatitis. 2022,	
173	Receptor-interacting protein kinase-1 ablation in liver parenchymal cells promotes liver fibrosis in murine NASH without affecting other symptoms.. 2022, 1	0
172	Physiological Changes in Chicken Embryos Inoculated with Drugs and Viruses Highlight the Need for More Standardization of this Animal Model.. 2022, 12,	0
171	A new detection system for serum fragmented cytokeratin 18 as a biomarker reflecting histologic activities of human nonalcoholic steatohepatitis.. 2022,	1
170	Comparison of thrombocytopenia between patients with non-alcoholic fatty liver disease and those with hepatitis C virus-related chronic liver disease.. 2022,	1
169	Endoscopic ultrasound-guided portal pressure gradient with liver biopsy: 6 years of endo-hepatology in practice.. 2022,	3
168	Prevalence and clinical significance of portal inflammation, portal plasma cells, interface hepatitis and biliary injury in liver biopsies from patients with non-alcoholic steatohepatitis.. 2022,	0
167	Evaluation of Liver Metabolism Biomarkers in Metabolic Associated Fatty Liver Disease According to Obesity Phenotype.. 2022, 1-8	
166	Mendelian Randomization Analysis Identifies Blood Tyrosine Levels as a Biomarker of Non-Alcoholic Fatty Liver Disease. 2022, 12, 440	2
165	Implementation of a healthy diet to lactating rats attenuates the early detrimental programming effects in the offspring born to obese dams. Putative relationship with milk hormone levels.. 2022, 109043	0
164	Lamivudine Treatment in Hbeag-Negative Chronic Hepatitis B Patients with Low Level Viraemia. 2005, 10, 319-325	6
163	Influence of Metabolic Syndrome, Viral Genotype and Antiviral Therapy on Superimposed Fatty Liver Disease in Chronic Hepatitis C. 2005, 10, 405-415	20



162	Serum $\alpha$ -fetoprotein Level Predicts Treatment Outcome in Chronic Hepatitis C. <b>2007</b> , 12, 797-803	29
161	HIV Coinfection and Antiretroviral Therapy Enhances Liver Steatosis in Patients with Hepatitis C, but Only in those Infected by HCV Genotype other than 3. <b>2008</b> , 13, 1057-1065	11
160	Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy. <b>2009</b> , 14, 45-54	25
159	Impact of non-invasive biomarkers on hepatology practice: Past, present and future.. <b>2022</b> , 76, 1362-1378	1
158	Favorable impact of long-term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5-year follow-up study.. <b>2022</b> ,	0
157	Bone morphogenetic protein 2 is a new molecular target linked to non-alcoholic fatty liver disease with potential value as non-invasive screening tool. <b>2022</b> , 10,	
156	Incidental hepatic tissue detected at cholecystectomy is potentially clinically significant. <b>2022</b> , 28, 300651	
155	Comparison of point-shear wave elastography (ElastPQ) and FibroScan for liver fibrosis staging in patients with NAFLD.	1
154	Vitamin E for people with non-alcoholic fatty liver disease. <b>2022</b> , 2022,	
153	Applications of Quantitative Systems Pharmacology (QSP) in Drug Development for NAFLD and NASH and Its Regulatory Application.	0
152	Nicotinamide Riboside Supplementation to Suckling Male Mice Improves Lipid and Energy Metabolism in Skeletal Muscle and Liver in Adulthood. <b>2022</b> , 14, 2259	0
151	The Role of Thiazolidinediones in the Amelioration of Nonalcoholic Fatty Liver Disease: A Systematic Review. <b>2022</b> ,	
150	A diet-induced murine model for non-alcoholic fatty liver disease with obesity and insulin resistance that rapidly develops steatohepatitis and fibrosis.	0
149	Non-invasive diagnosis and staging of non-alcoholic fatty liver disease.	0
148	Effect of exercise and curcumin on cardiomyocyte molecular mediators associated with oxidative stress and autophagy in aged male rats. <b>2022</b> , 143, 104380	0
147	Combinational elastography for assessment of liver fibrosis in patients with liver injury. <b>2022</b> , 50, 030006052211001	
146	Selective biliary occlusion in rodents: description of a new technique. <b>2022</b> ,	
145	Probiotics and their beneficial effects on alcohol-induced liver injury in a rat model: the role of fecal microbiota. <b>2022</b> , 22,	1

- 144 Ptpn1 deletion protects oval cells against lipoapoptosis by favoring lipid droplet formation and dynamics. 0
- 143 Inhibition of MAP4K4 Signaling Initiates Metabolic Reprogramming to Protect Hepatocytes from Lipotoxic Damage. **2022**, 100238
- 142 Non-Alcoholic Fatty Liver Disease and Extrahepatic Cancers: A Wolf in Sheep's Clothing?. **2022**, 29, 4478-4510 0
- 141 Histopathological findings of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. **2022**,
- 140 OBSTRUCTIVE SLEEP APNEA SYNDROME RISK IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE IS ASSOCIATED WITH OBESITY AND PRESENCE OF NASH. **2022**, 59, 251-256
- 139 Replication stress triggered by nucleotide pool imbalance drives DNA damage and cGAS-STING pathway activation in NAFLD. **2022**, 1
- 138 Digital pathology with artificial intelligence analyses provides greater insights into treatment-induced fibrosis regression in NASH. **2022**, 2
- 137 Diagnosing Pediatric NAFLD. **2022**, 1, 13-20
- 136 Current treatment of non-alcoholic fatty liver disease. 0
- 135 Altered branched-chain keto acid metabolism is a feature of NAFLD in individuals with severe obesity. 1
- 134 Characteristics of advanced liver fibrosis among patients with lower FIB-4 index or NAFLD fibrosis score. **2022**, 63, 342-345
- 133 AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review. **2022**, 6
- 132 HSPA8 Single-Nucleotide Polymorphism Is Associated with Serum HSC70 Concentration and Carotid Artery Atherosclerosis in Nonalcoholic Fatty Liver Disease. **2022**, 13, 1265 0
- 131 Correlation between hepatorenal index and attenuation imaging for assessing hepatic steatosis. 0
- 130 NASH Presence is Associated with a Lower Weight Loss One and 2 Years After Bariatric Surgery in Women with Severe Obesity. 0
- 129 The P2X7R-NLRP3 and AIM2 Inflammasome Platforms Mark the Complexity/Severity of Viral or Metabolic Liver Damage. **2022**, 23, 7447 0
- 128 Machine Learning Models Are Superior to Non-Invasive Tests in Identifying Clinically Significant Stages of NAFLD and NAFLD-Related Cirrhosis. 0
- 127 Hepatic patatin-like phospholipase domain-containing 3 levels are increased in I148M risk allele carriers and correlate with NAFLD in humans. 0

- 126 Celecoxib-mediated attenuation of non-alcoholic steatohepatitis is potentially relevant to redistributing the expression of adiponectin receptors in rats. **2022**, 8, e09872
- 125 Hiperbilirrubinemia: visi3n del pat3logo. **2022**, 176-190
- 124 New Insights of OLFM2 and OLFM4 in Gut-Liver Axis and Their Potential Involvement in Nonalcoholic Fatty Liver Disease. **2022**, 23, 7442 1
- 123 Species specific morphological alterations in liver tissue after biliary occlusion in rat and mouse: Similar but different. **2022**, 17, e0271975
- 122 Diagnosis and Therapy of Non-alcoholic Steatohepatitis (NASH). **2021**, 110, 1670-1676
- 121 Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial. 0
- 120 Prevalence and Significance of Antinuclear Antibodies in Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. **2022**, 2022, 1-12 0
- 119 Clinicopathologic features of de novo non-alcoholic steatohepatitis in the post-transplant setting. **2022**, 17, 0
- 118 BMP4 and Gremlin 1 regulate hepatic cell senescence during clinical progression of NAFLD/NASH. **2022**, 4, 1007-1021 1
- 117 Comparison of long-term prognosis between non-obese and obese patients with non-alcoholic fatty liver disease. 0
- 116 Quantitative Prediction of Steatosis in Patients with Non-Alcoholic Fatty Liver by Means of Hepatic MicroRNAs Present in Serum and Correlating with Hepatic Fat. **2022**, 23, 9298
- 115 LCHP Diet Enriched with Cholesterol Promotes Non-Alcoholic Fatty Liver Disease in Wistar Rats. **2022**, 12, 8266
- 114 Metabolic-associated fatty liver disease is associated with low muscle mass and strength in patients with chronic hepatitis B. **2022**, 14, 1652-1666 0
- 113 Ameliorating Effects of Bioactive Peptides Extracted from *Litopenaeus vannamei* Wastes on Oxidative Stress, Glucose Regulation, and Autophagy Gene Expression in Nonalcoholic Fatty Liver-Induced Rats. **2022**, 2022, 1-12
- 112 Benefits of Physical Exercise as Approach to Prevention and Reversion of Non-Alcoholic Fatty Liver Disease in Children and Adolescents with Obesity. **2022**, 9, 1174 1
- 111 The intake of 3-sterol partially counteracts metformin beneficial effects in diet-induced obese rats. **2022**, 96, 105223
- 110 Etat des lieux sur la physiopathologie, le diagnostic et les traitements de la st3to-h3patite non alcoolique (NASH). **2022**, 0
- 109 Ancestral BPA exposure caused defects in the liver of medaka for four generations. **2022**, 159067 0

- 108 Hepatic gene expression and functional changes associated with nonalcoholic steatohepatitis. **2022**, 26, 0
- 107 Non-alcoholic fatty liver disease (NAFLD) in lean individuals [Single centre large cohort clinicopathologic and immunophenotypic study. **2022**, 238, 154112 0
- 106 Diagnostik: Algorithmus und Leberbiopsie. **2022**, 167-179 0
- 105 Pathologie. **2022**, 21-28 0
- 104 The Change in the Fibrosis-4 Index for the Assessment of Liver Fibrosis After Pancreaticoduodenectomy. **2022**, 51, 624-627 0
- 103 Short-term high fat diet feeding of mice suppresses catecholamine-stimulated Ca<sup>2+</sup> signalling in hepatocytes and intact liver. 0
- 102 Increased Secreted Frizzled-Related Protein 5 mRNA Expression in the Adipose Tissue of Women with Nonalcoholic Fatty Liver Disease Associated with Obesity. **2022**, 23, 9871 0
- 101 Natural flavonoids: Potential therapeutic strategies for non-alcoholic fatty liver disease. 13, 0
- 100 Pulse-Echo Quantitative US Biomarkers for Liver Steatosis: Toward Technical Standardization. 0
- 99 Risk predictors of advanced hepatic fibrosis in patients with nonalcoholic fatty liver disease [A survey in a university hospital in Brazil. **2022**, 0
- 98 Morphofunctional State and Circadian Rhythms of the Liver of Female Rats under the Influence of Chronic Alcohol Intoxication and Constant Lighting. **2022**, 23, 10744 0
- 97 Association between SII and hepatic steatosis and liver fibrosis: A population-based study. 13, 2
- 96 The Role of FXR and TGR5 in Reversing and Preventing Progression of Western Diet-induced Hepatic Steatosis, Inflammation, and Fibrosis in Mice. **2022**, 102530 0
- 95 In vitro and in vivo hepatotoxicity study of Afriplex [GRT through an inflammatory response. **2022**, 9, 1920-1928 1
- 94 Outcomes of fatty liver disease with and without metabolic comorbidities and risk factors for mortality. 0
- 93 A 3-step approach to predict advanced fibrosis in nonalcoholic fatty liver disease: impact on diagnosis, patient burden, and medical costs. **2022**, 12, 0
- 92 Higher Risk of Tumor Recurrence in NASH-Related Hepatocellular Carcinoma Following Curative Resection. **2022**, 14, 2427 0
- 91 Predictive Power of Tissue and Circulating Biomarkers for the Severity of Biopsy-Validated Chronic Liver Diseases. **2022**, 11, 5985 0

90	Wnt/beta-catenin signaling and its modulators in nonalcoholic fatty liver diseases. <b>2022,</b>	0
89	Advancements in MAFLD Modeling with Human Cell and Organoid Models. <b>2022, 23, 11850</b>	1
88	The additive effect of genetic and metabolic factors in the pathogenesis of nonalcoholic fatty liver disease. <b>2022, 12,</b>	0
87	Low-molecular weight oligosaccharides from gum tragacanth ( <i>Astragalus gossypinus</i> ) ameliorate nonalcoholic fatty liver disease ( NAFLD ) in Wistar male rats.	0
86	Rhamnan sulfate reduces atherosclerotic plaque formation and vascular inflammation. <b>2022, 291, 121865</b>	1
85	Zinc normalizes hepatic lipid handling via modulation of ADA/XO/UA pathway and caspase 3 signaling in highly active antiretroviral therapy-treated Wistar rats. <b>2022, 368, 110233</b>	0
84	Identification of a Fatty Acid for Diagnosing Non-Alcoholic Steatohepatitis in Patients with Severe Obesity Undergoing Metabolic Surgery. <b>2022, 10, 2920</b>	0
83	Non-alcoholic fatty liver disease: the pathologist's perspective.	0
82	Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. <b>2022,</b>	1
81	Oral Administration of Recombinant Lactoferrin-Expressing Probiotics Ameliorates Diet-Induced Lipid Accumulation and Inflammation in Non-Alcoholic Fatty Liver Disease in Mice. <b>2022, 10, 2215</b>	1
80	RESISTIN GENE POLYMORPHISM AND NONALCOHOLIC FATTY LIVER DISEASE RISK.	0
79	Exosomal microRNAs and Progression of Nonalcoholic Steatohepatitis (NASH). <b>2022, 23, 13501</b>	1
78	Fully connected neural network-based serum surface-enhanced Raman spectroscopy accurately identifies non-alcoholic steatohepatitis.	0
77	Significance of elevated serum and hepatic NOD-like receptor pyrin domain containing 3 (NLRP3) in hepatitis C virus-related liver disease. <b>2022, 12,</b>	0
76	Pathologic features and differential diagnosis of chronic hepatitis. <b>2022,</b>	0
75	Deep learning-based quantification of NAFLD/NASH progression in human liver biopsies. <b>2022, 12,</b>	0
74	Comparative Study of Segmentation Methods of Rat Sinusoidal Network to Evaluate Nonalcoholic Steatohepatitis for Small Number of Medical Samples. <b>2022, 10, 192-202</b>	0
73	Dissecting the multifaceted impact of statin use on fatty liver disease: A multidimensional study. <b>2023, 87, 104392</b>	0

72	Manifestation of Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis in Different Dietary Mouse Models. 94-102	0
71	Association of serum albumin levels and long-term prognosis in patients with biopsy- confirmed nonalcoholic fatty liver disease.	0
70	Serum metabolomics-based heterogeneities and screening strategy for metabolic dysfunction-associated fatty liver disease (MAFLD). <b>2022</b> ,	1
69	Trends in prevalence of probable fibrotic nonalcoholic steatohepatitis in the United States, 1999-2016.	0
68	The human liver lipidome is significantly related to the lipid composition and aggregation susceptibility of low-density lipoprotein (LDL) particles. <b>2022</b> , 363, 22-29	0
67	Validation of a Diet-Induced Macaca fascicularis Model of Nonalcoholic Steatohepatitis with Dietary and Pioglitazone Interventions.	0
66	Amelioration of non-alcoholic fatty liver disease by targeting G protein-coupled receptor 110: A preclinical study.	0
65	Quantification of DNA methylation for carcinogenic risk estimation in patients with non-alcoholic steatohepatitis. <b>2022</b> , 14,	0
64	Cystic fibrosis rabbits develop spontaneous hepatobiliary lesions and CFLD-like phenotypes.	0
63	Ferroptosis plays a novel role in nonalcoholic steatohepatitis pathogenesis. 13,	0
62	Effects of a high-fat diet on the growth performance, lipid metabolism, and the fatty acids composition of liver and skin fat in Pekin ducks aged from 10 to 40 days. <b>2022</b> , 102429	0
61	Upper gut heat shock proteins HSP70 and GRP78 promote insulin resistance, hyperglycemia, and non-alcoholic steatohepatitis. <b>2022</b> , 13,	0
60	Increased Hepatic ATG7 mRNA and ATG7 Protein Expression in Nonalcoholic Steatohepatitis Associated with Obesity. <b>2023</b> , 24, 1324	0
59	Identification of patients with type 2 diabetes with non-alcoholic fatty liver disease who are at increased risk of progressing to advanced fibrosis: a cross-sectional study. <b>2023</b> , 13, e063959	0
58	Machine learning liver histology scores correlate with portal hypertension assessments in nonalcoholic steatohepatitis cirrhosis.	0
57	Gut microbiota and bile acids partially mediate the improvement of fibroblast growth factor 21 on methionine-choline-deficient diet-induced non-alcoholic fatty liver disease mice. <b>2023</b> , 195, 199-218	0
56	Clinical Significance of Pancreatic Fat in Children. <b>2022</b> , 51, 972-975	0
55	Non-alcoholic fatty liver disease: Definition and subtypes.	0

- 54 Caspase-11 promotes high-fat diet-induced NAFLD by increasing glycolysis, OXPHOS, and pyroptosis in macrophages. 14,
- 53 Liver fibrosis: the good, the bad and the patchy - an update. **2023**,
- 52 The transcription factor ATF3 switches cell death from apoptosis to necroptosis in hepatic steatosis in male mice. **2023**, 14,
- 51 Impact of a Novel Digital Therapeutics System on Nonalcoholic Steatohepatitis: The NASH App Clinical Trial. **2023**, Publish Ahead of Print,
- 50 Liver fibrosis is closely related to metabolic factors in metabolic associated fatty liver disease with hepatitis B virus infection. **2023**, 13,
- 49 Secondary bile acids improve risk prediction for non-invasive identification of mild liver fibrosis in nonalcoholic fatty liver disease.
- 48 Impaired Function of Solute Carrier Family 19 Leads to Low Folate Levels and Lipid Droplet Accumulation in Hepatocytes. **2023**, 11, 337
- 47 Unpaired virtual histological staining using prior-guided generative adversarial networks. **2023**, 105, 102185
- 46 Artificial intelligence and deep learning: New tools for histopathological diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. **2023**, 21, 2495-2501
- 45 Liver saturated fat content associates with hepatic DNA methylation in obese individuals. **2023**, 15,
- 44 Longitudinal ultrasound imaging and network modeling in rats reveal sex-dependent suppression of liver regeneration after resection in alcoholic liver disease. 14,
- 43 Hepatocytic ballooning in non-alcoholic steatohepatitis: Dilemmas and future directions.
- 42 Pharmacological inhibition of CFTR attenuates nonalcoholic steatohepatitis (NASH) progression in mice. **2023**, 1869, 166662
- 41 Monte Carlo modeling of hepatic steatosis based on stereology and spatial distribution of fat droplets. **2023**, 233, 107494
- 40 Special Population. **2023**, 27, 471-482
- 39 Does lithium attenuate the liver damage due to oxidative stress and liver glycogen depletion in experimental common bile duct obstruction?. **2023**, 466, 116489
- 38 Non-Neoplastic Disorders of the Liver. **2024**, 489-556
- 37 A novel non-invasive model for the prediction of advanced liver fibrosis in chronic hepatitis B patients with NAFLD. **2023**, 30, 287-296

- 36 Empagliflozin versus sitagliptin for ameliorating intrahepatic lipid content and tissue-specific insulin sensitivity in patients with early-stage type 2 diabetes with non-alcoholic fatty liver disease: A prospective randomized study. ○
- 35 The liver-kidney axis: Is serum leptin a potential link in non-alcoholic fatty liver disease-associated chronic kidney disease?. **2023**, 24, 52-57 ○
- 34 Technical acoustic measurements combined with clinical parameters for differential diagnosis of nonalcoholic steatohepatitis. ○
- 33 Myeloperoxidase-Sensitive T1 and T2 Switchable MR Imaging for Diagnosis of Nonalcoholic Steatohepatitis. **2023**, 17, 3324-3333 ○
- 32 Collagen co-localised with macrovesicular steatosis for fibrosis progression in non-alcoholic fatty liver disease. ○
- 31 Clinicopathological analysis of ischemia/reperfusion time-zero injury biopsies and its role in early allograft dysfunction in hepatic transplantation (retrospective cross-sectional study). **2022**, 42, 131 ○
- 30 Noninvasive tests predict liver-related events and mortality in patients with nonalcoholic fatty liver disease: sub-analysis of the CLIONE-Asia study. ○
- 29 Raman imaging of rat nonalcoholic fatty liver tissues reveals distinct biomolecular states. ○
- 28 Nicorandil reduces morphine withdrawal symptoms, potentiates morphine antinociception, and ameliorates liver fibrosis in rats. **2023**, 319, 121522 ○
- 27 Hepatocyte apoptosis fragment product cytokeratin-18 M30 level and non-alcoholic steatohepatitis risk diagnosis: an international registry study. **2023**, 136, 341-350 ○
- 26 Bifidobacterium-derived short-chain fatty acids and indole compounds attenuate nonalcoholic fatty liver disease by modulating gut-liver axis. 14, ○
- 25 The utility of non-invasive tests to assess advanced fibrosis in Asian subjects with chronic hepatitis B and concomitant hepatic steatosis. ○
- 24 Short-term high-fat diet feeding of mice suppresses catecholamine-stimulated Ca<sup>2+</sup> signalling in hepatocytes and intact liver. **2023**, 601, 1383-1405 1
- 23 Rifaximin-For liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trial. **2023**, ○
- 22 The Role of Olfactomedin 2 in the Adipose Tissue-Liver Axis and Its Implication in Obesity-Associated Nonalcoholic Fatty Liver Disease. **2023**, 24, 5221 ○
- 21 Spermidine suppresses the activation of hepatic stellate cells to cure liver fibrosis through autophagy activator MAP1S. ○
- 20 Dietary gluten worsens hepatic steatosis by increasing inflammation and oxidative stress in ApoE<sup>-/-</sup> mice fed a high-fat diet. **2023**, 14, 3332-3347 ○
- 19 Azonal steatosis correlates with disease severity and poor outcome of nonalcoholic fatty liver disease. ○



- 18 Low-Protein Diets Composed of Protein Recovered from Food Processing Supported Growth, but Induced Mild Hepatic Steatosis Compared with a No-Protein Diet in Young Female Rats. **2023**,
- 17 Expression of STING in Women with Morbid Obesity and Nonalcoholic Fatty Liver Disease. **2023**, 13, 496
- 16 Western Diet Decreases Hepatic Drug Metabolism in Male LDLr/ApoB100/100 Mice. **2023**, 2023, 1-12
- 15 Ficus Lyrata Bark Extract Alleviates Steatosis in Obesity- Induced Non-Alcoholic Fatty Liver Disease in Rats.
- 14 Vascular Disorders. **2024**, 687-725
- 13 Fatty Liver Disease. **2024**, 330-401
- 12 IL-15-producing splenic B cells play pathogenic roles in the development of autoimmune hepatitis. **2023**, 100757
- 11 Association of lysophosphatidic acid molecules with liver fibrosis [Different roles indicated].
- 10 Dietary ketone ester attenuates the accretion of adiposity and liver steatosis in mice fed a high-fat, high-sugar diet. 14,
- 9 The Role of the Soluble Interleukin-6 Receptor in the Progression of Nonalcoholic Fatty Liver Disease.
- 8 Hepatocellular carcinoma in patients cured of chronic hepatitis C: Minimal steatosis.
- 7 Is fatigue related to the severity of liver inflammation in patients with chronic liver disease? A cross-sectional study. **2023**, 13, e069028
- 6 Discovery of the First-in-Class Intestinal Restricted FXR and FABP1 Dual Modulator ZLY28 for the Treatment of Nonalcoholic Fatty Liver Disease.
- 5 Loss of CEACAM1 in endothelial cells causes hepatic fibrosis. **2023**, 155562
- 4 Noninvasive identification of probable fibrotic nonalcoholic steatohepatitis across the spectrum of glucose tolerance in the United States. **2023**, 110679
- 3 Technical Acoustic Measurements Combined with Clinical Parameters for the Differential Diagnosis of Nonalcoholic Steatohepatitis. **2023**, 13, 1547
- 2 Histopathological Changes in Liver of Patients With Chronic Pancreatitis Requiring Surgical Intervention and Their Clinical Significance. **2022**, 51, 1320-1326
- 1 Mitigating a Bioactivation Liability with an Azetidine-Based Inhibitor of Diacylglycerol Acyltransferase 2 (DGAT2) En Route to the Discovery of the Clinical Candidate Ervogastat.

